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Growth hormone (GH) is a pituitary peptide growth factor, regulating somatic 
growth and metabolism in an endocrine pattern. Aberrant secretion of GH has 
been determined to promote malignant transformation.  
  Although the role of hGH in breast cancer has been intensively investigated, 
the tumor initiating and metastatic potentials of autocrine hGH in breast 
cancer has yet to be determined. Previous studies in estrogen receptor positive 
breast cancer (ER+BC) cells have determined the effects of autocrine hGH on 
cell proliferation, survival, migration, invasion, EMT, angiogenesis and drug 
resistance in vitro, and tumor formation and local invasion in immunodeficient 
mice. ER negative breast cancer (ER-BC) represents a subtype of aggressive 
breast cancer with no effective therapeutic option currently. In this thesis, I 
determined the tumor initiating and metastatic effects of autocrine hGH in 
ER-BC cells. I demonstrated herein that autocrine hGH promoted CSC-like 
properties of ER-BC cells in vitro. Functional antagonism of hGH partially 
abrogated CSCs in ER-BC cells. In vivo, the xenograft assays with limited 
dilution demonstrated that autocrine hGH increased the tumor initiating 
capacity of ER-BC cells. I also observed that autocrine hGH promoted 
migration and invasion of ER-BC cells in vitro, and promoted lung and liver 
metastasis in vivo. Furthermore, qPCR array in a cohort of 24 ER-BC patient 
samples demonstrated that expression of hGH was positively correlated with 
expression of ALDH1, a CSC marker in breast cancer.  
Clinicopathological analysis has demonstrated that tumor expression of hGH 
associates with poor clinical outcomes in HCC patients. However, the 
x 
 
oncogenic effects of autocrine hGH in HCC is still unclear. In this thesis, I 
demonstrated that autocrine hGH promoted proliferation, survival, migration, 
invasion, and CSC-like properties of HCC cells. Furthermore, I determined 
that autocrine hGH promoted invasive and CSC-like properties of HCC cells 
through STAT3 mediated inhibition of claudin-1 expression.  Claudin-1 was 
determined as a target gene of STAT3 which transcriptionally inhibited the 
expression of claudin-1 through directly binding to the putative STAT3 
binding sites in the proximal region of claudin-1 promoter. Claudin-1 was 
identified as a tumor suppressor in HCC cells. Forced expression of claudin-1 
abrogated the invasive and CSC-like properties promoted by autocrine hGH. 
Conversely, depletion of claudin-1 promoted invasion and CSC-like properties 
of HCC cells.  
The results in this thesis described the tumor initiating and metastatic potential 
of autocrine hGH in ER-BC cells and the oncogenic effects of autocrine hGH 
in HCC cells, indicating functional inhibition of hGH as a therapeutic option 
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CHAPTER 1 Introduction 
1.1  Cancer 
1.1.1  Introduction of cancer 
Cancer is a general concept to recapitulate a class of diseases originating from 
any parts of the body. Although the diverse origins of different cancers, they 
share several common characteristics, such as their origins from normal cells, 
their uncontrolled proliferation that escape from “quiescence” and tissue 
constraint,  re-entering into a dedifferentiated status, and invading into the 
surrounding tissues that enables intravasation and metastasis to distant sites of 
the body. In 2000, Hanahan and Weinberg published the landmark review, 
which described the “hallmarks of cancer” [164]. In this review, Hanahan et al. 
proposed to delineate the six “acquired capabilities” for malignant 
transformation of normal cells, which are supposed to be shared by most 
human cancers (Figure 1-1). 
The “hallmarks of cancer” modal recapitulates the characteristics of cancer 
cells. However, it does not mean that cells necessarily develop these six 
hallmarks to become cancerous. Green et al. [150] suggested a model where 
deregulated proliferation and reduced apoptosis created a platform, from 
which cancer can develop. Invasion, metastasis and angiogenesis are 
considered as the consequence of the establishment of the platform for cell 
expansion (Figure 1-2). These two models are complementary as they 




Figure 1-1Acquired capabilities of cancer (Hanahan and Weinberg, 2000 [164]).  
These “acquired capabilities” have been described as the “hallmarks of cancer”, 






Figure 1-2 Concept of cancer development (adapted from Green et al., 2002 
[150]). 
Proliferation signals simultaneously promote apoptosis. If the survival signals block 
cell apoptosis leading to net cells expansion, and the manifestation of this expansion 
is as cancer. The deregulation of proliferation and reduction of apoptosis create a 
platform on which further malignant transformations (invasion, metastasis, 
angiogenesis, and et al.) may occur. This proposal sharply contrasts to models in 
which sequential blocks to transformation are bypassed by mutation and selection to 
ultimately produce an autonomous cancer. 
To maintain the normal tissue structure and function, the proliferation of 
normal cells is strictly regulated by carefully controlled cell cycle. However, 
cancer cells evolve several mechanisms to deregulate cell cycle, which are 
characterized by re-entering into cell cycle from a quiescent phase [269].  
This deregulation is characterised by intensive proliferation of cancer cells. 
The other important trait of cancer cells is anti-apoptosis [164], which may be 
required through different mechanisms. The loss-functional mutation of 
tumour suppressor gene p53 has been observed with high frequency in cancer 
cells. Conversely, the expression level of anti-apoptotic gene BCL2 is highly 
increased in cancer cells, including breast cancer. Such mutations confer 
immortality to cells, and facilitate cells to by-pass senescence [171, 237]. 
Senescence is described as an irreversible non-proliferative but viable state of 
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normal cells, which is mainly caused by shortening telomere during cell 
proliferation [69]. In cancer cells, the high expression level of the catalytic 
unit of human telomerase reverse transcriptase gene (hTERT) because of gene 
mutation or modification, maintains the length of telomere, and prevents 
senescence-triggered cell apoptosis.  The high proliferating rate and 
immortality of cancer cells induce genomic instability, which creates 
chromosomal aberrations leading to gene mutations [60, 460].  As a 
consequence of accumulated gene mutations, the regulators of cell cycle and 
telomerase activity can be deregulated, which may results in further 
hyper-proliferation of cancer cells, and then rapid tumour growth.  
Like normal tissues, tumours require sustained supply of nutrients and oxygen 
to maintain the hyper-proliferating state, as well as the ability to remove 
metabolic wastes. To support the rapid growth of tumour, new blood vessels 
are generated through a process termed as angiogenesis [164].  In normal 
tissues, neovasculature is strictly regulated by a process known as the 
“angiogenic switch”, which depends on the balance between pro-angiogenic 
and anti-angiogenic factors [47]. In tumours, the “angiogenic switch” is 
deregulated, with an increased production of pro-angiogenic factors (like 
vascular endothelial growth factor (VEGF) and angiopoietins) and a reduced 
expression of angiogenic inhibitors (like thrombospondins (Tsp)) [24, 185].  
Neovsculature in tumour is aberrantly shaped with hyper-permeability and 
irregular blood flow [24].  
Angiogenesis can be switched on by different factors including hypoxic and 
necrotic environment created by rapidly growing tumour, mechanical stress, 
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inflammatory response, as well as genetic alterations [24]. It is mediated 
through a series of complex cellular and molecular interactions occurred at 
different stages of tumour progression, depending on the nature of the tumour 
(Figure 1-3). Usually, recruitment of endothelial cells by activated angiogenic 
factors (like VEGF-A) is the key step of angiogenesis [42]. Besides of 
delivering nutrients and oxygen to the hypoxic and necrotic areas to facilitate 
tumour growth, the neovasculature also facilitates metastatic dissemination of 
cancer cells during the malignant transformation.  
 
Figure 1-3 Classic angiogenic switch (Bergers et al., 2003 [24]).   
(a) The proliferation and apoptosis of cells reach a steady- state, and then 
angiogenesis is initiated to ensure exponential tumour expansion. (b) Following 
perivascular detatchment and vessel dilution, the angiogenic sprouting is triggered.   
(c) Formation and mature of new blood vessels with recruitment of perivascular cells. 
(d,e) blood vessel formation will continues, especially in the hypoxic and necrotic 
areas to support tumour growth by supplying nutrients and oxygen.  
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One important process involved in malignant transformation of cancers is 
metastasis. During tumour metastasis, the “pioneer” cancer cells move out the 
primary tumour, invade adjacent tissues, enter into blood vessels or lymph 
nodes, and disseminate to distant secondary sites where they may succeed in 
establishing new lesions [341, 518].  Metastasis is a complex dynamic 
process, including phenotypic transformation of primary tumour cells and 
angiogenesis.  
1.2  Breast cancer 
1.2.1  Mammary gland Development 
The mammary gland, exclusively present in mammals, is developed to 
produce and deliver milk to the young offspring [213]. In more than one and a 
half centuries, the structure and development of mammary gland have been 
widely investigated to understand the mechanisms involved in regulating 
mammary epithelial cell proliferation, differentiation, and tumorigenic 
transformation [175].  
The mammary gland is composed of parenchyma and adipose stroma. 
Parenchyma forms the duct branching system, where the milk secreting acini 
develop. The adipose stroma, also known as mammary fat pad, plays a role as 
supporting substrate in which the parenchyma develops [213]. The 
parenchyma of the mammary gland consists of approximately 15-20 lobes, 
which are separated by adipose stroma. Each lobe is composed of a group of 
alveoli, which is lined with milk secreting mammary epithelial cells and 
embedded in myoepithelial cells (Figure 1-4). The myoepithelial cells able to 
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contract and propel secreted milk from alveoli toward nipple through 
lactiferous ducts.  
 
Figure 1-4 Structure of mammary gland (Ali et al., 2000 [10]).  
The mammary gland is composed of 15-20 lobes separated by adipose stroma, which 
consists of a series of branched ducts draining into the nipple. 
The cell origin of the mammary gland have been proposed to be developed 
from a group of multipotent mammary stem cells (MaSCs) [266].  The 
MaSCs recapitulate the capabilities of self-renewal, differentiating into the cell 
lineages, and reconstructing the mammary gland. It was not until 2006 that the 
self-renewal MaSCs are identified from mouse mammary gland using 
fluorescent activated cell sorting (FACS) based on the cell surface markers 
presented by MaSCs, which are different from differentiated mammary 
epithelial cells [394, 419]. Similarly, the human MaSCs were identified by 
using different cell surface markers [73, 418]. In vivo model has demonstrated 
that a single MaSC isolated from the mouse mammary gland can reconstruct a 
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complete functional mammary gland in cleared fat pat [394]. Intensive 
investigations have established a model to describe and outline the stem cell 
hierarchy of the mammary gland (Figure 1-5). The mulipotent MaSCs give 
rise to a population of bipotent progenitor cells, which proceed to differentiate 
to lineage-specific progenitor cells, the luminal progenitor and myoepithelial 
progenitor cells, which finally differentiate into ductal, alveolar and 
myoepithelial cells, respectively [266].  
 
Figure 1-5 The stem cell hierarchy within mammary gland (Macias and Hick, 
2012 [266]).  
The multipotent MaSCs maintain the self-renewal capability; meanwhile they can 
differentiate into committed bipotent progenitor cells. The bipotent progenitor cells 
can differentiate into lineage specific progenitor cells, which finally differentiate into 
mature mammary epithelial cells. These stem/progenitor and differentiated cells 
recapitulate the hierarchy of mammary gland. 
The mammary tissues are composed of epithelial and surrounding stromal 
compartments, which are derived from ectoderm and mesoderm, respectively 
start to appear at weeks 7-8 in human fetus [266].  At the embryonic stage, 
the mammary gland development similar between male and female is 
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regulated by signalling interaction between the epithelial and mesenchymal 
cells [176]. By completion of fetal development, the rudimentary mammary 
gland consists of adipose stroma with a small network of immature ducts lined 
with a layer of epithelial cells [289]. After birth, further development of the 
mammary gland is divided into distinct stages, regulated by a variety of 
steroid and peptide hormones involved into sexual development and 
reproduction [416]. 
Puberty mammary development 
The incipience of puberty accompanies increased levels of ovarian steroid 
hormone (i.e. estrogen) and pituitary growth factor (i.e. growth hormone), 
which lead to expansive proliferation of glandular epithelial cells resulting in 
elongation of terminal end buds (TEBs) at the end of growing ducts [416]. The 
TEBs arise from pluripotent MaSCs residing in the immature “ductal tree”. 
The cap cells of TEBs differentiated into myoepithelial cells, which 
encompass the ductal bilayer that encircles inner luminal cells which finally 
undergo apoptosis causing formation of duct lumens [215]. The TEBs 
bifurcate or trifurcate and infiltrate into the mammary fat pad, until the ducts 
reach the periphery of the entire fat pad.  
Estrogen and Growth hormone (GH) have been demonstrated to be the key 
factors regulating puberty mammary gland development. The estrogen 
receptor alpha (ERα) and growth hormone receptor (GHR) have been detected 
in the mammary epithelium and stroma [89, 125]. Compared to the wild type 
littermates, the mammary gland development of ERα-/- mice has been 
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impaired in puberty.  While Turner and Frank [449] demonstrated that 
estrogen stimulated development of mammary duct, the following studies 
demonstrated that in hypophysectomised animals estrogen only did not cause 
mammary development [144, 371], which indicated that one or more pituitary 
hormones interacted with estrogen to regulate mammary gland development. 
Much early work focused on the potential role of the pituitary prolactin (PRL) 
in mammary development, as PRL receptors (PRLRs) were identified in the 
mammary gland. However, further studies demonstrated that PRL did not 
stimulated mammary gland development [125]. Treatment of 
hypophysectomized primates with human growth hormone (hGH) + estrogen 
for two months restored mammary development back to normal state [214]. 
The effect of GH in mammary development is mediated by isulin like growth 
factor I (IGF-I)[381]. In IGF-I-/- knockout mice, the pubertal mammary 
development was impaired despite of the normal expression levels of GH and 
estrogen. Administration of IGF-I can restore ductal morphogenesis. Richards 
et al. have demonstrated that the local IGF-I production within the mammary 
gland is more important in regulating pubertal mammary gland development 
than that produced in the liver [376]. Wood et al. demonstrated that production 
of IGF-I was identified in epithelial and stromal compartments of mammary 
gland, and that loss of epithelial IGF-I resulted in ductal branching deficiency 
[470].  By studying the hypophysectomised and oophorectomized female rats, 
Ruan et al. found that while estrogen did not induce IGF-I mRNA expression 
in mammary glands not exposed to hGH, it enhances the effect of hGH on 
production of IGF-I mRNA [381, 454]. Besides estrogen, GH and IGF-I, other 
growth factors also participate in pubertal mammary gland development. For 
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example, the transforming growth factor beta (TGF-β) prevents overextension 
of the ducts in mammary fat pad in order to leave enough space for alveolar 
development during pregnancy and lactation [88].  
 
Pregnancy and lactation 
The development of alveoli structure is slow and cumulative in response to 
hormonal influences during the estrous cycle [289]. At this stage the alveoli 
development is mainly regulated by progesterone (Pg) and estrogen produced 
by corpus luteum. However, the alveoli development in nulliparous rodents 
and human is quite limited when compared to the alveoli development during 
pregnancy; increased Pg and PRL expression regulate both gland maturation 
and alveologenesis. The increased hormones stimulate intense proliferation of 
the mammary epithelium to generate alveolar buds, which finally 
differentiated into alveoli. At this stage, GH expression has been reduced. 
Studies have demonstrated that forced expression GH inhibits lactogenic 
differentiation of mouse mammary epithelial cells [314]. During this period, 
the number of epithelial cells is increased approximately 8-12 times. A few 
days after birth, increased PRL secretion stimulates lactation. After lactation, 
the mammary gland undergoes a process of involution that removes the 
increased number of epithelial cell during pregnancy/lactation through 
apoptosis and remodels the adipose tissue. The mammary gland retrieves back 
to a simple ductal structure similar to a pre-pregnancy state.   
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1.2.2  Incident rate and risk factor of breast cancer 
Breast cancer commonly originates from the ducts and the lobules of the 
mammary tissues, which are also termed as ductal carcinoma and lobular 
carcinoma respectively. Breast cancer is the most common non-skin cancers 
among women worldwide, especially in western countries, and accounts for 
nearly 1 in 3 new cancer cases diagnosed among women in the United States 
[99]. In every year more than one million of new breast cancer cases are 
diagnosed worldwide, which is the second leading cause of cancer-related 
death among women [99, 127]. In Singapore, breast cancer is the most 
common cancer among women with the highest mortality rates. The incidence 
rate of newly diagnosed breast cancers had increased about three-fold in the 
past four decades. About one thousand new cases are diagnosed very year and 
an estimated 270 women die from breast cancer each year in Singapore [198]. 
The incidence rate of breast cancer in Eastern Asia is up to five-fold lower 
than in Western countries, indicating a probably relation of cancer incidences 
to environmental rather than genetic factors [358]. Many of these factors are 
related to extended exposure to female reproductive hormones (like estrogen, 
progesterone), such as early menarche, late menopause, hormone replacement 
therapies, and consumption of oral contraceptives [189]. In addition, fat intake 
and alcohol consumption are also observed to be correlated with increased risk 
of breast cancer in women. Pregnancy is considered as a factor to reduce the 
risk of breast cancer. The early first full-term pregnancy lowers the risk of 
postmenopausal breast cancer. However, women experiencing their first 
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pregnancy after 30 years old have a higher risk to develop breast cancer than 
nulliporous women [173, 189].  
Besides the environmental factors, family history is well-established as a risk 
factor of breast cancer. Inherited gene mutations represent almost 10% of total 
breast cancer cases [437]. BRCA1 gene, since identified in 1994 [296] has 
been intensively investigated as a well-established breast cancer susceptibility 
gene. Women carrying BRCA1 mutations have a 55-70% of chance to develop 
breast cancer during their lifetime [29]. Loss-functional mutations of these 
tumour suppressor genes BRCA1 and BRCA2 account for approximately 20% 
of familial breast cancer [18]. Both genes get involved into genomic stability 
and regulation of transcription. DNA damage induces phosphorylation of 
BRCA1 mediated by ATM and CHK2 proteins. Besides binding with BRCA2 
and RAD51 to regulate recombination-mediated repair of double stranded 
breaks of genomic DNA, phosphorylated BRCA1 also activates the 
transcription of p21, which arrests cells at G2 stage [318]. In addition to 
BRCA1 and BRCA2, some other gene mutations are also indentified to be 
associated with increased breast cancer risk: Mutations in PTEN gene are 
associated with a 20-30% lifetime risk of breast cancer[244]; homozygous 
germline mutations in ATM gene increase incidences of breast and ovarian 
cancer[313].  Although the additional genes have been associated with breast 
cancer susceptibility, no one is comparable with BRCA1 mutation in respect 
of breast cancer penetrance.  
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1.2.3  Molecular subtypes of breast cancer 
Breast cancer is a heterogeneous disease on molecular, histopathologic, and 
clinical levels.  The molecular heterogeneity of breast cancer is well defined 
by the differences in genomic aberrations and differential gene expressions 
[347, 412]. Based on the gene expression profiles five distinct subtypes of 
breast cancer have been identified, termed as luminal-A, luminal-B, 
ERBB2/HER2-positive, normal breast-like, and basal-like subtype (Figure 1-6). 
More recently, a new molecular subtype has been identified and termed as 
claudin-low group, which is characterized by reduced expression of tight 
junction proteins claudins and epithelial marker E-Cadherin[162, 357].  
The different gene expression profiles of these subtypes represent different 
clinical outcomes, responses to adjuvant therapies, metastasis and recurrence. 
The luminal A subtype, expressing the highest level of ERα and some luminal 
specific genes, like keratins 8/18 usually exhibits the best clinical outcome 
comparing to other subtypes. Compared to the luminal A subtype, the luminal 
B subtype expresses lower levels of ERα and luminal specific genes with 
worse clinical outcome. However, both luminal A and luminal B subtypes are 
designated as ER+ breast cancers. The ERBB2/HER2 positive subtype 
represents around 20% of all breast cancers, which has been characterized 
with overexpression or amplification of HER2/neu gene locus [347, 412]. The 
basal like tumors, which represent approximately 15% of invasive ductal 
breast cancers, are also termed as triple negative (TN) breast cancers due to 
the lack of ER, progesterone receptor (PR), and HER2/neu in these tumors 
[26]. The epidemiological, phenotypic and molecular characteristics of 
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basal-like subtype are distinct from other molecular subtypes. The basal-like 
subtype is associated with poor survival rates and more aggressive than other 
molecular subtypes, due to the characteristics of overexpressions of epidermal 
growth factor receptor (EGFR) and KIT, mutations of BRCA1 and TP53 genes 
[62, 412, 483]. Previous studies indicated that the basal-like breast cancers 
may originate from MaSCs since the basal-like breast cancers express variety 
of genes commonly observed in MaSCs [25, 254]. However, more recent 
studies have demonstrated that BRCA1 mutated basal-like tumors originate 
from aberrant luminal progenitor cells based on analysis of gene expression 
profiles [246, 307]. The latest identified claudin-low subtype tumors are 
characterized with low levels of luminal differentiation markers, and high 
level of EMT markers. In addition, the claudin-low tumors exhibit features of 
stromal cells and MaSCs, indicating their origination from MaSCs. Most of 
the claudin-low tumors are triple negative, characterized with poor prognosis. 
However, their response to standard pre-operative chemotherapy is better than 
basal-like tumors [162, 357].   
 
Figure 1-6 Subtypes of breast cancer (Sørlie, et al., 2001[412]).  
Based on the gene expression patterns, breast cancer has been clustered into different 
subtypes with distinct clinical prognosis.  
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1.2.4  Diagnosis and therapeutics of breast cancer 
Breast cancer is a heterogeneous disease, which has been classified into 
several molecular subtypes based on the gene expression profiles. Accordingly, 
targeted therapeutic strategies are also developed to eradicate these 
heterogeneous lesions. Because of improvement in developing diagnosis and 
treatment of breast cancer, the mortality rate has steadily decreased. Early 
diagnosis has achieved during physical examination and mammogram 
screening, which increases the opportunity to eradicate the primary lesion 
before metastasis occurs [18].   
The progression of human breast cancer is tightly regulated by steroid 
hormones, such as estrogen, and peptide growth factors, such as EGF. 
Expression of ER occurs in about 70% of breast tumors [464]. ER status is an 
important prognostic factor in breast cancer [100], which indicates a more 
favourable prognosis than other molecular subtypes of breast cancer, due to 
their better response to endocrine therapy. The anti-estrogen agent, Tamoxifen 
(TAM) has been widely used to treat breast cancer patients since 1970s and 
remains the primary choice for ER+ breast cancer patients [72, 76]. TAM 
fulfils its estrogen antagonistic effect by competing with estrogen to bind with 
ER and inducing conformational change of ER, which deprives of the 
transcriptional activity of ER [287, 464]. However, TAM exhibits ER 
agonistic effect in breast cancer with overexpression of HER2/neu gene, which 
partially explains the reason for the development of TAM resistance in ER+ 
breast cancer patients [287]. Although TAM treatment reduces the risk for 
osteoporosis [72], long-term exposure to TAM brings the risks of promoting 
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endometrial proliferation and hence increases the development of endometrial 
carcinoma [287].  
To overcome the problems caused by agonistic effects of TAM, aromatase 
inhibitors (such as exemestane, anstrazole and letrozole) and Fulvestrant 
(Faslodex
®
) are introduced into the regime of anti-estrogen therapy [287, 464]. 
Aromatase inhibitors (AI) block estrogen production by inhibiting the catalytic 
activity of aromatase, which controls the last but rate-determining step of 
estrogen biosynthesis [464]. The clinical efficacy of AIs in postmenopausal 
patients with advanced breast cancer failure to TAM treatment has been 
intensively investigated. Treatment with AIs has significantly prolonged 
disease-free survival and delayed tumor recurrence, as well as reduced distant 
metastasis, compared to TAM treatment [184]. In addition, treatment with AIs 
also reduces the incidence of developing endometrial carcinoma [184]. 
Fulvestrant is a novel ER antagonist, that competitively binds to ER with a 
much higher affinity than TAM [203, 287], but lacks the agonistic effect of 
TAM. Fulvestrant is a steroidal analogue of 17β-estradiol, which inhibits ER 
dimerization and increases ER turnover. These lead to decreased cellular level 
of ER, disruption of ER interaction with DNA, and abrogation of gene 
transcription regulated by ER [287, 464]. Fulvestrant is recommended to treat 
postmenopausal women with ER+ metastatic breast cancer, who fail to 
anti-estrogen therapy [287].  
Resistance to anti-estrogen therapy is considered as a complex phenomenon, 
with intrinsic singaling interactions. Anti-estrogen therapy takes effects in 
patients with ER+ breast cancer; however, HER/neu overexpression has been 
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implicated into ani-estrogen therapy resistance, which leads to reduced 
expression of ER, increased ER phosphorylation and transcriptional activity 
[23, 354, 370, 378]. In addition, long-term exposure to anti-estrogen therapy, 
including TAM, elicits increased expression of HER2/neu and EGFR in 
cancer cells [114, 324]. Treatment with gefitinib, an EGFR tyrosine kinase 
inhibitor restored the anti-tumor effect of TAM in MCF7 cells with forced 
expression of HER2/neu [399]. Inhibition of HER2/neu pathway enhances the 
effects of anti-estrogen treatment in HER2/neu positive breast cancer patients 
[227, 325]. The HER2/neu positive status has been identified as an 
independent prognostic factor in breast cancer, which represents one-fourth of 
total breast cancer [464]. Trastuzumab (Herceptin
®
) is the first therapeutic 
antibody developed to target against the extracellular domain of HER2/neu 
protein with high affinity [353]. Clinical study has demonstrated that 
tratuzumab treatment after adjuvant therapy significantly reduced the 
recurrence among women with HER2/neu+ breast cancer [464].    
Triple negative breast cancer (TNBC) (including basal-like and claudin-low 
subtype) is more aggressive than other subtypes, which do not have an 
effective targeted therapy. Although earlier clinical studies have indicated the 
high rate of response and sensitivity to standard chemotherapy [46, 345],  
patients with TNBC have an overall worse prognosis, with higher rates of 
early recurrence and distant metastasis, as well as higher risk of cancer-related 
deaths, compared to other subtypes of breast cancer [46, 347, 401, 412].   
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1.3  Hepatocellular carcinoma  
1.3.1  Incidence rate and distribution of hepatocellular carcinoma 
Primary liver cancer, consisting predominantly of hepatocellular carcinoma 
(HCC), is the sixth most prevalent cancer, and ranked as the third most 
common cause of cancer-related mortality [127]. In 2008, it was estimated that 
748,000 new cases were diagnosed and 685,000 cases died. HCC accounts for 
more than 85% of primary liver cancers. Besides HCC, there are some other 
rare types of liver cancers, including cholangiocarcinoma, hepatoblastoma and 
angiosarcoma, which are derived from different cellular origins [112]. The 
burden of liver cancer is not evenly distributed through the world. More than 
80% of HCC cases occur in sub-Saharan Africa, Southeast Asia, and Eastern 
Asia. In contrast, the incidence rates of HCC in North and South America, 
Northern Europe and Oceania are very low. The prevalence of HCC in Eastern 
Asia is prominently associated with the high risk of hepatitis B (HBV) and 
hepatitis C (HCV) virus infection. China alone accounts for almost 50% of the 
world’s HCC cases, where HBV infection is relatively prevalent and often 
occurred at young age, whereas the low-incidence areas such as America 
exhibit low risk of hepatitis virus infection [32]. Generally males are more 
susceptible to HCC development than females, with a sex ratio between 1.3 
and 3.6 [396]. Besides the different exposure to environment factors (like 
smoking and alcohol consumption), androgen stimulation is considered as a 
potential factor for the vulnerability of male to HCC development [281]. In 
Singapore, Liver cancer is the fourth most common cancer diagnosed in male 
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with 2,049 new cases during 2008-2012, and ranked as the third most 
mortality cancer in male.  
1.3.2  Development of hepatocellular carcinoma 
Development of HCC is a complex neoplastic progress involving multiple risk 
factors. The prominent risk factors include chronic infection of HBV and HCV 
and aflatoxin-B1 exposure, which account for approximately 80% of HCCs. 
The less prevalent risk factors which include excessive alcohol consumption, 
smoking, long term oral constraceptive intake, metabolic disorders, diabetes, 
non-alcoholic fatty liver disorders (NAFLD) and non-alcoholic steatohepatitis 
(NASH) have also been proposed to lead to HCC [124].  
Hepatocarcinogenesis is a slow and complex process which may take more 
than 30 years. During this progress, the hepatocellular phenotype from normal 
hepatocyte transforms to dysplastic hepatocytes, and finally to hepatocellular 
carcinoma. Such phenotypic transformation is due to extensive genetic and 
epigenetic alterations, that involve numerous cellular behaviours such as cell 
proliferation, apoptosis, differentiation, immortality, as well as genetic 
integrity[439] .   
The most common and unified condition associated with hepatocarcinogenesis 
is cirrhosis, which is characterized by the formation of abnormal liver nodule 
surrounded by collagen deposition and fibrous scar tissue [112, 124]. Seventy 
to ninety percent of HCCs are diagnosed with a setting of cirrhosis, while 
some risk factors may induce HCC independent of the cirrhosis stage [67, 
334].  Like HCC, cirrhosis is caused by several risk factors such as HBV and 
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HCV infection, and aflatoxin-B1toxicity. The chronic liver diseases caused by 
these risk factors lead to necrosis, which trigger hyperproliferation of normal 
hepatocytes. The destructive proliferation of hepatocytes is accompanied with 
shortening of telomere resulting in accumulation of senescent hepatocytes at 
the stage of cirrhosis. The shortening telomere induces chromosomal 
instability, meanwhile activates DNA repairing leading to chromosomal fusion, 
which accelerates the accumulation of genetic aberrations.  The abnormally 
proliferating hepatocytes rapidly expand in the cirrhotic liver, and form 
hyperplastic nodule, subsequently dysplastic nodule, and finally hepatocellular 
carcinoma (Figure 1-7). The malignant transformation is accompanied with 
consecutive genetic alterations, such as restoring the activity of telomerase and 
loss-functional mutation of tumor suppressor gene P53. Meanwhile several 
oncogenic signaling pathways, such as the Wnt/β-catenin pathway and 
PI3K/Akt pathway, have been activated [396].   
 
Figure 1-7 Histopathological progression and molecular features of HCC (Farazi 
and DePinho,2006 [124]).  
Liver injury incurred by these risk factors (HBV, HCV, alcohol and aflatoxin B1) 
leads to necrosis, which is followed by hepatocyte proliferation. The destructive 
continuous proliferation of hepatocyte causes the chronic disease condition, and 
finally reaches the cirrhosis stage, which is characterized by abnormal liver nodules. 
Subsequently, the hyperplastic nodules are formed, followed by dysplastic nodules, 
and finally the formation of HCC.  
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1.3.3  Treatment of hepatocellular carcinoma 
HCC is mainly diagnosed by radiological imaging and measuring serum level 
of Alpha Fetoprotein (AFP). In patients with pre-existence of chronic hepatitis 
or cirrhosis, there is a higher likelihood of developing HCC.  
The dilemma for HCC treatment is to eradicate the malignant lesion and 
meanwhile reserve the normal liver function. Many HCC patients die from 
liver failure induced by HCC, rather than distant metastasis. The primary 
therapeutic choice for HCC patients is surgical resection. However, there are 
less than 30% of HCC patients suitable for surgical resection at the time of 
diagnosis[231], as most HCC patients are diagnosed at advanced stage with 
large primary tumor and intrahepatic metastasis. Although the 5-year survival 
rate of HCC patients received surgical resection is quite promising (>52%), 
tumor recurrence (>43%), due to intrahepatic metastasis or de novo tumor 
development, is still the major challenge for HCC treatment [4, 123, 317]. 
Compared to surgical resection, orphotopic liver transplantation (OLT) is a 
more promising therapeutic alternative for patients with unresectable HCC, 
with a higher 5-year survival rate (>70%) and lower recurrence rate (<15%) 
[122, 283]. However, this therapeutic option is limited due to the scarcity of 
available organs. In addition, the immunosuppressive drugs (Cyclosporine and 
Tacrolimus) used in OLT are controversial for the potential tumor-promoting 
effects [156].  
For many years, systematic chemotherapy remains the only approach for 
treating HCC patients at advanced stage or recurrence of surgery. However, 
the outcome of systematic chemotherapy is not satisfactory. Among the 
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available agents, doxorubicin is widely used to treat HCC patients at advanced 
stage. However, doxorubicin has a very low response rate and does not 
significantly improve patient survival [12]. Compared to doxorubicin 
treatment, a regimen of IFN-alpha2b, 5-Fluorouraci (5-FU), cisplatin and 
doxorubicin increased response rate and median survival of HCC patients 
from 10.5 to 20.9% and 6.8 to 8.7 months, respectively. However, the 
improvements were not statistically significant. In addition, the combined 
regimen was also associated with toxicity[494]. Due to the lack of survival 
benefit from the treatment with conventional chemotherapeutic drugs, 
development of novel therapeutic strategy is urgently needed. The recent 
progression in identificating critical signal pathways in HCC development has 
shed light in the development and emergence of molecular-targeted therapy in 
advanced HCC [12]. Currently, the only targeted therapeutic agent available 
for HCC is sorafenib, which functions to abrogate the mitogen-activated 
protein kinase (MAPK) signal pathway by blocking the activity of some 
receptor tyrosine kinases (RTKs), as well as the serine/threonine kinase Raf, 
thereby resulting in the inhibition of tumor proliferation and angiogenesis 
[467]. In a murine xenograft model of human HCC cell line, sorafenib inhibits 
tumor growth in a dosage-dependent pattern. In this model, the tumor 
angiogenesis and signaling through Raf/MEK/ERK pathway are also inhibited, 
meanwhile sorafenib induces cell apoptosis [252]. In a multicenter and 
double-blinded phase III clinical trial with a cohort of 602 HCC patients, 
although sorafenib treatment did not improve the median time to symptomatic 
progression, the radiological progression has been delayed by sorafenib 
treatment (sorafenib group: 5.5 months; placebo group: 2.8 months) [258]. 
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However, similar to conventional chemotherapy, sorafenib treatment is also 
accompanied with severe side effects leading to drug discontinuation in 15% 
of the patients.  
1.4 Growth hormone 
Growth hormone (GH), also known as somatotropin, is a polypeptide hormone 
synthesized by somatotroph cells within the anterior pituitary gland and plays 
as the major regulator of postnatal growth. It has been demonstrated that the 
pituitary gland regulates somatic growth since early 1900s; however, it was 
not until 1945 the functional growth factor was successfully isolated from 
bovine pituitary gland [239, 240]. Since then, the effects of GH in somatic 
growth and pathological events have been intensively investigated.  
1.4.1 Growth hormone gene and protein 
GH is categorized in a large family of evolutionarily related protein hormones 
including prolactin (PRL), placental lactogen (PL), and several newly 
identified members, as mouse proliferin (mPLF), mouse proliferin-related 
protein (mPRP), rat decidual PRL-like protein (rdecPRP), and somatolactin 
[222].  The human GH (hGH) gene locates on the long arm of chromosome 
17, included in a gene cluster composed of five closely related genes GH-N 
(GH-normal), CS-L (chorionic somatomammotropin-like), CS-A, GH-V 
(GH-variable) and CS-B [178, 297] (Figure 1-8). These five genes share more 
than 92% DNA sequence identity in their coding and flanking regions [297]. 




The hGH protein is translated from GH-N (GH1) gene, which is 
approximately 2.6kb long and consisted of five exons and four introns [297]. 
Whereas, the GH-V protein is encoded by GH-V (GH2) gene, and is 
exclusively present in placenta [79, 129]. After birth, GH-N protein becomes 
the dominant circulating GH in plasma. The hGH protein is encoded as a 
precursor protein with a signal peptide at the end of aminal terminal which is 
removed when secreted. The hGH gene gives rise to a 22-kDa protein, as well 
as a 20-kDa protein based on an alternative pre-mRNA splicing [238]. The 
22-kDa protein is the predominant form of hGH in pituitary gland and plasma 
[20]. hGH protein shares approximately 75% of amino acid sequence 
similarity with bovine GH (bGH) protein [275]. The crystal structure of hGH 
protein was determined in 1992 [95] while the three-dimensional structure of 
porcine GH (pGH) was analysed in 1987 [1]. Both GH proteins share similar 
topological structure, containing four helices with a specific orientation of 
up-up-down-down topology (Figure 1-9). The GH protein contains two 
disulfide bridges at Cys53-Cys164 and Cys181-Cys189, which are conserved 





Figure 1-8 Schematic representation of GH gene cluster (Kopchick and Andry, 
2000 [222]).  
The GH gene cluster is consisted of five evolutionarily related genes. The GH-N gene 
is approximately 2.6kb in length, containing five exons and four introns.  
 
 
Figure 1-9 Crystal structure of porcine GH (Kopchick and Andry, 2000 [222]).  
The cylinders represent the four helices (I-IV). The thin tubes represent the non-helix 
regions. The amino and carboxyl terminals are indicated as N and C, respectively.   
1.4.2 Growth hormone secretion and regulation 
GH is predominantly produced, stored and secreted by somatotroph cells in 
the anterior pituitary gland. It has also been demonstrated to be produced in a 
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number of extrapituitary sites, including central nervous system (CNS)[147], 
the epithelial cells of mammary gland[393], bone marrow[28],  
lymphocytes[170], endothelial cells of blood vessels [471], and fibroblasts 
[338]. The extra-pituitary GH regulates proliferation and tissue specific effects 
in an autocrine/paracrine pattern [253]. The secretion of pituitary GH is 
mainly regulated by two peptide hormones synthesized in hypothalamic 
neuroendocrine neurons: GH releasing hormone (GHRH) and somatostatin 
(SS)[316], as well as ghrelin, a peptide isolated from the stomach of the rat 
[217]. Both GHRH and SS bind to their specific receptors expressed on the 
somatotroph cells to promote or inhibit GH releasing, respectively (Figure 
1-10).  In addition to the neuroendocrine control, IGF-I production stimulated 
by GH also regulates GH secretion in a negative feedback loop. Both GH and 
IGF-I are the key modulator of postnatal growth and development [235]. The 
“Dual Effector” theory has proposed that GH stimulates precursor cells 
differentiation, and IGF-I stimulated by GH promotes proliferation of the 
differentiated cells [151]. In skeleton development, several lines of evidence 
indicate that GH promotes differentiation of prechondrocytes to chondrocytes 
in the germinal zone of the growth plate, and meanwhile renders the 
differentiated chondrocytes susceptible to clonal expansion stimulation of 
IGF-I in the proliferative zone of growth plate during the process of 




Figure 1-10 Regulation of pituitary GH secretion.  
The GHRH expressed in hypothalamus promotes GH production and secretion from 
pituitary. Whereas, SS produced in hypothalamus inhibits GH secretion from 
pituitary. Pituitary GH stimulate IGF-I production in liver, which, together with GH, 
regulates postnatal growth. The increased concentration of IGF-I stimulate SS 
releasing from hypothalamus, and inhibit GH releasing from pituitary.  
The GHRHs released from hypothalamus bind to its GHRH receptors 
expressed on somatotroph cells.  The GHRH receptor is a 
seven-transmembrane G-protein coupled receptor [282]. Upon binding with 
GHRH, the activated GHRH receptor activates adenylyl cyclase, which 
catalyzes the synthesis of cAMP from ATP [282]. Increased production of 
cAMP in somatotroph cells concomitantly increases the concentration of the 
pituitary specific transcription factor Pit-1, a member of the POU homedomain 
family [285], which specifically binds to the proximal promoter region of hGH 
gene and promotes gene transcription [398]. The synthesized GH is stored in 
the secretory granules of somatotroph cells and is stimulated to be released 
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into plasma by increased intracellular concentration of Ca
2+
, which is 
regulated by activated GHRH receptors [311].  However, the hypothalamic 
SS binding to its specific receptor on cell surface of somatotroph inhibits the 
catalytic activity of adenylyl cyclase and reduces the intracellular 
concentration of Ca
2+
 in somatotroph cells,   and then blocks GH synthesis 
and secretion [107].  
Overall, pituitary GH secretion has been dynamically regulated by GHRH and 
SS from hypothalamus. In addition, GH regulates its own secretion in a short 
negative feedback loop, which has been clearly demonstrated with the 
involvement of GHR. Administration of hGH in CNS dramatically decreases 
the concentration of plasma GH, attributed to inhibition of GHRH synthesis 
and release, as well as increase of SS activity [346]. Another mechanism of 
negative regulation of pituitary GH release involves hepatic IGF-I, which is 
mainly synthesized by liver in response to the stimulation of pituitary GH, as 
well the hypothalamic IGF-I synthesis.  IGF-I inhibits GH release at the 
levels of both pituitary and hypothalamus. Increased IGF-I concentration 
stimulates the expression and release of SS in hypothalamus [6].  In general, 
GH, IGF-I, GHRH and SS dynamically regulate each other’s secretion.  
1.4.3 GH-mediated signal transduction 
The various effects of GH are mediated through hormone interacting with 
GHR which was first recognized to be abundant in liver tissue. With the 
development of more sensitive techniques, the expression of GHRs was 
identified in several other tissues, such as muscle, mammary gland, adipose, 
brain, bone, and embryonic stem cells [210, 331]. In addition to GHR, GH can 
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also bind with prolactin receptor (PRLR) [476]. The GHR structure, GH-GHR 
interaction, and the signal transduction induced by this interaction have been 
intensively studied to better understand the growth effects of GH.  
1.4.3.1 Growth hormone receptor 
GHR belongs to the class I cytokine receptor family which also includes the 
PRLR, erythropoietin (EPO) receptor, and thrombopoietin [222]. The class I 
cytokine receptors are single trans-membrane with N-terminal extracellular 
domain consisted of two tandem fibronectin III-like motifs. These family 
members share approximately 14-25% sequence identity in the extracellular 
domain. There are several conserved cystein residues crosslinked by disulfide 
bonds at the extracellular domain, and a conserved tryptophan residue 
proximal to the second cysteine in the N-terminal fibronectin III motif. The 
class I cytokine receptors do not contain the tyrosine kinase activity. Whereas, 
the proline-rich motif referred to as Box1 in the intracellular domain is the 
docking site for Janus kinase 2 (JAK2) which activates signal transducer and 
activators of transcription (STATs), mitogen-activated protein kinase (MAPK), 
insulin recptor substrates (IRS) signal pathways. The GHR also includes a 
second proline rich motif termed Box2 [514].     
GHR is a 70kDa protein, which is usually modified by glycosylation and 
ubiquitination.  The receptor contains five potential N-linked glycosylation 
sites [167] and nineteen ubiquitination sites [420] (Figure 1-11). The 
interaction of GH with GHR has previously been explained as a “two-step 
model”, in which the strong binding site of GH (site1) interacts with the 
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extracellular domain of one GHR, and then the weak binding site of the same 
GH (site2) interacts with the extracellular domain of the second GHR, 
resulting in GHR dimerization [37, 514]. Dimerization of GHR was 
considered to be essential for GH mediated signal transduction. However, 
more recent studies have demonstrated the existence of GHR dimer on cell 
surface in absence of GH interaction [37, 38]. The interaction of GH with 
dimerized GHR gives rise to conformational change of the intracellular 
domain of GHR, which is essencial for signal transduction [245, 380].  
 
Figure 1-11 Schematic representation of GHR structure (adapted from 
Ridderstrale, 2005[377]).  
The GHR contains several functional motifs required for signal transduction, 
including N-linked glucosylation sites (N), three pairs of conserved systein residues 
(C) crosslinked by disulfide bonds and WSXWS-like motif in the extracellular 
domain; two tandem proline-rich motifs (Box1 and Box2) and 10 tyrosine residues (Y) 
in the intracellular domain, which provide docking sites for JAK2 and proteins 
containing SH2 domain.   
Growth hormone binding protein (GHBP), a glycoprotein, has been identified 
in all tissues examined in previous studies. However, the concentration of 
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GHBP in liver is 10 times more than in muscle and fat [130]. GHBP has been 
considered as the transporter and reservoir of plasmic GH. Corresponding to 
the extracellular domain of GHR, the GHBP can be produced by two different 
mechanisms dependent on the species analyzed: proteolysis of the 
membrane-bound GHR or alternative splicing of GHR precursor mRNA [21, 
277]. The GHBP can be generated by both mechanisms in monkeys [277].  It 
has been shown that up to 60% of plasmic GH is bound to the GHBP, 
indicating the physiological significance of GHBP [22]. In vitro studies have 
demonstrated the antagonistic effect of GHBP which competes with GHR for 
GH, thus restraining the GH action [272]. However, the antagonistic effect of 
GHBP is not observed in vivo, which may attribute to the prolonged half-life 
of GH by binding with GHBP. 
1.4.3.2 Growth hormone mediated signal pathways 
The GHR, like other members of the class I cytokine receptor family, lacks the 
intrinsic tyrosine kinase activity [222]. The signal transductions mediated 
through GHR rely on recruitment of receptor and non-receptor tyrosine 
kinases, among which JAK2 is the most important mediator of GHR signal 
transduction [13] (Figure 1-12), although several studies also identified the 
importance of JAK1 and JAK3 activities [202, 406]. In response to GH 
binding, the GHR dimer confers to conformational change, which enhances 
the binding affinity of JAK2 with GHR through the Box1 motif. Two 
molecules of JAK2 binding to the dimerized GHRs transphosphorylate and 
activate each other.  The activated JAK2, in turn, phosphorylates the tyrosine 
residues located at the intracellular domain of GHR, providing docking sites 
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for other signal transduction molecules [406]. Activation of JAK2 has been 
considered as the initial step of GHR mediated signal transduction [13].   
GH activated STATs (including STAT1, STAT3, STAT5A and STAT5B) 
through tyrosine phosphorylation regulates the transcription of several genes, 
involved into cell proliferation and apoptosis [192].  STAT5 is the 
predominant member utilized by GH. Phosphorylation and activation of 
STATs require JAK2 activation by GH [163, 453]. Studies have shown that 
STAT5 activation require the tyrosine phosphorylation of GHR intracellular 
domain, which provides the docking sites for STAT5 binding through the 
Src-homolog 2 (SH2) domain, suggesting that STAT5 directly binds with 
GHR [406, 413, 457, 459]. However, STAT1 and STAT3 do not exhibit the 
requirement of interaction with GHR and is thus likely that they directly 
interact with JAK2 rather than GHR [406, 413, 459]. Upon phosphorylated 
and activated by JAK2, the cytoplasmic STATs form homodimers or 
heterodimers, and translocate into nucleus, bind with DNA and regulate gene 
transcription [192, 392]. The GH-activated JAK2/STATs pathway is able to be 
switched off by a family of cytokine-inducible inhibitors of signaling (SOCS) 
in a negative feedback loop [119]. The SOCS family includes at least 8 
members (SOCS-1 to SOCS-7, and CIS), which have a conserved SH2 
domain, and SOCS box spanning approximately 40 amino acids at the 
C-terminus. SOCS genes can be rapidly but transiently induced for 
transcription by several cytokines and growth factors, including GH, through 
STAT dependent transcriptional activity [14, 280]. GH treatment induces 
rapid increase of SOCS-3 mRNA in F442 fibroblast cells. Meanwhile, SOCS-1, 
SOCS-2 and CIS are also upregulated, although to a less extent [5].   The 
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SOCS proteins negatively regulate JAK2/STAT signal pathways by multiple 
mechanisms. SOCS-1 directly associates with JAK2 and reduces the tyrosine 
kinase activity of JAK2 [119]; SOCS1 and CIS compete with STAT5 for the 
docking sites on the intracellular domain of GHR [415]; in addition, it has also 
been proposed that binding of CIS with GHR-JAK2 complex triggers GHR 
degradation in a proteasome-dependent pattern, which can be blocked by 
treatment of proteasome inhibitor MG132 [364].  
 
Figure 1-12 schematic representation of GH mediated signal pathways (Okada 
and Kopchick, 2001 [335]). 
Besides of activation of STATs, PI3-kinase and MAPK pathways, GH also activates 
protein kinase C (PKC), which regulates the insulin-like effects of GH as activated 
PI3-kinase pathway, as well as stimulates Ca
+
 uptake. 
Besides activating JAK2/STAT signal pathways, GH also activates the 
mitogen-activated protein kinases (MAPK) by JAK2 activation.  The tyrosine 
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phosphorylated GHR provides docking sites for the SH2 domain containing 
protein SHC, which is then phosphorylated by activated JAK2. The tyrosine 
phosphorylated SHC generates a binding site for the SH2 domain of growth 
factor receptor bound 2 (Grb2) proteins, which binds via its SH3 domain to the 
son of Sevenless (SOS) protein. The SHC-Grb2-SOS protein complex initiates 
activation of the small GTP binding protein Ras by the guanine nucleotide 
exchange activity of SOS. Ras then associates with and activates the 
serine/threonine kinase Raf, which eventually phosphorylates and activates 
MAP-ERK kinase (MEK), followed by phosphorylation and activation of 
ERK1 and ERK2 [453].  The activated MAPK pathway gets involved in 
GH-dependent gene expression. One example is that the transcription of c-fos 
gene requires activation of MAPK signal pathway in the GH-dependent 
transcriptional regulation [145].  
GH also activates the PI3-kinase pathway via the JAK2 activation. PI3-kinase 
is a downstream molecule of insulin receptor substrates (IRSs), which include 
IRS-1, IRS2 and IRS3. GH-mediated PI3-kinase activity is mainly associated 
with IRS-1 and IRS-2 [465]. IRS-1 is the major mediator of PI3-kinase 
activity. GH activated JAK2 phosphorylates IRS-1 proteins, which bind with 
PI3-kinase, thereby activating PI3-kinase leading to the insulin like effects of 
GH such as glucose uptake, glycogenesis, anti-lypolysis, and lypogenensis [63, 
336, 484, 487]. However, in IRS-1 deficient mice, tyrosine phosphorylation of 
IRS-2 is significantly elevated in comparison to wild-type mice [441].  
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1.4.3.3 Biological effects of growth hormone 
GH is the major endocrine regulator of postnatal growth, and cellular 
metabolism and differentiation. The GH promotes lypolysis, protein synthesis, 
and gluconeogenesis that represent the anti-insulin like effect of GH [51]. 
Administration of GH in patients with hyponitrogeenous diet improves the 
nitrogen equilibrium and prevents decline in the content of free amino acids in 
skeletal muscle [263]. In addition, GH treatment of catabolic patients can 
trigger hyperinsulinemia, lypolysis and ketogenesis, leading to decreased 
weight loss, retention of nitrogen, and increased free fatty acids and glycerol 
[273].  
GH exerts its postnatal growth and development effects either directly on 
targeted tissues or indirectly through the mediator of IGF-I which is mainly 
secreted from hepatocytes in response to the stimulation of pituitary GH [387]. 
Both GH and IGF-I modulate postnatal growth and development [235] 
through the “Dual Effector” theory which proposed that GH stimulates 
differentiation of precursor cells, and IGF-I stimulated by GH promotes 
proliferation of the differentiated cells [151]. For example, GH has direct 
effect in promoting the differentiation of cultured preadipocytes to adipocytes, 
and the newly differentiated adipocytes in response to GH are more sensitive 
to the mitogenic effect of IGF-I than the preadipocytes [505]. The hepatic 
IGF-I in circulation had been proposed to be the major mediator of GH in 
regulating growth and development. However, further studies had identified 
the existence of IGF-I and IGF-IR expression in all tissues examined, like 
mammary gland, adipose, and bone [35, 44, 351, 376, 405, 470]. Tissue 
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specific knock-down of IGF-I in liver, reducing the concentration of 
circulating IGF-I, did not affect normal postnatal growth[481]. Similarly, 
liver-specific deletion of IGF-I did not diminish the mammary gland 
branching morphogenesis [376].  
The aberrant secretion of GH is associated with several pathological 
conditions. Hyposecretion of GH is a disorder occurred in childhood or in 
adults, which can be caused by genetic aberrances or congenital 
malformations. GH deficiency in children can lead to dwarfism and delayed 
sexual maturity. In contrast, excess of GH secretion leads to gigantism, 
acromegaly and type II diabetes in adults [75]. High concentration of 
circulating GH and long-term exposure to exogenous GH replacement therapy 
increase the incidence of development of cancer, which will be discussed in 
the following section.  
1.5 Growth hormone and cancer 
The role of GH in cancer development and progress has been intensively 
investigated in animal models as well as humans. The association of GH/IGF-I 
axis and cancer development has been well established in animals and humans 
[480]. An early clinical study has demonstrated that hypophysectomy reduces 
the remission of metastatic breast and prostate cancers, suggesting a 
correlation between GH/IGF-I axis and malignant transformation in humans 
[262]. Elevated IGF-I in circulation has been linked to increased incidence of 
cancer developed in mammary gland, prostate, lung and colon in several 
epidemiological studies [228, 382, 480]. A genome-wide association study 
(GWAS) has determined 64 single nucleotide polymorphism sites (SNPs), 
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associated with susceptibility of lung cancer, of which 11 have been mapped 
to genes of the GH/IGF-I axis [382]. Epidemiological studies have also 
demonstrated the increased levels of serum GH in breast cancer patients [117].  
The GWAS has demonstrated GH signal pathway as the third most highly 
enriched pathway observed in breast cancer [290].  Together with the 
epidemiological studies, the genomic analysis implicates the tumorigenic 
potential of GH, which will be demonstrated in the following sections in 
animal models and humans.  
1.5.1 Animal studies 
The evidence that GH as an etiological factor in tumorigenesis has been 
demonstrated in numerous animal studies. Transgenic mice with 
overexpression of hGH exhibit higher incidences of breast cancer and liver 
cancer [407, 443]. The incidence of lymphosarcoma in rats injected with 
pituitary GH was much higher than in control rats in an early animal study 
[308].  The increased plasma GH concentration through administration of 
progestin in dogs and cats results in an acromegaly-like phenotype with the 
development of benign mammary tumors [304]. The production of GH is 
confined in the canine mammary gland. Further studies have demonstrated 
that systemic GH treatment induces mammary gland hyperplasia in aging 
rhesus monkeys [322]. Conversely, administration of SS, which suppresses 
pituitary GH secretion, significantly reduces mammary carcinogenesis in rats 
[379].  Furthermore, the GHR/BP knockout mice exhibit lower and delayed 
occurrence of fatal neoplasm, particularly lymphoma and adenocarcinoma 
compared with wild type littermates [193]. It has also been demonstrated that 
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the chemically induced liver tumors in lit/lit mice is much lesser than in their 
wild type counterparts [40]. The lit/lit mice carry a spontaneously 
homogenous missense mutation in GHRH receptor gene resulting in reduced 
secretion of GH and IGF-I. Several studies have also demonstrated that the 
spontaneous dwarf rat due to the mutation of GH gene is almost completely 
refractory to chemically induced mammary caricnogenesis. The tumor 
repressive effect is abrogated by administration of bovine GH in the dwarf rat, 
restoring mammary carcinogenesis to that of wild type counterparts [366, 395, 
438].  
Further transgenic studies with human tumor xenografts have elucidated the 
tumorigenic effects of GH/IGF-I axis in animal models. The tumor xenograft 
growth from a transplantation of human mammary carcinoma cell line MCF-7 
in lit/lit mice has been retarded compared with that in their wild type 
counterparts [492].  It has been proposed that the tumor suppressive effect is 
due to the reduced circulating IGF-I rather than GH, as mouse GH does not 
bind to the hGHR expressed in MCF-7 exnograft [49, 236]. Similar results 
have also been observed in studies on transplantation of five other human 
sarcoma cell lines in lit/lit mice [98]. Recent studies have provided valuable 
implication of disruption of GH signaling to abrogate estrogen independent 
breast cancer. The C3(1)/Tag mice are susceptible to develop estrogen 
receptor negative breast cancer. The development of mammary hyperplasia in 
GHR mutated C3(1)/Tag mice is delayed compared with that in C3(1)/Tag 
mice with wild type GHR gene [508]. Furthermore, several transgenic and 
xenograft studies have implicated the clinical potential of GHR antagonists in 
treatment of cancers. Mice transgenic for a GHR antagonist, hGH-G120R, are 
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smaller in size and body weight, have lower levels of circulating IGF-I, and 
exhibit resistant to chemically induced mammary tumors [355]. Accordingly, 
intraperitoneal administration of the commercial GHR antagonist Pegvisomant 
in mice carrying MCF-7 xenografts results in 70-80% decresse of circulating 
IGF-I levels, and causes shrinkage of MCF-7 xenografts associated with 
twofold decrease in proliferation and a twofold induction of cell apoptosis. 
However, Pegvisomant treatment has no effect on MDA-231 or MDA-435 
xenografts, which are IGF-I independent [102]. This study indicates that 
Pegvisomant inhibits growth of breast tumor xenografts in an IGF-I-dependent 
manner. A similar study with COLO205 colorectal cancer xenografts has 
demonstrated that Pegvisomant treatment remarkably reduces the size and 
weight of these xenografts with increased apoptosis. In addition, the 
Pegvisomant treatment reduces the expression of IGF-I in the COLO205 
xenografts [84].  However, the Pegvisomant treatment in nude mice 
harbouring human meningioma xenografts has suggested the direct effects of 
GH on this tumor. Daily Pegvisomant treatment of human meningioma 
xenografts induces tumor regression, accompanied by only 20% reduction of 
serum IGF-I levels in comparison to the control group. Besides that, the in situ 
expression of IGF-I and IGF-II are not detected in the meningioma xenografts 
[286].   
1.5.2 Epidemiological and clinical investigations 
Despite transgenic models strongly support the tumorigenic potential of GH, 
there have been few corresponding clinical evidence supporting this in humans. 
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Recently, however, accumulating clinical studies implicates the role of hGH in 
human malignancy.  
It  has been recognized for many years that hypophysectomy reduces the 
remission of metastatic breast and prostate cancers implicating a correlation 
between GH/IGF-I axis and malignant transformation in humans [262]. 
Several studies have also identified increased serum levels of hGH in breast, 
gastric, large bowel and lung cancer patients [117, 284, 445]. Numerous 
studies have demonstrated that increased circulating levels of hGH lead to 
elevated IGF-I expression which has been associated to malignant risk [211, 
228, 480]. In lung cancer patients, however, the inceased serum hGH and 
steady decreased serum IGF-I have been observed, compared with in normal 
controls [284]. The increased serum hGH may be caused by lost-negative 
regulation of pituitary secretion of hGH because of reduced serum levels of 
IGF-I in lung cancer patients, which implicates that hGH may get involved in 
malignant transformation in an IGF-I independent manner.  Consistently, the 
GWAS of over 1,000 breast cancer cases has identified the hGH/JAK2 
signaling pathway as the third most enriched pathway in breast cancer, rather 
than the polymorphisms in IGF-I gene [290].  
hGH has been identified as the main regulator of longitudinal growth and 
development. Increased birth weight, which is correlated with higher serum 
levels of hGH and IGF-I, is considered as an independent indicator of breast 
cancer risk [7, 294]. Numerous studies have also demonstrated the association 
between height and risk of breast cancer [7, 94, 160]. Similarly, a large-scale 
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cohort study has demonstrated that increasing adult height is positively 
associated with elevated incidences of cancer development in women [152].  
Several pathological conditions with disruption of GH/IGF-I axis also alter the 
incidences of cancer development. Acromegalic patients, characterized with 
hypersecretion of pituitary hGH and increased serum levels of IGF-I have an 
increased risk of developing breast, prostate and thyroid cancers [200]. A 
recent study has shown increased risk of developing colorectal cancer in 
acromegalic patients (2.46-fold) [374]. However, there is no statistical 
association of colorectal cancer risk with serum levels of IGF-I in the 
acromegalic patients, which implicated an IGF-I independent effect of hGH on 
cancer development in acromegaly. Conversely, a study has demonstrated that 
patients with Laron syndrome, characterized with deficiency of serum IGF-I 
do not develop cancer in the age range between 3 and 75, whereas 24% of 
their first and second degree family members have been reported with 
malignancies[397]. A 22-year study on Ecuadorian individuals, carrying 
mutations in the hGHR gene that lead to severe deficiencies of hGHR and 
IGF-I, has find that the individuals with hGHR deficiency do not exhibit lethal 
malignancy, whereas 17% of control subjects have been diagnosed with 
cancer development [158]. Given the effects of hGH on human malignant 
progression, it is thus not surprising to notice the potential risk of developing 
cancer in a cohort of patients receiving recombinant hGH (rhGH) treatment 
for several postnatal growth disorders. Although several studies have 
implicated no association between rhGH replacement therapy during 
childhood and tumorigenic risk during adulthood [17, 270, 319, 385], several 
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recent studies have observed that rhGH treatment increases the risk of 
developing secondary neoplasms [120, 319, 385, 404].  
1.5.3 Autocrine hGH and breast cancer 
Expression of GH has been identified in several extrapituitary sites, especially 
in mammary gland. Previous studies have shown the expression of autocrine 
hGH and hGHR in normal luminal epithelial and myoepithelial cells of human 
mammary gland [291, 292, 305, 362]. In addition, pathological analysis has 
demonstrated that in proliferative disorder of mammary gland the expression 
of hGH has been increased [362]. Furthermore, the de novo expression of hGH 
is found to be associated with the progression of mammary gland proliferative 
disorders. The metastatic mammary carcinoma cells express elevated hGH 
levels as compared to the normal mammary epithelial cells. This study has 
suggested a critical role for autocrine hGH in malignant transformation of 
human mammary gland. Consistently, a recent large-scale clinical study has 
demonstrated the association of in situ expression of hGH and clinical 
parameters in mammary carcinoma [472]. The expression of hGH mRNA and 
protein is positively associated with higher clinical stage and HER-2 positivity 
in mammary carcinoma. Besides that, hGH mRNA expression is correlated 
with lymph node metastasis. The Kaplan-Meier analysis has demonstrated that 
the expression of hGH implicates poor relapse-free survival (RFS) and overall 
survival (OS), compared with patients without in situ hGH expression [472].  
To determine the oncogenic effects of autocrine hGH, a well-established 
breast cancer cell model MCF-7 has been intensively investigated (Figure 
1-13). The non-invasive breast cancer cell line MCF-7 that harbours stable 
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transfection of hGH gene consecutively expresses hGH protein [208]. In this 
cell model, several studies have demonstrated that autocrine hGH increases 
MCF-7 cell proliferation and inhibits MCF-7 cell apoptosis [208, 515, 517].  
In addition, autocrine hGH also promotes cell proliferation of the 
immortalized human mammary epithelial cell line MCF-10A [515]. The 
autocrine stimulation of MCF-7 cell proliferation by hGH is independent of 
IGF-I as there is no detectable IGF-I expression in MCF-7 cells with forced 
expression of hGH gene [208]. In addition, it has been shown that the 
hyperproliferative stimulation of autocrine hGH is mediated through p38 and 
p44/42 MAPK singaling pathways. The specific p38 and p44/42 MAPK 
inhibitors abrogates the proliferative effect of autocrine hGH in MCF-7 cells 
[208].  The protection of MCF-7 cells from apoptosis by autocrine hGH is 
partially meidiated through the induced expression of C/EBP homologous 
protein (CHOP) by autocrine hGH [293]. Phosphorylation of CHOP by p38 
MAP kinase activates the CHOP-mediated transcription.  Furthermore, 
autocrine hGH activated p44/42 MAP kinase signaling pathway also protects 
MCF-7 cells from apoptosis. Autocrine hGH activated p44/42 MAP kinase 
stimulates the transcription of catalase gene, which protects cell from 




Figure 1-13 The oncogenic effects of autocrine hGH in mammary carcinoma 
(Perry, et al., 2006 [348]).  
Autocrine hGH exerts its effects on cellular proliferation, anti-apoptosis, 
immortalization, oncogenic transformation, and angiogenesis through multiple 
signaling pathways.  
Autocrine hGH confers the immortalized mammary epithelial cells MCF-10A 
anchorage-independent growth, a characteristic of oncogenic transformation 
[515]; and the oncogeic transformation of autocrine hGH is mediated by 
activated JAK2. The GH/JAK2 signaling transductions has been determined as 
one critical singal pathway in breast cancer [290]. When cultured in 
Matrigel
TM
, the MCF-10A cells form acinar structures resembling the 
mammary gland development, which is coordinated with mammary epithelial 
proliferation and apoptosis[97]. However, MCF-10A cells with hGH 
overexpression generate large disorganized acinar structures with filled lumina 
[515], due to increase expression of genes related to cell proliferation and 
anti-apoptosis such as c-Myc, Cyclin D1, Bcl-2. The xenograft analysis has 
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demonstrated that hGH only is sufficient to fulfil tumorigenic transformation 
of MCF-10A cells. Transcription of Homeobox protein A1 (HOXA1) gene 
induced by autocrine hGH has been determined to get involved in hGH 
mediated oncogenic transformation [509]. HOXA1 has been demonstrated to 
modulate the p44/42 MAPK and JAK/STAT signaling pathways [301, 302], 
and both signaling pathways get involved in HOXA1-mediated oncogenic 
transformation in human mammary carcinoma. HOXA1 upregulates 
transcription of GRB2 and MEK1 gene, thus increasing p44/42 MAP kinase 
activity [301]. Furthermore, HOXA1 also upregulates STAT3 and STAT5B 
mRNA as well as protein expression levels, resulting in enhanced 
transcriptional activation [302].  
   Autocrine hGH has also been shown to increase telomerase activity by 
upregulation of mRNA and protein levels of hTERT in human mammary 
carcinoma cells [116]. Together with the oncogenic transformation potential, 
hGH has been considered as “one-step” oncogene in human mammary 
carcinoma [350].  
Finally, autocrine hGH promotes the metastatic potential of mammary 
carcinoma cells by inducing phenotypic transformation and angiogenesis [39, 
315]. Autocrine hGH induces epithelial to mesenchymal phenotypic 
transformation (EMT) of MCF-7 cells. The EMT transformation is 
accompanied with altered expression of epithelial and mesenchymal marker 
genes. Autocrine hGH increases the expression of a mesenchymal marker 
vimentin. Simultaneously, the expression of epithelial marker plakoglobin is 
reduced. Although the mRNA and protein level of E-cadherin is not affected 
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by autocrine hGH, autocrine hGH induces relocalization of E-cadherin to the 
cytoplasm, thus disruption of cell junctions [315].  The in vitro functional 
assays have shown that overexpression of hGH enhances migration and 
invasion of MCF-7 cells. The increased invasiveness is mediated through 
upregulation of MMP2 and MMP9 by autocrine hGH [315]. The in vitro 
works have been confirmed by in vivo xenograft assay in nude mice. 
Autocrine hGH stimulates the local infiltration of MCF-7 xenograft, analogous 
to invasive ductal carcinoma. Angiogenesis is essential to the survival and 
growth of tumors, as well as facilitates metastatic dissemination of tumor 
cells[24, 47]. Autocrine hGH has been demonstrated to promote angiogenesis 
of mammary carcinoma [39]. Autocrine hGH enhances expression and 
secretion of VEGF-A from MCF-7 cells, which stimulates migration and 
invasion of human microvascular endothelial cells HMEC-1, concomitantly 
inducing tube formation in vitro. Moreover, the expression of hGH and hGHR 
has also been detected in HMEC-1 cells.  Autocrine hGH stimulated 
phenotypic conversion and angiogenesis facilitates metastasis of mammary 
carcinoma.  
1.5.4 Growth hormone and hepatocellular carcinoma 
GHR expression was first identified and characterized in liver [191].Through 
interaction with the GHR in liver tissue, pituitary GH stimulates expression of 
hepatic IGF-I, the major resource of circulating IGF-I. The pituitary GH and 
hepatic IGF-I together regulate somatic growth.  
Several animal studies have implicated aberrant GH signaling transduction in 
the development of HCC.  GH transgenic mice with high circulating levels of 
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GH exhibits significantly higher rate of spontaneous development of HCC 
[408] and carcinogen-induced HCC [407], due to increased hepatic 
proliferation and inflammation. In contrast, the lit/lit mice with mutated 
GHRH receptors are resistant to chemically induced hepatocarcinogenesis 
with sexual differences [40]. In humans, hGH has been implicated in the 
pathological progress of liver diseases. Patients with chronic liver disease 
exhibit increased serum levels of hGH and decreased circulating IGF-I, 
indicative of GH resistance [103]. In addition, increased circulating hGH has 
also been identified in HCC patients [391]. In situ hybridization (ISH) and 
immunohistochemical techniques have detected higher levels of hGHR in 
HCC tissues than in normal livers, and also demonstrated the localization of 
hGHR in the cytoplasm and nucleus [133]. In vitro studies have demonstrated 
that recombinant hGH (rhGH) treatment promotes the proliferation of hGHR 
positive human HCC cell line Bel-7402 [242]. In addition, rhGH treatment 
also induces expression of VEGF in Bel-7402 cells, indicating the hGH may 






Figure 1-14 In situ expression of hGH in HCC patient samples (unpublished 
data) 
A) In situ hybridization and immunohistochemical analysis of hGH expression in 
hepatic normal tissue and carcinoma ISH (upper panels) and IHC (lower 
panels)analysis demonstrated higher hGH expression in hepatocellular carcinoma 
tissue than in normal hepatic tissue on both mRNA and protein levels. B) hGH 
mRNA levels in fresh HCC and adjacent normal tissues detected by qPCR HCC 
samples expressed higher level of hGH mRNA than adjacent normal tissues. 
Although previous studies have demonstrated increased serum hGH in HCC 
patients as well as increased expression of hGHR in HCC tissues. The in situ 
expression status of hGH in HCC tissues and prognostic relevance are still 
unclear. Our group have recently investigated the expression of hGH in HCC 
patient samples (Figure 1-14). By using ISH and IHC techniques, we have 
identified that the mRNA and protein expression of hGH in HCC tissue 
specimens are higher than in the corresponding adjacent non-tumorous hepatic 
tissues. In addition, the qPCR assay analysing paired normal hepatic tissues 
and HCC samples demonstrate the elevated expression of hGH mRNA in 
HCC tumors.  The in situ expression of hGH mRNA is positively associated 
with larger tumor size and higher histological grade. The Kaplan-Meier 
analyses have demonstrated that HCC patients with high levels of tumor 
expressing hGH mRNA exhibit worse RFS and OS outcomes than patients 
with low tumor expressing levels of hGH mRNA. Based on the 
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clinicopathological investigation, further study is guaranteed to determine the 
oncogenic behaviours of autocrine hGH in HCC cells, and elucidate the 
potential mechanisms.    
1.6 Cancer stem cell 
In the past decades, the concept of cancer stem cell (CSC) has been developed 
from a hypothesis to real existence in hematopoietic and solid tumors.  
Tumor has been recognized as a heterogeneous structure, rather than a 
homogenous cell population sharing same genetic and phenotypical properties. 
A small portion of cells in tumor mass recapitulating the capability to 
reconstitute the heterogeneity of primary tumor has been termed as CSCs, 
which share several characteristics with the normal tissue specific stem cells. 
Recent studies have implicated that CSCs get involved in disease progression, 
recurrence, relapse, and therapeutic resistance. By gaining more knowledge on 
the properties of CSC, it may facilitate the development of novel therapeutic 
strategies to benefit patients suffering from the malignancy.  
1.6.1 Normal stem cells and their characteristics 
The existence of tissue specific stem cells was first identified in the bone 
marrow of mice, capable to differentiate into several haematopoietic lineages 
when transplanted into irradiated mice [440].  The identification of 
haematopoietic stem cells serves as a paradigm for the later development and 
identification stem cells in other tissues (for example, in the skin, fat, breast, 
liver, brain, lung, et al) [323]. Unlike the differentiated mature cells, the 
tissue-specific stem cells share two essential characteristics: long-term 
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self-renewal capability and differentiation into multiple cell lineages [85]. 
Stem cells maintain tissue homeostasis by tightly controlling the balance of 
self-renewal and differentiation according to milieu stimuli and genetic 
modifications. Self-renewal has been considered to be critical for maintain the 
stem cell pool in tissues. By dividing symmetrically or asymmetrically, the 
tissue-specific stem cells modulate and balance the stem cell pool and tissue 
homeostasis (Figure 1-15). In symmetrical division, one stem cell divides into 
two identical daughter cells, both acquiring the stem-like properties and 
resulting in expansion of stem cell pool. While in asymmetrical division, one 
daughter cell maintains the stem-like properties; the other daughter cell is a 
proliferating progenitor cell which will finally differentiate into tissue-specific 
mature cells to replace the apoptotic mature cells and maintain tissue 
homeostasis.   
The deviant behaviours of normal stem cells ascribed to carcinogen-induction, 
irradiation, and other environmental factors, lead to malignant transformation 
and tumor initiation. The aberrant tissue-specific stem cells are finally 
transformed into CSCs. In this regard, cancer can be considered as a stem cell 




Figure 1-15 Characteristics of normal stem cells ( Neuringer and Randell, 2004 
[321]) 
Stem cells exhibit two essential properties: self-renewal and differentiation. During 
self-renewal, the stem cell pool is maintained. The stem cells can also differentiate 
into amplifying progenitor cells, which will proliferate and finally differentiate into 
the nature cells to modulate the structure and function of tissues. 
1.6.2  The cancer stem cell hypothesis 
Accumulating studies in stem cell biology shed light on the understanding of 
tumor initiation and heterogeneity. The clonal evolution and CSC models are 
put forward to elucidate the initiation, progression and heterogeneity of 
cancers (Figure 1-16).  
The clonal evolution model proposes that tumor initiates from a single normal 
cell carrying mutations with selective growth advantage.  The gene mutations 
can be passed to daughter cells, which accumulate further gene alterations, and 
experience stepwise clonal selection. Eventually the daughter cells with 
selective advantages become the dominant population with capabilities of 
proliferation and tumor initiation (“tumor Darwinism”) [329]. According to 
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this model, clonal selection occurs throughout the lifetime of a tumor, and 
most of the tumor cells can potentially become invasive and lead to metastasis 
or become therapeutic resistance and lead to relapse [43]. The clonal evolution 
model is supported by findings that primary tumors, metastases and 
recurrences share similar patterns of genetic alterations within individual 
patients, which indicates that the tumor originates from a single cell. However, 
some genetic alterations in primary tumors and metastases are unique within 
individual patients, indicating the continuous mutations during stepwise clonal 
selection [428, 456, 468]. The clonal evolution model has also been supported 
by studies in various drug-resistant clones observed after cancer therapies [190, 
427].  
Despite the clonal evolution model has well explained the development of 
most cancers, there are several hurdles yet resolved. For example, the clonal 
evolution model has demonstrated the heterogeneous property of tumor, 
however further studies have shown that in addition to heterogeneity the tumor 
is also organized hierarchically, which cannot be explained by clonal 
evolution model. In addition, the accumulation of genetic alterations that 
finally initiates tumorigenesis needs a quite long period, which cannot be 
achieved in a few passages of cell division. The majority of mature cells in 
tissues are terminal differentiated with limited amplifying potential. Therefore, 
these mature cells are not possible to be the targets of oncogenic 
transformation.  
In the CSC model, tumor cells are organized in hierarchy where a very rare 
subpopulation of tumor cells acquires stem cell-like properties, called “cancer 
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stem cells”[466]. The CSCs share several characteristics with normal stem 
cells, including unlimited self-renewal and differentiation, and are responsible 
for tumor initiation, progression and recurrence. Unlike the clonal selection 
model which proposes that most of the tumor cells are capable of initiating a 
tumor, the CSC model demonstrates that only the rare CSCs in the tumor bulk 
acquire the capability to initiate a new tumor. The CSCs differentiate into 
multilineage of well-differentiated tumor cells, which constitute the hierarchy 
of tumor and comprise the tumor bulk. These well-differetiated tumor cells are 
incapable of self-renewal and tumor initiation. The existence of CSCs was 
firstly identified in acute myeloid leukaemia by xenotransplantation into 
immunodeficient mice [31, 230]. Further studies have determined the 
existence of CSCs in solid tumors, and identified several markers to isolate 
and enrich CSCs to analysis their functions and signaling transduction.  
Although clonal selection and CSC models explain tumor initiation differently, 
both models are not exclusive. Recent studies with advances in technologies of 
sequence and analysis have demonstrated the complementation of both models. 
With deeper sequencing and improved bioinformatic methods, it has been 
demonstrated that tumors are composed of a dominant genetic clone and 
several genetically distinct subclones [135]. The CSC model has proposed that 
the tumor originates from a normal stem cell which accumulated aberrant 
genetic alterations. However, the progeny CSCs from this deviated normal 
stem cell may suffer from different selective pressures from the 
microenvironment and accumulate distinctive genetic alterations, and finally 
recapitulate several subclones in the tumor with distinctive genetic scenarios 
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[226]. The heterogeneous genetic background of CSCs in the same tumor 
further facilitates drug resistance and recurrence.  
 
Figure 1-16 two models of tumor heterogeneity (adapted from Reya et al., 2001 
[375]) 
(a) The clonal selection model proposes that tumor can be initiated from any cell with 
accumulated genetic alterations; and most of the tumor cells are equally 
tumorigenetic. (b) The CSC model proposes that tumor is initiated from a CSC 
characterized with properties of self-renewal and differentiation. The CSCs 
recapitulate the capability of tumor initiation and reconstitute tumor heterogeneity 
and hierarchy.  
The exact origin of CSCs has yet determined, but three resources for CSCs 
have been proposed with accumulating support from recent studies (Figure 
1-17). The establishment of a stable malignant phenotype requires the 
accumulation of a series of genetic alterations induced by environmental 
factors, which unlikely happen within a few cell divisions that will deplete the 
well-differentiated cells of the proliferation potential. By contrast, the 
tissue-specific stem cells reserve the life-long self-renewal capability; and the 
progenitor cells also recapitulate the potential for differentiating into one or 
several lineages of tissue-specific mature cells. The long lifespan of 
stem/progenitor cells makes them the ideal targets for fully malignant 
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transformation [323].  Previous studies have demonstrated that a single 
mammary stem cell can recapitulate a completed functional mammary gland 
in vivo [394]. These stem/progenitor cells have been found to be highly 
susceptible to immortalization and transformation [157], suggesting they are 
the primary targets of mammary carcinogenesis. Gene expression profiling 
analysis in breast cancers have indicated that the “normal-like” or claudin-low 
subtypes of mammary carcinoma may originate in mammary stem cells; and 
the basal subtype may originate in luminal progenitor cells [246]. The third 
resource of CSCs is the well-differentiated mature cells undergoing 
dedifferentiation and acquiring the self-renewal capability. The definitive 
mechanism that promotes dedifferentiation of mature cells is still unclear. 
However, recent studies have demonstrated an avenue to “re-program” human 
somatic cells into pluripotent stem cells by expressing only four stem cell 
factors, suggesting the dedifferentiation process may not very complicated in 





consecutive EGFR activity enables astrocyte dedifferentiation, accompanying 
with high-grade glioma phenotype [15]. These observations implicate that the 




Figure 1-17 the origins of cancer stem cells (Goldwaite, 2006[143]) 
Three proposed origins of CSCs: 1, the accumulated genetic alterations in normal 
stem cells; 2, the genetic mutations occurred in progenitor cells; 3, dedifferentiation 
of well-differentiated cells acquiring stem-like properties. 
1.6.3 Existence of cancer stem cells in various cancers 
The pioneering work that proves the existence of CSCs in cancers has been 
fulfilled in patients with acute myeloid leukaemia (AML) [230]. Limiting 
dilution xenograft analysis has shown that the tumor initiating and 
self-renewal cells in AML patients exist in a very low frequency (1 in 250,000 
cells) in the peripheral blood of AML patients. The very rare sub-population 
of CSCs in AML patients has been characterized with cell surface markers 




 AML cells 







 cells) are incapable of inducing 
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leukaemia in SCID mice. In addition, the CSCs in AML patients share the 
same phenotypic patterns of CD34 and CD38 with the normal hematopoietic 
stem cells (HPSCs) suggesting that the CSCs in AML patients originate from 
HPSCs. Further study has also demonstrated that, like HPSCs, the CSCs in 
AML patients are able to differentiate into leukemic blasts in vivo 
recapitulating the hierarchy of leukaemia [31]. The self-renewal potential of 
CSCs in AML patients has been verified by serial xenotransplantation assays 
[31, 183].  
The pioneering studies in leukaemia have inspired further investigations to 
indentify the existence of CSCs in solid tumors.  The discovery of CSCs in 
breast cancer has been another hallmark for the CSC model. Al-Hajj et al. 
have characterized a rare subpopulation of CSCs in breast cancer patients 
based on the cell surface markers CD44 and CD24[9]. In vivo xenograft assay 




 cells are able to initiated 
tumor when inoculated into the fat pad of NOD/SCID mice, whereas 




 cells cannot induce tumors. In addition, 
this tumor-initiating subpopulation can be serially passaged in NOD/SCID 
mice and recapitulate the entire phenotypic heterogeneity of the initial tumor. 
Besides of breast cancer, the cellular surface mark CD44 has also been utilized 
to determine CSCs in other solid tumors including HCC, colorectal cancer [86, 
516], which indicates that the CSC markers have been widely shared among 
different types of solid tumors. Similarly, the cell surface marker CD133 has 
also been used to identify CSCs in HCC, glioma and colorectal cancer [132, 
330, 495]. Other cell surface markers have also determined to identify CSCs in 
a variety of solid tumors, such as CD90, CD26, CD13, and EpCAM, 
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suggesting that CSCs across various malignancies may share marker 
expression as well as biological characteristics.  
In addition to these cell surface markers, CSCs can also been isolated and 
enriched based on several other features. It has been believed that CSCs, as 
their normal counterparts, express higher level of ATP-binding cassette (ABC) 
transporter proteins, including ABCG2, which has been partially ascribed for 
the drug resistant property of CSCs [141]. The increased levels of ABC 
transporter proteins in CSCs restrict the intake of Hoechst 33342 dye 
compared with the non-CSC population, which has been defined as side 
population (SP). The tumor initiating potential of SP has been intensively 
investigated in a variety of solid tumors [68, 179, 344]. CSCs have also been 
identified in suspension culture, as well as by determining the activity of 
Aldehyde dehydrogenase [138, 356].  
Although several markers have been determined to identify and enrich CSCs 
in a variety of solid tumors, the definition of CSC is still based on the tumor 
initiating potential in xenograft transplantation. To date, there is no perfect 
approach to identify the CSC population in a specific tumor. More recent 
studies have demonstrated that even in a specific tumor the CSC population is 
heterogeneous [226].  In primary breast cancer tissue two different 
subpopulations of CSCs have been characterized by distinct expression of 




 CSCs exhibits mesenchymal 
phenotype and gene expression profile with high invasive potential, whereas 
the ALDH1+ CSCs exhibits epithelial phenotype and gene expression profile 
with intensive proliferation. Furthermore, the CSCs display a cellular 
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plasticity that enables them to transit between epithelial and mesenchymal 
states, which may be regulated by tumor microenvironment [255].  
1.7 Metastasis 
Metastasis is one of the main cause of cancer-related death due to resistance of 
disseminated tumor cells to conventional therapeutic strategies, accounting for 
90% of mortality from cancer [53, 383]. Thus, prevention of metastatic 
dissemination may propose an effective strategy to alleviate cancer-associated 
morbidity and mortality.  
Metastasis is a succession of multistep events, termed invasion/metastasis 
cascade [451]. The primary tumor cells fulfil the establishment of metastatic 
lesions by executing the following sequence of steps: invade into the 
surrounding tissues through extracellular matrix (ECM); enter into the lymph 
and blood microvasculature (intravasation); survive and transport to the distant 
organ sites through microvessels; exit from the blood vessels and seed into the 
parenchyma of distant tissues (extravasation); and finally survive in the 
metastatic sites and reinitiate macroscopic secondary tumor (colonization) 
(Figure 1-18). This multistep progression has been regulated by molecular 




Figure 1-18 The invasion/metastasis cascade (Valastyan and Weinberg, 2011 
[451]) 
Formation of clinically detectable macroscopic metastasis represents a complex 
process. During metastasis, tumor cells dissociate from the primary tumor and invade 
into surrounding stroma, followed by intravasation, survival in the systematic 
circulation, extravasation, and formation of macrometastasis.  
More than 80% of life-threatening cancers arise in epithelial tissues that are 
well organized by lateral cell-cell adhesion complex and separated from 
surrounding stroma by a basement membrane.  During the invasive 
transformation, the primary carcinoma cells must breach the basement 
membrane barrier in order to invade into surrounding stroma. The process of 
EMT has been suggested to be involved into this malignant transformation [70, 
435].  During EMT the adherens and tight junctions that maintain the 
tight-organized epithelial sheets, have been disrupted. Meanwhile, the 
epithelial cells lose cellular polarity, and acquire a more motile and invasive 
mesenchymal morphology [436].  The process of EMT has involved into the 
formation of multiple tissue types during early embryonic morphogenesis 
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[328], as well as tissue regeneration during wound healing [205]. In recent 
years, myriad of studies have demonstrated the involvement of EMT in 
malignant transformation [435]. EMT is defined by deregulation of cellular 
adherent proteins, with downregulation of epithelial proteins, such as 
E-cadherin, occludin, claudins and catenin proteins; and upregulation of 
mesenchymal proteins, including N-cadherin, vimentin, lamentin β1 as well as 
tenascin C [70, 199]. The best characterized event in EMT process is the loss 
of E-cadherin, the prominent element of assembling epithelial cell sheets and 
maintaining its integrity. Loss of E-cadherin has been frequently observed in 
human carcinoma, strongly supporting its role as a key suppressor of EMT 
process [27, 52].  The EMT process has been induced by a number of 
singaling pathways, including the transforming growth factor β (TGF- β) [503], 
Receptor Tyrosine Kinases (RTKs) [3, 149, 259, 389], WNT [187], NOTCH 
[278], and NFκB [186]. These signal pathways regulate the transcription of 
EMT marker through a panel of pleiotropically acting transcription factors, 
such as the snail family (Slug and Snail), ZEB family (ZEB1 and ZEB2), and 
TWIST [19, 45, 78, 110, 187, 489].  In addition, certain miRNAs also 
regulate EMT programs. For example, the miR-200 family members promote 
the epithelial phenotype through posttranscriptionally inhibiting expression of 
ZEB1 and ZEB2 [153].  Some of these transcription factors repress 
expression of E-cadherin by directly binding to the promoter region of 
E-CADHERIN gene [435]. Besides of increasing the motility and invasiveness 
of carcinoma cells, EMT also promotes metastasis through remodelling 
extracellular matrix (ECM). The carcinoma cells undergoing EMT have 
devised numerous ways to increase the activity of maealloproteinases (MMPs) 
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[199], which cleave the ECM components like laminin 5 and collagen IV. 
ECM degradation by MMPs also releases mitogenic and angiogenic factors 
sequestered by the ECM, stimulating invading carcinoma cell proliferation and 
angiogenesis [137, 475]. Once penetrating the ECM, invading carcinoma cells 
enter the stroma, and encounter a variety of tumor-associated stromal cells, 
including fibroblasts, myofibroblasts, endothelial cells, adipocytes, 
mesenchymal stem cell recruited from bone marrow, and several types of 
immune cells including tumor-associated macrophages [204]. The invasive 
carcinoma cells have tamed the stroma cells, which reciprocally enhance the 
invasive behaviours of carcinoma cells.   
Entry into the stroma provides plenty opportunities for tumor cells to access 
the circulating system and disseminate to distant sites. Intravasation is 
characterized by entry of locally invasive tumor cells into lymphatic and blood 
vessels, facilitating distant dissemination of invasive tumor cells [161].  
Several signaling pathways that stimulate cell motility and invasiveness also 
promote intravasation. Intravasation of mammary carcinoma cells has been 
promoted by TGF-β, EGF, and colony-stimulating factor-1 (CSF-1) [136, 473, 
474]. In addition, the neovasculature generated by carcinoma cells within the 
local microenvironment also facilitates intravasation.  Unlike the vasculature 
in normal tissue, the neovasculature in local invasive carcinoma is highly 
permeable and under continuous reconfiguration [48].  Once entry into the 
blood vessels, the circulating tumor cells (CTCs) must survival from  aniokis,  
hemodynamic shear forces and immune surveillance before reaching the 
distant metastatic sites. One study has demonstrated that tyrosine kinase TrkB 
suppresses aniokis of CTCs during metastatic progression [109]. The display 
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of tissue factors and L- and P-selectins on the surface of CTCs attracts shroud 
of aggregating platelets, shielding CTCs from shearing damage and escaping 
from immune surveillance [41, 327].  
Once lodged in the blood vessels of distant metastatic sites, CTCs may 
immediately start intraluminal proliferation to form microcolony which 
eventually disrupts the surrounding walls of microvessels, and subsequently 
has directly contacts with the foreign tissue parenchyma. Alternatively, the 
CTCs penetrate the endothelial walls and the pericyte layers of the 
microvessels and invade into the tissue parenchyma, a process termed as 
extravasation [196, 386, 469].  Unlike the neovasculature derived from the 
primary tumor, the microvessels in the normal distant tissues are 
well-organized with high intrinsic permeability. CTCs have evolved several 
mechanisms to overcome the physical barrier. The secreted protein 
angiopoietin-like-4 (Angptl4) from primary breast cancer remodels the 
microenvironments of lung, thus enhancing the vascular permeability and then 
facilitating extravasation of CTCs into pulmonary parenchyma [337]. 
However, failure of Angptl4 to enhance extravasation of the same breast 
cancer cells in bone indicated that extravasation is a cell-biological program 
requiring specific modification in certain distant tissues [337]. Moreover, the 
recruitment of inflammatory monocytes to the metastatic sites depending on 
CCL2 secretion from tumor and stroma, reciprocally drives extravasation of 
human breast cancer cells in lungs [360].  
Before successful colonization in the distant metastatic sites, extravasated 
carcinoma cells first need to survive in the foreign microenvironment that is 
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greatly different from the site of primary tumor formation. A “premetastatic 
niche” model has been proposed to address the incompatibility of 
microenvironment at the metastatic site [359]. According to the “premetastatic 
miche” model, the systematic signals released from primary tumor remodel 
the microenvironment of metastatic site into a more hospitable site for future 
seeding of disseminated carcinoma cells prior to their arrival. In human breast 
cancers, the hypoxia-induced lysyl oxidase (LOX) from primary tumors 
crosslinkes collagen IV in the basement membrane of lung, which in turn 
leads to the mobilization of bone marrow-derived cells (BMDCs) to the 
metastatic site. The recruited BMDCs remodel the metastatic site through 
secreting MMP2 and MMP9, which facilitate seeding of metastatic breast 
cancer cells in lung [121].  Meanwhile, the disseminated cancer cells must 
adapt to the foreign microenvironment for persisting viability [510].  
Even the disseminated cancer cells survival in the foreign microenvironment 
of metastatic sites to form micrometastases, the establishment of macroscopic 
secondary tumor is not guaranteed. The micrometastases may present in a state 
of long-term dormancy before accumulating enough genetic and epigenetic 
alterations to facilitate the establishment of macrometastases [54]. 
Alternatively, the micrometastases maintain a counterbalance between 
continuous proliferation and apoptosis because of the limitations in the foreign 
environment [54].  The micrometastases evolve several mechanisms to 
convert the foreign microenvironment into a more hospitable niche, and in 
turn promote the establishment of macroscopic metastases. The recruitment of 
BMDCs into metastatic sites has been demonstrated to promote the 
establishment of macrometastases [121].  Moreover, angiopoietin-2 (ANG2) 
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promotes the vascularisation capability of tumor-infiltrating myeloids in 
mammary and pancreatic cancers, which in turn facilitates metastatic 
colonization [24].   
Taken together, metastasis is a complex multistep process, requiring the 
continuous alterations in cancer cells and microenvironments.  
1.8  Project rationale 
This thesis focuses on investigating the oncogenic effects of autocrine human 
growth hormone in estrogen receptor negative breast cancer (ER-BC) cells and 
hepatocellular carcinoma (HCC) cells.  
Numerous studies have demonstrated the contribution of hGH in tumor 
progression. Previous studies in our group have demonstrated the oncogenic 
effects of autocrine hGH in ER+BC cells and endometrial carcinoma cells. 
autocrine hGH has been demonstrated to promote cell proliferation, cell 
survival, EMT, local invasion and angiogenesis in MCF-7 cells. ER-BC 
represents a subtype of aggressive breast cancer with limited therapeutic 
options. ALDH1 has been identified as a CSC marker, associating with tumor 
metastasis and ER- status in breast cancer. Our clinical investigation in a 
cohort of 24 ER-BC patients’ samples has demonstrated a positive 
correlationship between hGH expression and ALDH1 expression. It should be 
reasonable to postulate that autocrine hGH may regulate the CSC-like 
properties and promote metastasis of ER-BC cells. In this thesis, I will 
determine the effects of autocrine hGH on CSC-like properties, migration and 
invasion of ER-BC cells in vitro. Furthermore, the tumor-initiating and 
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metastatic effects of autocrine hGH in ER-BC cells will be determined by 
xenograft assays.  
Despite advances in the diagnosis and treatment of HCC, the long-term 
survival is still unsatisfactory due to the high incidence of metastasis and 
recurrence. We have recently observed increased mRNA and protein 
expression of hGH in HCC tumor tissues compared with normal liver tissues. 
hGH expression was significantly associated with tumor size and tumor 
histological grade. In addition, tumour expression of hGH associates with poor 
clinical outcomes in HCC patients (have been done in collaboration with Dr. 
Wu Zheng-Sheng). The clinicopathological analysis has implicated the 
oncogenic effects of autrocrine hGH in HCC development. The purpose of my 
current study is to investigate the oncogenic behaviours of autorcine hGH in 
HCC cells, and elucidate the potential molecular mechanisms using 
established HCC cell models with hGH overexpression. Hopefully my study 
could lead to novel therapeutic option to improve the clinical outcomes of 







CHAPTER 2 Material and methods  
2.1 Buffer preparation 
 Phosphate buffered saline (PBS) ( 2.7mM  KCl, 137mM  NaCl, 
1.4mM  KH2PO4, 4.3mM  Na2HPO4, pH 7.4) 
 TE Buffer (10mM Tris-HCl, 1mM EDTA, Ph 8.0) 
 Bacteria Culture 
o LB broth (0.5% (w/v) Bacto-yeast extract, 1% (w/v) 
Bacto-tryptone, 0.5% (w/v) NaCl, Ph 7.0) 
o LB agar (0.5% (w/v) Bacto-yeast extract, 1% (w/v) 
Bacto-tryptone, 0.5% (w/v) NaCl, 2% (w/v) Bacto-agar) 
 DNA agarose gel electrophoresis 
o 1X TBE (100mM Tris, 90mM Boric Acid, 1mM EDTA) 
o 6X Sample loading dye (0.25% (w/v) Xylene cyanol, 0.25% 
(w/v) Bromophenol blue, 30% (v/v) glycerol) 
 SDS-PAGE and Western blot 
o 1.5M Tris, pH 8.8 (0.4% (w/v) SDS, pH adjusted to 8.8 with 
37% (w/v) HCl) 
o 0.5M Tris, Ph 6.8 (0.4% (w/v) SDS, pH adjusted to 6.8 with 
37% (w/v) HCl) 
o 1X SDS-PAGE Running buffer (25mM Tris base, 920 mM 
Glycine, 0.1% (w/v) SDS) 




o 1X TBS-T buffer (50mM Tris.HCl, pH 7.4, 150mM NaCl, 0.1% 
(v/v) Tween-20) 
o Blocking buffer (3% (w/v) Bovine Serum Albumin (BSA) in 
1X TBS-T buffer) 
o 5X Loading Dye (250mM Tris-HCl, pH 6.8, 500 mM DTT, 
0.25% Bromophenol blue, 50% Glycerol, 10% SDS ) 
 SDS- PAGE gel 
o 12% Resolving gel 
 dH2O  3.3ml 
 30% Acrylamide 4.0ml 
 1.5M Tris (pH 8.8) 2.5ml 
 10% SDS 0.1ml 
 10% APS 0.1ml 
 TEMED 0.004ml 
o 5% Stacking gel 
 dH2O  6.8ml 
 30% Acrylamide 1.7ml 
 0.5M Tris (pH 6.8) 1.25ml 
 10% SDS 0.1ml 
 10% APS 0.1ml 
 TEMED 0.01ml 
 Protein extraction 
o 1X RIPA buffer (50mM Tris at pH 7.5, 150mM NaCl, 1% 
(v/v) TritoX100, 0.1% (w/v) SDS, 0.5% Na-Deoxycholate. 
Protease inhibitor cocktail (Sigma-Aldrich, MO, USA) and 
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phosphatase inhibitor (Sigma-Aldrich, MO, USA) were added 
freshly before use) 
 Measurement of cell viability 
o 5mg/ml MTT Solution (5mg MTT powder was dissolved in 
1ml 1X PBS and filtered) 
2.2 Cell lines and culture conditions 
Cell lines used in this study were chosen based on the expression status of 
hGH and hGHR. All cell lines chosen in this study are hGHR positive. 
MDA-MB-453 and SKBR3 breast cancer cells were purchased from American 
Type Culture collection (ATCC, Manassas, VA, USA). The liver cancer cells 
HepG2, Huh7, Hep3B, and normal hepatic cell LO2 were purchased from the 
institute of Virology, Chinese Academy of Medical Sciences (Beijing, China). 
Media and supplements were obtained from Hyclone (Logan, UT, USA) 
unless otherwise indicated. MDA-MB-453 cells were maintained in Leibovitz 
L-15 medium. SKBR3 cells were maintained in McCoy’s 5A medium. LO2 
and all of these liver cancer cells were maintained in DMEM medium.  All of 
these media were supplemented with 10% heat inactivated fetal bovine serum 
(FBS). These cells were cultured in a 37℃ incubator with 5% CO2. These 
cells were subcultured in 25 cm
2
 or 75 cm
2
 flasks (NUNC, NY, USA) every 
two days with a passaging ratio of 1:5 or 1:3. For setting up experiments, cells 
were resuspended from flasks by trypsinization, and span down by 
centrifugation at 500rpm. Cells were resuspended in fresh medium and 




2.3.1 Small-interfering RNA (siRNA) transfection 
Cells were seeded at a concentration of 2x10
5
 cells/well in a 6-well plate at 24 
hours before transfection. The transfection reagent used is Lipofectamine 
RNAiMAX (Invitrogen Life Technology, Grand Island, NY) according to the 
manufacturer’s instructions. 1h prior to transfection, cells was changed to 
Opti-MEM media (Invitrogen, Life Technologies, Grand Island, NY) without 
antibiotics. Lipofectamine RNAiMAX and siRNAs were separately diluted 
into 100µl Opti-MEM media for 5min before mixing together for another 
15min of incubation. The mixture were subsequently added to the cells and 
returned back to incubator for 6h. After that, the media was removed, and cells 
were supplemented with fresh complete growth media for another 24h before 
harvesting these cells for functional assays or protein and RNA extractions. 
For CLDN1 siRNA transfection, the final concentration of siRNA is 25nM.  
2.3.2 siRNA oligo 




Scramble siRNA (ambion, Life Technologies, Grand Island, NY) 
2.3.3 Plasmid constructions 
The hGH expression plasmid, pcDNA3.1-hGH was previously constructed by 
our lab staff. The constructions of constitutively active STAT3 (STAT3CA), 
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dominant-negative STAT3 (STATDN), and small interfering RNA targeting at 
STAT3 (siSTAT3) were previously described [429]. The wild type CLDN1 
promoter-driven luciferase reporter plasmid was a kind gift from prof. 
Yoshiaki Ito (Cancer Science Institute of Singapore, National Univeristy of 
Singapore) [55]. Based on this wild type CLDN1 promoter-dreiven luciferase 
reporter plasmid, I constructed the STAT3-binding site mutated CLDN1 
promoter-driven luciferase reporter plasmids using QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Three 
STAT3-binding sites had been identified in the CLDN1 promoter region. The 
forward primers used to construct the mutated CLDN1 promoter-driven 
luciferase reporter plasmids are as following: M1, 5’-ACACGAACATGGTC 
TTGTCCTCCCCAGCTGATAGGAGAAAGACAG-3’; M2, 5’-ATCAAAG 
GGGATATTTTGGGTCCCCTTGATATGTAGTGGAAAGCAG-3’; M3, 
5-GACAAGTGATGGAACGACCGGGACAGAAGAGAGCAGAGAG-3’. 
The mutated STAT3 binding sites are highlighted in these primer sequences. 
All constructs were confirmed by DNA sequencing to make sure there are no 
PCR-generated artifacts.  
To construct a CLDN1-expression plasmid, the CLDN1 gene was amplified 
from the cDNA of normal hepatic cells LO2 using the following primers: 
forward, 5’- GGATCCATGGCCAACGCGGGGCTG-3’; reverse, 5’- GCGG 
CCGCTCACACGTAGTCTTTCCCGCTGGAA-3’. The amplified DNA 
segment was cloned into the pIRESneo3 vector (Clontech Laboratories, 
Mountain View, CA) between the BamH I and Not I restriction sites.  The 




2.3.4 Transient transfection 
For transient plasmid transfection, the transfection reagent FUGENE6 
(Promega, Madison, WI) was used. Cells were plated into 6-well plate with a 
confluence of 30-50% 24h before transfection. The optimal ratios of 
FUGENE6 and plasmid DNA were 4µl:1 µg. One hour before transfection, 
the cells were changed to serum-free media. For each well of the 6-well plate, 
4µl FUGENE6 was added into 100 µl serum-free media in an eppendorf tube, 
and incubated for 5min at room temperature before adding 1µl plasmid DNA. 
This reagent and DNA mixture was incubated for 15min at room temperature, 
and subsequently added directly into each well in a dropwise manner. 
Following 6h incubation at 37°C, the serum free media was removed and 2ml 
of complete media was replenished into each well. After 24h of transfection, 
the transfected cells were applied to functional assays or RNA and protein 
extractions. 
2.3.5 Construction of stable cells 
For stable construction of hGH overexpression cells, the pcDNA3.1 vector and 
pcDNA3.1-hGH plasmids were used. The wild type cells (including 
MDA-MB-453,SKBR3, Huh7, HepG2 and Hep3B cell lines) were seeded into 
25 cm
2
 flasks with a confluence between 30% to 50%. The transfection 
procedure was similar as transient transfection. After 24h of transfection, the 
transfected cells were selected using complete media supplemented with G418 
(Sigma-Aldrich, MO, USA) at different concentrations, based on the cell lines 
used (MDA-MB-453, 800 µl/ml; SKBR3, 1000 µl/ml; Huh7, 900 µl/ml; 
Hep3B, 500 µl/ml; HepG2, 800 µl/ml). The media was changed every four 
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days. After one month of selection, all of the non-transfected cells were dead. 
The stably transfected cells were trypsinized and seeded into 225 cm
2
 flasks 
for expansion. Once cells got confluent, they were stored into liquid nitrogen 
for further works.  
2.4 Functional assays 
2.4.1 Total cell count assay 
Cells were plated into a 6-well plate at 1×10
4
 cells per well (The cell densities 
varied based on the experimental purposes or cell lines used) and maintained 
in complete media at a 37°C 5% CO2 incubator. The cells were trypsinized 
and counted using a haemocytometer every two days over a period of ten to 
twelve days. The assay was set up in triplicate.  
2.4.2 MTT cell viability assay 
To assess cell viability, the MTT assay was applied. Cells were seeded into a 
96-well plate at a density of 5×10
3
 cells per well. After treatment, the media 
was removed. In each well with 100 µl fresh complete media, 10 µl of 5mg/ml 
MTT solution was added. After incubation for 4h at 37 °C the blue formazan 
crystals were apparent. One hundred microliter 10%SDS-0.01M HCl solution 
(HCl was freshly added before experiment) was added into each well and the 




2.4.3 Bromodeoxyuridine (BrdU) incorporation assay 
The cell cycle was directly assayed by using BrdU cell Proliferation Assay Kit 
(Millipore, Bedford, MA) to measure the BrdU incorporation. 
BrdU Labelling Cells were seeded in triplicate in 96-well plate at a density of 
5×10
3
 cells per well.  After 48h of incubation in 5% CO2 incubator at 37°C, 
the media was removed. Meanwhile, the BrdU stocking solution was diluted 
500 times into fresh complete media. 100 µl of diluted BrdU solution was 
added into each well. One well of cells was added with 100 µl fresh media 
without BrdU as background control. The plate was then returned back to the 
5% CO2 incubator at 37°C, and incubated for 2-24h.  
Fixation After incubation of 2-24h, the media was removed and 200 µl Fixing 
Solution was added into each well. The plate was placed at room temperature 
for 30min. The fixed cells may be store at 2°C to 8°C for upto one month.  
Wash The 50×Wash Buffer was diluted in distilled water. Fixing Solution was 
removed from each well. The wells were completely filled with wash buffer. 
The wash buffer was aspirated and the blot was dried on paper towels. The 
plate should be washed three times thoroughly.  
Incubation with primary and secondary antibodies 100 µl of preliluted mouse 
anti-BrdU antibody solution was added into each well, and incubated at room 
temperature of 1h. After 1h of incubation, the primary antibody was removed, 
and the plate was washed thrice according to the washing step described above. 
Subsequent to washing, 100ul diluted Peroxidase Conjugated Goat anti-Mouse 
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IgG solution was added into each well, and incubated at room temperature for 
30min. Following secondary antibody incubation the plate was washed by 
using wash buffer for three times firstly, and then the plate was washed by 
flooding distilled water. Finally, the plate was patted dry on paper towels.   
Adding substrate and stop solution one hundred microliter TMB Peroxidase 
Substrate was added into each well, and incubated for 30min at room 
temperature in the dark. After that, 100 µl of acid Stop Solution was added 
into each well to terminate the reaction. The absorbance was measured at 
450nm using a spectrophotometer microplate reader.  
2.4.4 Caspase 3/7 activity assay 
To determine cell apoptosis, the Caspase3/7 activity was measured using the 
Caspase-Glo
®
 3/7 Assay Kit (Promega, Madison, WI) as described in the 
manufacturer’s protocol. Cells were seeded into 96-well plate at a density of 
5×10
3
 cells per well. After 24h of culture, the cells were washed by 
pre-warmed PBS three times and then changed to 100µl serum free media for 
another 24h of culture. Then 100 µl Caspase-Glo
®
 3/7 reagent was added into 
each well (Blank: a well added with 100 µl serum free media and 100 µl 
Caspase-Glo
®
 3/7 reagent; Background: cells were present in a well, but 
without Caspase-Glo
®
 3/7 reagent) and the plate was incubated at room 
temperature for 30min-3h in the dark. The luminescence was determined using 
a spectrophotometer microplate reader.  
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2.4.5 Colony formation in soft agar 
To investigate the oncogenic transformation potential of hGH in vitro, the soft 
agar assay was used.  
Each well of a 96-well plate was coated with 0.5% agarose in serum free 
media. DNA grade agarose was dissolved into serum free media with a 
concentration of 0.5% (w/v), and then 100 µl of 0.5% agarose gel was added 
into each well and left to set at room temperature for 30min. The coated plate 
can be stored at 4°C for as long as one month. A 0.7% (W/V) DNA grade 
agarose was dissolved in serum free media and incubated in a heat block at 
42°C. at 42°C, the cell viability was maintained and meanwhile prevent 
polymerisation of the agarose. Cells were trypsinized and resuspended into 
serum free media. The suspended cells were filtered through 40 µl cell strainer 
(BD Biosciences, San Jose, CA) to achieve a single-cell suspension. The same 
volumes of cell suspension and warmed 0.7% agarose was mixed to reach a 
final concentration of 1000 cell per 100 µl. the mixture was added into each 
well of pre-coated plate (100 µl per well). The plate was left in 37°C incubator 
for 1h to allow agarose to set, and then 100 µl complete media was added to 
each well. The media was changed every two days for 12-14 days. At the end 
of this experiment, each well was taken a picture under the bright field 
microscopy and the colony number was counted. Each experiment was 
performed in triplicate.  
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2.4.6 Three-dimensional culture in MatrigelTM 
The growh factor reduced Matrigel
TM
 was purchased from BD Biosciences 
(San Jose, CA). The Matrigel
TM 
was stored at -20°C, and thawn at 4°C before 
use. The 96-well plate was coated with 100% Matrigel
TM
 (50µl per well) and 
incubated at 37°C for 30min to allow solidification of the basement membrane. 
In the meantime, cell were trypsinized and resuspended into 5ml complete 
media, and centrifuged at 500rpm for 5min. Then the supernatant was 
aspirated, and cells were resuspended in 2ml serum free media. The suspended 
cells were filtered through 40 µl cell strainer to obtain a single-cell suspension. 
Cell number was determined using a haemocytometer. Cells were mixed with 
4% Matrigel
TM
 in 5%FBS media to ensure a final concentration of 10
4
 cells 
per ml (4% Matrigel
TM 
is the final concentration). 100 µl of the 4% Matrigel
TM
 
cell suspension was added into each well pre-coated with 100% Matrigel
TM
. 
Cells were cultured in a 5% CO2 humidified incubator at 37°C for 10 to 14 
days. The 5%FBS media containing 4% Matrigel
TM
 was added to the wells 
every two days. At the end of this experiment, the cell viabilities were 
determined by MTT assay as previously described.  
2.4.7 Wound healing assay 
Cells were cultured in a 6-well plate until 100% confluence. Three 
perpendicular equal straight artificial wounds were drawn using a pipette tip 
followed by several gentle washes with serum free media in order to remove 
floating cells. Cells were then maintained with 5%FBS media. Pictures were 
then taken at 0, 24, 48 and 72h after drawing the wounds.  
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2.4.8 Migration and invasion assays 
To determine the migrating and invasive potentials of cancer cells, 
migration/invasion assays were performed using BD cell culture inserts (BD 
Biosciences, San Jose, CA) with a pore size of 8µm. for invasion assay, the 
inserts were first coated with 10% Matrigel
TM
 diluted in serum free media.  
Cells (10
4
 cells for migration assay, 2×10
4
 for invasion assay) were seeded 
with serum free media in the upper chamber of the insert, while complete 
media (500 µl) was added in the bottom well as chemoattractant.   
After 48h of culture, the media in the upper chamber and bottom well was 
removed, and cells were fixed using cold methanol at -20°C for 5min. the 
non-migrated and non-invaded cells were swabbed away. The inserted was 
washed using PBS for 3 times. And then the migrated and invaded cells were 
stained using 5ug/ml Hoechst dye (Sigma-Aldrich, MO, USA) at room 
temperature for 15min in the dark. After rinsing with PBS, the cell number 
was counted under fluorescent microscopy.  
2.4.9 Suspension culture (Mammosphere in breast cancer and 
hepatosphere in HCC)  
To determine the CSC-like properties, these cancer cells were cultured in a 
suspension system as previously described in other publication [104]. 
Monolayer cells were trypsinized and carefully resuspended in the CSC 
growth meida, which is Dulbecco’s Modified Eagle’s Meidim F12 (Invitrogen, 
Life Technology, Grand Island, NY) supplemented with 20ng/ml recombinant 
human EGF (Sigma-Aldrich, MO, USA), 20ng/ml recombinant human basic 
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FGF (BD Biosciences, San Jose, CA), 2% B27 (Invitrogen, Life Technology, 
Grand Island, NY), penicillin-streptomycin (Invitrogen, Life Technology, 
Grand Island, NY), and 5µg/ml bovine insulin (Sigma-Aldrich, MO, USA). 
Suspended cells were passed through a 40µm cell strainer to assure single-cell 
suspension. The single-cell suspension were plated in ultra low attachment 
96-well plate (Corning Life Sciences, Tewksbury, MA) at a density of 
100cells per 100 µl. subsequent passages were grown as the same density, and 
the colony number was counted as described previously [104]. For B2036 
treatment, the parental MDA-MB-453 and SKBR3 cells were treated by 
B2036 at the concentrations of 1000nM, 3000nM, and 5000nM. Meanwhile 
the control cells were treated with BSA at the same concentrations of B2036.   
2.4.10 Aldefluor assay 
The Aldefluor assay was performed using ALDEFLUOR
TM
 Kit (STEMCELL 
Technologies, USA) as the manufacturer’s instruction. Briefly, cells were 
trypsinized and centrifuged at 500rpm/min for 5min. The cells were 
resuspended in Aldefluor assay buffer at a concentration of 10
6
 cells per ml. 
Suspended cells were stained with the ALDH substrate BODIPY
TM
 
aminoacetaldehyde (BAAA) at a concentration of 3µM, and incubated for 
30min at 37°C. For a negative control for each sample of cells, an aliquot was 
treated with 30µM diethylaminobenzaldehyde (DEAB), a specific ALDH 
inhibitor. The stained cells were passed through 40µl cell strainers to achieve 
single cell suspension and then analyzed using FACS LSR II machine (BD 
Biosciences, San Jose, CA)  
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2.4.11 Side population analysis 
The side population analysis was performed according to protocol described 
by Goodell et al with slight modification [146]. Cells were harvested by 
trypsinization and centrifuge. The harvested cells were incubated in DMEM 
media containing 2%FBS and Hoechst 33342 (5µg/ml final concentration) for 
90min at 37°C with or without the ABC transporter inhibitor verapamil 
(50µM final concentration, Sigma-Aldrich, MO, USA). After incubation, cells 
were centrifugated at 500rpm for 5min, resuspended into 1ml cold PBS and 
then passed through 40µm cell strainers to receive single-cell suspension. 
Samples were analysed using FACS LSR II machine. 
2.5 Molecular biology methods 
2.5.1 RNA extraction 
To extract mRNA, the RNeasy
®
 Mini Kit (QIAGEN, Germany) was used by 
following the manufacturer’s manual. The cultured cells (50-70% confluence) 
were harvested by trypsinization and centrifuge. The supernatant media was 
removed, and cell pellets were stored at -80°C for future work, or immediately 
used for RNA extraction. Cell lysis buffer RLT (350 µl per sample) was added 
into cell pellet, where cell lysate was homogenized by pipetting up and down 
for several times. One volume of 70% ethanol (350 µl) was added to the lysate 
and mixed well by pipetting. The well mixed sample (maximum 700 µl) was 
transferred to an RNeasy Mini spin column placed in a 2ml collection tube and 
then centrifuge the tube at >12,000rpm for 15s. After discarding the 
flow-through, 350 µl buffer RW1 was added to the RNeasy column, and 
centrifuged at >12,000rpm for 15s, and then the flow-through was discarded. 
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To remove the genomic DNA contamination from mRNA purification, the 
RNase-Free DNase Set (QIAGEN, Germany) was used. 10µl DNase I stock 
solution was added to 70 µl Buffer RDD and mix gently, and then DNase 
solution was directly transferred to RNeasy column membrane, and placed at 
room temperature for 15min. After the incubation, 350 µl buffer RW1was 
added to RNeasy column, and centrifuged at >12,000rpm for 15s, and then the 
flow-through was discarded. 500 µl buffer RPE was added to the RNeasy spin 
column, and centrifuged at >12,000rpm for 15s to wash the column. The 
column was washed again by adding 500 µl buffer RPE to the RNeasy spin 
column, and centrifuging at >12,000rpm for 2min. The 2ml collection tube 
was discarded, and the RNeasy spin column was put into a new 1.5ml 
collection tube, and then added 30-50 µl RNase-free water. the tube was 
incubated at room temperature for 5min, and then centrifuged at >12,000rpm 
for 1min to elute purified RNA.  The ND-1000 Spectrophotometer (Thermo 
Scientific, USA) was used to measure the concentration of RNA. The purified 
RNA was aliquot and stored at -80°C to prevent RNA degradation. 
2.5.2 cDNA isolation 





cDNA Synthesis Kit (Invitrogen, Life Technology, Grand Island, NY), which 
was stored at -20°C. Before use, all components were thawed on ice, and 
added into a PCR tube with the following receipt: 4 µl of 5X VILO
TM
 
Reaction Mix, 2 µl of 10X SuperScript
®
 reverse transcriptase mix, purified 
RNA (upto 2µg), and DEPC-treated water (total volume of 20 µl). The 
contents in the tube were mixed gently by pipetting and then span down. The 
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PCR tubes were then placed into a PCR machine, incubated at 25°C for 10min, 
followed by 42°C for 60min, and terminated at 85°C for 5min. The cDNA 
product was aliquoted and stored at -20°C for semi-quantitative PCR or 
real-time quantitative PCR.  
2.5.3 Semi-quantitative PCR 
The GoTaq
®
 Green Master Mix (Promega, Madison, WI) was used to perform 
semi-quantitative PCR. The reaction complex was prepared as the following 




 Green Master Mix, 2X 10μl 
Forward Primer (10µM) 0.5μl 
Reverse Primer (10µM) 0.5μl 
cDNA 1μl 
H2O 8μl 
Table 2-1 Reaction components for semi-quantitative PCR 
The GeneAmp
®
 PCR System 9700 (Applied Biosystems, CA) was used to 
perform the semi-quantitative PCR reactions. The reaction was started with 
2min at 95°C to denature the cNDA templates and heat-activate the Taq 
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polymerase, followed by 25-35 cycles of DNA amplification. The primers 
used were listed in Table 2-2. 
Gene 
Primer sequence 



































568 60 20 
Table 2-2 Primers and reaction conditions for semi-quantitative PCR 
The PCR products were separated on a 2% agarose gel prepared in 1X TBE 
buffer with 1X GelRed
TM
 Nucleic Acid Gel Stain (10,000X) (BIOTIUM, 
USA). The polymerised agarose gel was placed into 1X TBE buffer. An 
appropriate amount (6 μl) of each PCR product was loaded into each well of 
the gel. The 100bp DNA ladder (Promega, Madison, WI) was used to define 
the DNA molecular weight. The electrophoresis was carried out at 80 V for 
30-60min. The dissolved PCR products were visualized and photographed 
using Gel Doc
TM
 XR+ System (Bio-Rad Laboratories, USA). 
85 
 
2.5.4 Real-time quantitative PCR 
The ABI 7900HT
®
 Real-Time PCR system (Applied Biosystems, USA) was 
used to perform the real-time quantitative PCR and data analysis. Two 
housekeeping genes ACTB and GAPDH were used as internal controls to 
normalize relative gene expressions, which were presented as fold-change. For 
each gene, 5ng of cDNA was added into a well of 96-well or 384-well plate 
with Fast SYBR
®
 Green Master Mix (Invitrogen, Life Technology, Grand 
Island, NY), DEPC-treated water and 200nM primers (Table 2-3). Triplicate 
reactions were performed for every gene using a two-step amplification 
method with initial denature of 95°C for 1min, followed by 40 cycles of 95°C 
for 10s and 60°C for 20s. A melt curve step was performed at the end of 
reaction to confirm there was no unspecific amplification and primer dimer. 
The standard curve was obtained using serial dilutions of untreated cDNA. 
Data analysis was performed as previously described [339]. 
Gene Primer sequence (5’ to 3’) 
CDH1 F: CGAGAGCTACACGTTCACGG 
R: GGGTGTCGAGGGAAAAATAGG 
OCLN F: TGCCGCGTTGGTGATCTTT 
R: GCCCAGGATAGCACTCACTATT 
CTNNA1 F: CCATGCAGGCAACATAAACTTC 
R: GGCTCCAACAGTCTCTCAACT 
CTNNB1 F: CCCACTGGCCTCTGATAAAGG 
R: ACGCAAAGGTGCATGATTTG 




TWIST1 F: GTCCGCAGTCTTACGAGGAG 
R: GCTTGAGGGTCTGAATCTTGCT 
VIM F: CCTTGAACGCAAAGTGGAATC 
R: GACATGCTGTTCCTGAATCTGAG 
FN1 F: GGTGACACTTATGAGCGTCCTAAA 
R: AACATGTAACCACCAGTCTCATGTG 
CDH2 F: AGCCAACCTTAACTGAGGAGT 
R: GGCAAGTTGATTGGAGGGATG 
SNAIL1 F: AATCGGAAGCCTAACTACAGCG 
R: GTCCCAGATGAGCATTGGCA 
SNAIL2 F: AAGCATTTCAACGCCTCCAAA 
R: GGATCTCTGGTTGTGGTATGACA 
FOXC2 F: CCTCCTGGTATCTCAACCACA 
R: GGTCGAGTTCTCAATCCCCA 
ZEB1 F: TTACACCTTTGCATACAGAACCC 
R: TTTACGATTACACCCAGACTGC 
ZEB2 F: GCGATGGTCATGCAGTCAG 
R: CAGGTGGCAGGTCATTTTCTT 
ABCG2 F: ATGAAACCTGGTCTCAACGC 
R: CGGTGCTCCATTTATCAGAAC 
CLDN1 F: CAGCATGGTATGGCAATAGAATC 
R: GGGGACAGGAACAGCAAAGTA 
CD133 F: GGAGGCGGAATTCTTGACC 
R: GATGACCGCAGGCTAGTTTTC 
CD24 F: CTCCTACCCACGCAGATTTATTC 
R: AGAGTGAGACCACGAAGAGAC 
CD44 F: CCCATCCCAGACGAAGACAG 
R: ACCATGAAAACCAATCCCAGG 
KLF4 F: CCCACATGAAGCGACTTCCC 
R: CAGGTCCAGGAGATCGTTGAA 




EGFR F: AGGCACGAGTAACAAGCTCAC 
R: ATGAGGACATAACCAGCCACC 
NCAM1 F: TGTGTGGTTACAGGCGAGGA 
R: TTGGCGCATTCTTGAACATGA 
ALDH1 F: GCACGCCAGACTTACCTGTC 
R: CCTCCTCAGTTGCAGGATTAAAG 
BMI1 F: GCTGCCAATGGCTCTAATGAA 
R: TGCTGGGCATCGTAAGTATCTT 
LIN28A F: AGCGCAGATCAAAAGGAGACA 
R: CCTCTCGAAAGTAGGTTGGCT 
NANOG F: TTTGTGGGCCTGAAGAAAACT 
R: AGGGCTGTCCTGAATAAGCAG 
SOX2 F: GCCGAGTGGAAACTTTTGTCG 
R: GGCAGCGTGTACTTATCCTTCT 
POU5F1 F: CTTGAATCCCGAATGGAAAGGG 
R: CCTTCCCAAATAGAACCCCCA 
SALL4 F: GGGCCGACACTCTGAAGAC 
R: GGCTTGTTTCAAGGCATCCAG 
NOTCH1 F: ACCTGCCATGACCGTGTGG 
R: GCAGTTGGAGCCCTCGTTAC 
hGH F: ACACCTACCAGGAGTTTGAAGAA 
R: TGTTGGAGGGTGTCGGAAT 
β-ACTIN F: GCACTCTTCCAGCCTTCCTT 
R: GCGGATGTCCACGTCACA 
GAPDH F: TGCACCACCAACTGCTTAGC 
R: GGCATGGACTGTGGTCATGAG 
Table 2-3 Primers used for Real-time quantitative PCR 
2.5.5 Competent cells preparation 
The original Escherichia coli (E.Coli) strain TOP10 was obtained from 
Invitrogen (Invitrogen Life Technology, Grand Island, NY). To expand the 
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competent cells, the following protocol was used. Firstly 2µl of TOP10 cells 
were grown in 5ml LB medium without ampicillin overnight at 37°C, and then 
1ml of precultured cells growth was transferred in 200ml LB medium without 
ampicillin for approximately 2h at 37°C, meanwhile the optical density (O.D) 
was closely monitored. When the O.D. reached 0.6, the cultured cells were 
splitted into four 50ml-falcon tubes, and incubated on ice for 20min. 
Subsequently, the cells were centrifuged at 3000rpm for 15min at 4°C. The 
supernatant was discarded, and cell pellet was resuspended with 1ml ice-cold 
0.1M CaCl2, and incubated on ice for 1h. Meanwhile, the 1.5ml eppendorf 
tubes were cold-down at -20°C. After 1h of incubation, cells were span down 
at 3000rpm for 15min at 4°C. The supernatant was discarded and the cell 
pellet was resuspended with 2.5ml of 0.1M CaCl2/14% glycerol, and then 
incubate on ice for 1h. After the incubation, the cells were aliquoted into 
pre-cold eppendorf tubes with 50 µl per tube, and stored at -80°C 
immediately.  
2.5.6 Bacterial transformation of plasmids 
Plasmid amplification was performed in a TOP10 strain of E.Coli bacteria. 
The competent TOP10 cells were thawed on ice before use. 1µl of plasmid 
(10-100ng) was added into the thawed competent cells and incubate on ice for 
30min. Following incubation, the tube containing competent cells and plasmid 
was put into a water bath at 42°C for 90s to heat-shock the competent cells, 
and then immediately moved back into ice for 2min. Then 1ml of LB broth 
was added to the tube following incubation in a 37°C bacterial incubator for 
1h. Following 1h of incubation, the mixture was spread on LB agar plates 
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containing 50µg/ml of ampicillin, which served as a selective marker 
inhibiting growth of non-transformed cells. Then the LB agar plates were 
placed into a 37°C bacterial incubator for 20-36h, dependent on the growth of 
bacterial colonies. Then a single bacterial colony was picked and transferred to 
400ml LB broth with 50 µg/ml of ampicillin. The tranfected bacteria was 
cultured in an incubator shaker with vigorously shaking (200rpm) for 20h at 
37°C.  
2.5.7 Plasmid DNA purification 
Following a 20h culture in the LB broth supplemented with 50 µg/ml of 
ampicillin, plasmid DNA in transformed TOP10 bacteria was purified using 
PureLink
®
 HiPure Plasmid DNA Purification Kit (Invitrogen Life Technology, 
Grand Island, NY) according to the manufacturer’s manual. Firstly, 10ml 
Equilibration Buffer (EQ1) was added to the HiPure Midi Column, and the 
solution in the column was drained by gravity flow to equilibrate the column. 
The bacteria were harvested by centrifuging the LB broth culture at 6000rpm 
for 10min, and removed the media. The harvested bacteria were suspended in 
10ml Resuspension Buffer (R3) with RNase A, followed by adding 10ml 
Lysis Buffer (L7), mixing thoroughly by gently inverting the capped tube five 
times, and incubating at room temperature for 5min. Subsequently, 10ml 
Precipitation Buffer (N3) was added, and immediately inverted the capped 
tube to mix the solution until the mixture was homogenous, and then 
centrifuged the lysate at >16,000rpm for 10min at room temperature.  The 
supernatant was carefully transferred to the equilibrated column without 
disturbing cell debris, and let the solution to be drained by gravity flow. 
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During this process, the plasmid DNA bound to the column. The column was 
then washed by adding 60ml of Wash Buffer (W8), following which the 
plasmid DNA was eluted into a sterile 50ml-centrifuge tube by adding 15ml 
Elution Buffer (E4) into the column.  The eluate was well mixed with 10.5ml 
isopropanol and centrifuged the tube at >16,000rpm for 30min at 4°C. The 
supernatant was discarded, the DNA pellet was washed with 5ml 70% ethanol, 
and then centrifuged the tube at >16,000rpm for5min at 4°C. The solution was 
removed from the tube; the pellet was air-dried for 10min at room temperature; 
and then 200µl sterile water was added to the tube to resuspend the purified 
plasmid DNA. The concentration of plasmid DNA was measured using the 
ND-1000 Spectrophotometer (Thermo Scientific, USA). Purified plasmid 
DNA was stored at -20°C. 
For small-scale plasmid DNA purification, the QIAprep
®
 MiniPrep Kit 
(QIAGEN, Germany) was used following the manufacturer’s protocol. Firstly, 
the bacterial culture media (5ml) was centrifuged to harvest the bacterial cells. 
The bacterial pellet was resuspended in 250µl Buffer P1 and transferred to a 
1.5ml centrifuge tube. 250 µl Buffer P2 was added to the bacterial 
resuspension and mixed thoroughly by inverting the tube 4-6 times. Then 350 
µl Buffer N3 was added into the tube. The tube was then centrifuged 
at >16,000rpm for 10min at room temperature. After centrifugation, the 
supernatant was transferred to the QIAprep spin column, and centrifuged the 
column for 60s. The flow-through was discarded, and then added 0.75ml 
Buffer PE to wash the column by centrifugation for 60s. The flow-through 
was discarded, and the column was centrifuged for 2min to remove residual 
wash buffer from the column. The collection tube was discarded; the column 
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was placed into a new sterile 1.5ml tube and 30-50 µl sterile water was added 
into the column to elute purified plasmid DNA from the column by 
centrifugation at 16,000rpm for 1min. The concentration of purified plasmid 
DNA was determined using the ND-1000 Spectrophotometer (Thermo 
Scientific, USA).  
2.6 Protein methods 
2.6.1 Protein extraction 
The cultured cells at 50-70% confluence were washed by pre-warmed PBS, 
and then harvested by using cell scraper, rather than trypsinization which may 
destroy the tran-membrane proteins. The scraped cells were span down at 
500rpm for 5min and then resuspended in 100µl RIPA lysis buffer, and placed 
on ice for 30min with interval vortex. The concentration of protein was 
determined using DC Protein Assay Kit (Bio-Rad Laboratories, USA). 
2.6.2 DC protein assay 
To measure the concentrations of protein samples, the DC Protein Assay Kit 
was used according to the manufacturer’s protocol. “Working reagent A” was 
prepared by adding 20 µl of reagent S to 1ml of reagent A. Serial diluted BSA 
was used as protein standard from 0 µg/ µl to 10 µg/ µl. The BSA standard 
and protein samples were added into 96-well plate with triplicate. The working 
solution A (20 µl) was added into each well, followed by adding 160 µl 
reagent B. The plate was incubated at room temperature for 15min in dark. 
The bubbles were removed by using clean pipet tips, and the absorption was 
measured under 750nm using a spectrophotometer microplate reader. The 
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standard curve was plotted based on the absorptions of BSA standards, and the 
concentrations of protein samples were calculated based on the standard curve. 
2.6.3 Western blot analysis 
The polyacrylamide gel (PAGE) and buffers were prepared as described in 
Section 2.1. The PAGE gel was casted by using the Bio-Rad Mini-PROTEIN 
II system. Protein samples were mixed with 5X Loading Dye (Section 2.1) 
supplemented with 5% fresh β‑ mercaptoethanol to reduce disulfide bonds, 
and boiled for 10min. the boiled protein samples and protein marker were 
loaded into each well of the PAGE gel. The electropherosis was performed in 
the 1X SDS-PAGE Running buffer at 80V for 30min, followed by 120V for 
60 to 120min, dependent on the size of protein analysed.  
After electropherosis, the PAGE gel was removed from glass plates and 
immersed in 1X Transfer buffer containing 20% freshly added methanol. 
Meanwhile, the Polyvinylidene Difluoride (PVDF) membrane (Bio-Rad 
Laboratories, USA) was immersed in methanol for 1min before use. The 
PAGE gel and PVDF membrane were packed into filter papers and sponges to 
form a sandwich cassette. The wet membrane transferring was carried out in 
1X Transfer buffer containing 20% freshly added methanol at a constant 
voltage of 100V for 1 to 2h.  
After membrane transferring, the PVDF membrane was blocked using 
blocking buffer (3%BSA in TBS-T buffer) at room temperature for 2h, and 
then the blocked PVDF membrane was incubated with the respective primary 
antibody (Table 2-4) diluted in blocking buffer at 4°C overnight. The next day, 
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primary antibody-blocked PVDF membrane was washed by TBS-T for thrice 
for 15min and then incubated with secondary antibody for 1h. Following 
incubation of secondary antibody, the PVDF membrane was finally washed 
thrice, and subsequently incubated with the West Pico Chemoluminescence 
Substrate (Thermo Scientific, USA) for 2min in the dark. The protein image 
was developed using X-ray film in the Kodak film processor.  
For reblotting, the primary and secondary antibodies were stripped off by 
incubating in 0.2M NaOH for 5min at room temperature with rigorous shaking. 
The stripped membrane was washed with milliQ water and TBS-T for 5min, 
respectively, and then blocked by using Blocking Solution, followed with 
antibody incubation as described above.  
Antibody Origin Supplier 
Band size 
(kDa) 
β-actin (sc-58222) Mouse Santa Cruz 42 
STAT3 (9139) Mouse Cell Signaling 79,86 
p-STAT3 (9131) Rabbit Cell Signaling 79,86 
ERK (sc-93) Rabbit Santa Cruz 44/42 
p-ERK (sc-7383) Mouse Santa Cruz 44/42 
pan-AKT (ab8805) Rabbit Abcam 56 
p-AKT1 (ab66138) Rabbit Abcam 56 
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Claudin-1 (ab15098) Rabbit Abcam 23 
ZO-1 (sc-10804) Rabbit Santa Cruz 220 
N-Cadherin 
(ab98952) 
Mouse Abcam 100 
E-Cadherin (ab1416) Mouse Abcam 110 
Fibronectin1 
(ab2413) 
Rabbit Abcam 262 
hGH Rabbit 
National Hormone and 
Peptide Program 
20/22 
Occludin (ab31721) Rabbit Abcam 59 
Vimentin (ab20346) Mouse Abcam 54 
Table 2-4 Antibodies used in western blot analysis 
2.7 Chromatin Immunoprecipitation (ChIP) 
To determine whether pSTAT3 directly binds to the promoter region of 
CLDN1 gene, and identify the pSTAT3 binding sites in CLDN1 promoter 
region, the Chromatin Immunoprecipitation was performed using EZ-Magna 
ChIP
TM
 A one-DAY Chromatin Immunoprecipitation Kits (Millipore, Bedford, 
MA) according to manufacturer’s instructions with optimization.  
The cultured cells with 50-70% confluence in cell culture dish were 
crosslinked by adding 550µl of 37% formaldehyde into 20ml of growth media, 
and incubated at room temperature for 10min. After incubation, 2ml of 
10×Glycine was added to the cell culture dish to terminate the reaction of 
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cross-link.  The dish was swirled to mix the Glycine with media and 
incubated at room temperature for 5min. the dish was then placed on ice. 
Media was removed as much as possible, and then 20ml of cold PBS was 
added to wash cells twice. After PBS wash, cold PBS (2ml) containing 1× 
Protease Inhibitor Cocktail II was added into the cell culture dish, and cells 
were scraped into a falcon tube. The cells were centrifuged at 700g for 5min, 
the supernatant was discarded, and subsequently cells were resuspended in 
1ml of SDS Lysis Buffer containing 1× Protease Inhibitor Cocktail II. The cell 
lysate can be stored at -80°C for one month. The cell lysate was sonicated 
using Bioruptor
®
 Sonication System (Diagenode Inc., Denville, NJ) to sheer 
the chromatin DNA to proper sizes (200-1000bp) with optimal sheering 
condition. The sonicated cell lysate was centrifuged at 12,000rpm for 10min at 
4°C for removal of cell debris. The supernatant was transferred to a fresh tube 
in 50µl aliquots. The sheered crosslinked chromatin can be stored at -80°C for 
upto 2 months. Dilution Buffer (450µl) containing Protease Inhibitor Cocktail 
II was added into each tube containing 50µl of cell lysate.  5µl supernatant 
was stored as “input” and stored at 4°C. For each sample, 10µl pSTAT3 
antibody (9131, Cell Signaling) and 20 µl fully suspended protein A magnetic 
beads was added. For the negative control, 5µg of Normal Rabbit IgG 
antibody was added. The mixtures had been incubated for 4h at 4°C with 
rotation. After incubation, the magnetic beads were washed as the following 
sequential: Low Salt Immune Complex Wash Buffer, High Salt Immune 
Complex Wash Buffer, LiCl Immune Complex Wash Buffer, and TE Buffer. 
For every washing, the supernatant should be removed completely. To release 
the chromatin DNA from protein A magnetic beads, the washed magnetic 
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beads had been incubated in 100µl ChIP Elution Buffer containing Proteinase 
K at 62°C for 2h, followed by incubating at 95°C for 10min. The supernatants 
were separated from the magnetic beads using a magnetic separator and 
transferred into new tubes. The chromatin DNA was purified using spin 
columns, and purified DNA was eluted into 30µl DEPC-treated water and 
stored at -20°C for PCR amplification.  
To determine whether pSTAT3 directly binding to the promoter region of 
CLDN1 gene, three pairs of primers was designed to amplify three putative 
pSTAT3 binding sites in the promoter region of CLDN1 gene. The sequences 
were listed in Table 2-5.  
Binding site 
Primer sequence 
(5’ to 3’) 
Product size  
(bp) 
#1 












Table 2-5 Primers for amplifying pSTAT3 binding sites in the promoter region 
CLDN1 gene 
 
2.8 Luciferase reporter assay 
Promoter activity of CLDN1 was determined using Dual-Luciferase
®
 Reporter 
Assay Systems (Promega, Madison, WI). Cells were seeded into 12-well plate, 
and cultured overnight before transfection. The CLDN1 promoter-driven 
luciferase reporter plasmids and Renilla luciferases were co-transfected into 
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cultured cells. After 24h of transfecion, cells were washed by PBS gently and 
then dispensed with 200µl 1×lysis buffer PLB into each well. The plate was 
incubated on ice for 30min with shaking. Cell lysates were transferred into 
new tubes and span down at 1,200rpm for 5min to remove cell debris. The 
supernatants were transferred into new tubes. The supernatant (20µl) was 
added into a luminometer tube, followed by adding 100µl LAR II reagent, and 
the firefly luciferase activity as measured by using the Berthold Luminometer 
with 10s period, and then 100µl Stop&Glo
®
 Reagent was added to terminate 
the reaction and measure the Renilla luciferase activity. The Renilla luciferase 
activity was used as internal control to normalize the relative acitivity of 
CLDN1 promoter in each sample.  
2.9 Xenograft analysis 
All animal studies were conducted in accordance with a protocol approved by 
animal care and ethics committee of University of Science and Technology of 
China. The xenograft assays were performed as previously described [339, 
515]. For the tumor initiating assay, MDA-MB-453-vec and 
MDA-MB-453-hGH cells were suspended in 100µl PBS with serial dilutions 
and injected into the fourth mammary fat pad of 3- to 4- week-old BALB/c 
Nude mice (Slac Laboratory Co, Shanghai, China). Primary tumor sizes were 
measured using a caliper twice every week. After one month of inoculation, 
the nude mice were sacrificed to determine tumorigenicity, which was 
measured by tumor incidence (i.e., the number of tumors/number of 
injections).  For tumor metastasis, 5×10
6
 MDA-MB-453-vec and 
MDA-MB-453-hGH cells were injected into the fourth mammary fat pad of 3- 
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to 4- week-old BALB/c Nude mice. Tumor sizes were measured twice every 
week. In this assay, the latency of the tumor from the nude mice is around one 
week, and tumors were harvested one month after inoculation. At necropsy, 
primary tumors, lungs and livers were fixed in 4% paraformaldehyde and 
stained with hematoxylin and eosin (H&E) to assess the morphology of 
primary tumor and the presences of micrometastasis in lung and liver.  
2.10 Bioinformatics tools 
2.10.1 Statistical analysis 
The Microsoft Excel and Sigma Stat 3.1 were used for statistical analysis in 
this thesis. The graphical presentations were generated using GraphPad Prism 
V5 (Mathlab) and Microsoft Excel. All experiments in this thesis were 
performed at least three times and a single representive figure was presented. 
All data were expressed as means   SEM of triplicate determinants. Data 
were analyzed using an unpaired two-tailed t test or  2 test. 
2.10.2 Primer design 
The software Primer Premier 5 was used to design oligo-primers for RT-PCR 
and real-time quantitative PCR. The primer sequences were verified in 
National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/BLAST/) or the UCSC genome Browser 




CHAPTER 3 Human Growth Hormone Stimulates the Tumor 
Initiating Capacity and Metastasis of ER Negative Breast Cancer 
Cells 
3.1 Introduction 
Breast cancer, which is one of the main causes of cancer deaths in women 
world-wide [206], is a heterogeneous disease at both the molecular and 
clinical level [347, 412]. The differences in molecular characteristics and gene 
profiling predict distinct outcomes and response to treatment in breast cancer 
patients [412]. Despite progresses in breast cancer diagnosis and treatment, the 
estrogen receptor negative subtype of breast cancer (ER-BC) is still associated 
with poorer prognosis compared with other molecular subtypes [64]. Thus, 
further study is warranted to effectively target this clinically challenging 
subgroup of mammary carcinoma.  
Cancer stem cells (CSCs) were first identified in acute myeloid leukaemia, and 
provided the earliest evidence that normal stem cells were the targets of 
transforming mutation [31]. Recent studies have identified the existence of 
CSCs in solid tumors [96], and implicated them in tumor initiation, growth, 
epithelial-to-mesenchymal transition (EMT) [271], drug resistance and tumor 
recurrence [96], thereby compromising complete therapeutic eradication of the 
tumor.  CSCs have also been proposed to play a crucial role in tumor 
metastasis [241]. ALDH1-positive CSCs isolated from breast cancer cell lines 
have recently been demonstrated to increase invasive capacity compared with 
ALDH1-negative cells in NOD/SCID mice [59]. Hence, understanding the 
basic molecular mechanisms involved in CSC function is pertinent for the 
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development of targeted therapeutic strategies to eradicate the CSC population, 
and to maximize clinical response of subgroups of breast cancer that are 
resistant to conventional therapies.  
Human growth hormone (hGH) is a 22-kDa protein secreted from the anterior 
pituitary [61]. Endocrine hGH exerts direct effects on the regulation of 
somatic growth through stimulation of hepatic insulin-like growth factor-I 
(IGF-I) secretion, and through independent mechanisms [348]. A relationship 
between endocrine GH and cancer has been described in both humans and 
animal models. Acromegaly patients with increased GH circulation have a 
higher incidence of colon, thyroid, and possibly breast cancer [159, 463]. In 
addition, breast cancer patients have significantly higher levels of serum GH 
and IGF-I compared with individuals without cancer [118, 352]. Conversely, 
two recently published studies found that the incidence rate of cancer amongst 
individuals with a GH receptor (GHR) mutation which disrupts GH-mediated 
signaling, was much lower than their normal relatives [158, 417]. The 
oncogenic potential of GH in animal models has also been widely reported [98, 
322, 492].   
Besides the classical endocrine actions of hGH, this peptide hormone also 
functions in autocrine and paracrine manners, and is secreted locally in the 
mammary gland [253]. hGH is involved in pubertal mammary gland 
development and is essential for ductal elongation and differentiation of ductal 
epithelia into highly proliferative terminal end buds structure [213, 416]. hGH 
mRNA and protein expression has been identified in human mammary gland, 
as well as mammary tumor tissue [305, 362, 472]. Recently, histopathological 
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analysis has demonstrated that hGH expression in mammary carcinoma 
positively correlates with lymph node metastasis, higher clinical stage and 
HER2-positive tumors [472]; In addition, tumor expression of hGH predicts 
poor survival outcome in patients with mammary carcinoma or endometrial 
carcinoma [472].  
The functional effects of hGH pertaining to oncogenicity have been 
demonstrated in immortalized mammary epithelial or breast cancer cell lines. 
It has been demonstrated that autocrine hGH promotes cell proliferation [208] 
and cell survival [293] in both the breast cancer cell line, MCF-7, as well as in 
an immortalized human mammary epithelial cell line, MCF-10A [515]. 
Remarkably, forced expression of hGH is capable of oncogenically 
transforming the human mammary epithelial cell with consequent tumor 
formation [515]. Our studies have also demonstrated that forced expression of 
hGH in MCF-7 cells induces epithelial-to-mesenchymal transition (EMT) and 
a migratory and invasive cellular phenotype [315]. Consequently autocrine 
hGH may increase the metastatic potential of human breast cancer cells [315]. 
In addition to enhanced oncogenicity, autocrine hGH has been demonstrated 
to promote angiogenesis [39] and therapy resistance [33, 34, 298, 303, 502] in 
breast cancer cells. The functional effect of autocrine hGH on the tumor 
initiating potential and metastasis of ER-BCs has not previously been 
established.  
I demonstrate here that forced expression of hGH in ER-BC cells promoted a 
CSC-like phenotype and increased migration and invasion in vitro. In addition, 
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forced expression of hGH enhanced MDA-MB-453 cells tumor initiation and 

















3.2.1 Establishment of stably transfected ER-BC cells expressing hGH 
We have previously published the functional effects of forced expression of 
hGH (autocrine hGH) in ER+BC cells [33, 34, 39, 208, 293, 298, 303, 315, 
502]. However, histopathology studies have also demonstrated hGH 
expression in ER-BC [472]. To determine the functional consequences of 
autocrine hGH in ER-BC cells, two ER-BC cell lines (MDA-MB-453 and 
SKBR3) were stably transfected with hGH expression vector (termed 
MDA-MB-453-hGH and SKBR3-hGH) or the empty pcDNA3.1 vector 
(designated MDA-MB-453-Vec and SKBR3-Vec). Expression of hGH mRNA 
and protein in stably transfected MDA-MB-453-hGH and SKBR3-hGH cells 
was verified by RT-PCR and western blot analysis, respectively (Figure 3-1). 
Semi-quantitative RT-PCR analysis also demonstrated that 
MDA-MB-453-Vec and SKBR3-Vec express low levels of endogenous hGH 
mRNA. However, endogenous hGH protein expression was only detectable in 
MDA-MB-453-Vec cells by western blot analysis (Figure 3-1B). The 
secretion of autocrine hGH from MDA-MB-453 and SKBR3 stable cells has 







Figure 3-1 hGH expression in ER-BC cells 
MDA-MB-453 and SKBR3 cells stably transfected with hGH were cultured in 
growth media (A) Semi-quantitative RT-PCR analysis of hGH mRNA levels in 
MDA-MB-453 and SKBR3 stable cells. β-actin was used as an internal control. (B) 
Western blot analysis of hGH protein expression in MDA-MB-453 and SKBR3 stable 
















3.2.2 Forced expression of hGH increases cell numbers of ER-BC cells 
We have previously reported that forced expression of hGH stimulated cell 
proliferation in MCF-7 cells [208].  To determine the effect of autocrine hGH 
on MDA-MB-453 and SKBR3 cell number, a total cell number assay was 
performed over 10-12 days. In growth media (supplemented with 10% FBS),  
MDA-MB-453-hGH and SKBR3-hGH cells had a significantly higher cell 
number than the respective control cell lines, MDA-MB-453-Vec and 
SKBR3-Vec (Figure 3-2).   
 
Figure 3-2 Total cell number assays 
Total cell number assays performed in growth media (supplemented with 10% FBS) 
over 12 days for MDA-MB-453-Vec/hGH cells and 10 days for SKBR3-Vec/hGH 









3.2.3 Forced expression of hGH increases MDA-MB-453 and SKBR3 cell 
viability in three-dimensional Matrigel
TM 
Growth in 3D Matrigel
TM
 was assessed to determine the effect of forced 
expression of hGH on MDA-MB-453 and SKBR3 anchorage independent 
growth. After 7 days growth in 4% Matrigel
TM
, the MDA-MB-453-hGH and 
SKBR3-hGH cells exhibited significantly higher viability than their respective 
control cell lines as measured by MTT assays (Figure 3-3).  
 
  
Figure 3-3 Three-dimensional growth in Matrigel
TM 
Stably transfected cells were seeded in 4% Matrigel
TM
. After 7 days culture, cell 











3.2.4 Forced expression of hGH promotes mammosphere formation 
potential of ER-BC cells 
Previous study has demonstrated that mammary stem/progenitor cells were 
able to proliferate and maintain undifferentiated state in suspension culture as 
spherical structures, termed mammospheres[104]. To determine the effect of 
hGH on the CSC-like behavior of MDA-MB-453 and SKBR3 cells, a 
mammosphere assay was conducted. When cultured under ultra-low 
attachment conditions, MDA-MB-453-hGH and SKBR3-hGH cell lines 
exhibited significant increases in the size and number of mammospheres when 
compared with the respective control cell lines, MDA-MB-453-Vec and 
SKBR3-Vec (Figure 3-4). Studies have reported that the growth of 
mammospheres generated upon serial passaging provides an indirect measure 
of mammary stem cell self-renewal [104, 224]. Therefore, to confirm that the 
increase in mammosphere represented the progeny of individual CSCs rather 
than the aggregation of quiescent cells, I examined the ability of primary 
mammospheres to form secondary and tertiary mammospheres. Forced 
expression of hGH significantly enhanced the number of secondary and 
tertiary mammospheres generated by MDA-MB-453 and SKBR3 cells, 
compared with the respective control cell lines, MDA-MB-453-Vec and 






Figure 3-4 hGH enhances the mammosphere formation potential of ER-BC cells 
MDA-MB-453-Vec/Hgh (A) and SKBR3-Vec/hGH (B) cells were seeded in ultra 
low attachment plates in mammospheric growth media. The number of 
mammospheres formed was counted after 9 days in culture. The first generation (G1) 
of mammospheric cells were sequentially cultured for the second (G2), and the third 
generation (G3) of mammosphere formation. Images represent the first generation of 
mammospheres formed by MDA-MB-453-Vec/hGH and SKBR3-Vec/hGH cells. 






3.2.5 B2036 treatment inhibits mammosphere formation in MDA-MB-453 
parental cells 
To determine the effect of functional inhibition of hGH on CSC-like 
properties I used the hGHR specific antagonist, B2036 in the mammosphere 
formation assays. B2036 is the protein component of pegvisomant (Pfizer) 
which is used clinically in the treatment of acromegaly [223, 452]. As 
demonstrated in Figure 3-1, endogenous hGH protein expression was 
detectable in MDA-MB-453 parental cell line, but not in the SKBR3 cell line 
used in these studies. Treatment with B2036 under low-attachment conditions 
abrogated the mammosphere formation capacity of MDA-MB-453 wild-type 
cells in a dosage dependent pattern (Figure 3-5A). However, B2036 treatment 
did not exert any effect on mammosphere formation in the SKBR3 cell line 
(Figure 3-5B).  
 
Figure 3-5 Effect of B2036 on mammosphere formation of MDA-MB-453 and 
SKBR3 parental cells 
MDA-MB-453 and SKBR3 parental cells were seeded in ultra low attachment plates 
in mammospheric growth media with different concentrations of B2036 or BSA. The 
number of mammosphere was counted after 9 days in culture. **, p<0.01; #, no 
statistic significance.  
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3.2.6 Forced expression of hGH increases the ALDH1+ population in 
ER-BC cells 
Previous studies have demonstrated that aldehyde dehydrogenase 1 (ALDH1) 
is a marker of normal and malignant human mammary stem cells [59, 138, 
224]. To determine whether hGH modulates the ALDH1-positive (ALDH1+) 
cell population, I measured the ALDH1+ cell number in MDA-MB-453-hGH 
and SKBR3-hGH cell lines using an ALDFLUOR assay. Forced expression of 
hGH significantly increased the percentage of ALDH1+ cells in both 
MDA-MB-453 and SKBR3 cell lines (Figure 3-6).  
 
Figure 3-6 hGH modulates ALDH1+ populations in MDA-MB-453 and SKBR3 
cells with forced expression of hGH 
hGH modulates ALDH1+ cell population in MDA-MB-453 and SKBR3 cells with 
forced expression of hGH. A representative figure of three repeats was shown here. 
Cells were incubated with Aldefluor substrate (BAAA, BODIPY-aminoacetaldehyde) 
to define the ALDH1+ cell population. A specific inhibitor of ALDH1, 
diethylaminobenzaldehyde (DEAB), was used to establish the base-line fluorescence. 




3.2.7 Forced expression of hGH modulates side-population in ER-BC cells 
The Side Population (SP) phenotype, which is characterized by an increased 
ability to efflux Hoechst 33342 dye due to increased ABC transporter activity, 
has also been postulated to represent a marker of a stem cell population in 
adult tissues [11]. Previous studies have identified SP cells in solid tumors 
with CSC-like properties [68, 74, 498]. I therefore utilized a Hoechst 33342 
efflux assay to determine the effect of forced expression of hGH on 
MDA-MB-453 and SKBR3 SPs. Flow cytometry analysis demonstrated that 
forced expression of hGH significantly increased the size of the SP in both 
MDA-MB-453 and SKBR3 cells compared with respective control cell lines 







Figure 3-7 hGH enhances SP in MDA-MB-453 and SKBR3 cells with forced 
expression of hGH 
Cells were stained with Hoechst 33342 in the absence or presence of verapamil, an 
ABC transporter inhibitor. Verapamil was used to establish the baseline fluorescence 
of these cells. Incubation of cells with Hoechst33342 in the absence of verapamil 
stained a small but distinct side population of cells in the respective ER-BC cells. 











3.2.8 hGH enhances tumor initiating capacity of MDA-MB-453 cells in 
vivo 
Previous studies have intensively investigated that CSCs were involved into 
tumor initiation in vivo [9, 138, 224]. To determine whether the CSC-like 
properties promoted by forced expression of hGH in ER-MC cells in vitro also 
contribute to tumorigenicity in vivo, we implanted 5×10
6
 MDA-MB-453-Vec 
and MDA-MB-453-hGH cells into the fourth mammary fat pad of 
immunodeficient nude mice and examined tumor growth (have been done in 
collaboration with Prof. Zhu Tao’s group). All of the mice injected with 
MDA-MB-453-Vec and MDA-MB-453-hGH cells had formed palpable 
tumors one month after inoculation. However, MDA-MB-453-hGH tumors 
grew significantly faster than MDA-MB-453-Vec tumors (Figure 3-8A). 
Necropsy confirmed that MDA-MB-453-hGH cells generated larger tumors in 
nude mice than MDA-MB-453-Vec cells (Figure 3-8B).   
 




MDA-MB-453-vec and MDA-MB-453-hGH cells were injected into the fourth 
mammary fad pad of immunodeficient nude mice with Matrigel as vehicle. (A) 
Tumor volumes were measured twice every week. *, p<0.05; **, p<0.01. (B) After 
one month of inoculation, the mice were sacrificed, and primary tumors were 




To determine the tumor initiating capacity of autocrine hGH in MDA-MB-453 
cells, MDA-MB-453-Vec and MDA-MB-453-hGH cells were serially diluted 
and injected into the fourth mammary fat pad of nude mice. Mice were 
sacrificed 30 days after inoculation and tumor formation was determined 
(Table 2-1). Overall, MDA-MB-453-hGH cells generated larger tumors than 
MDA-MB-453-Vec cells. In addition, fewer MDA-MB-453-hGH cells were 
required for tumor formation compared with MDA-MB-453-Vec cells. At 
1×10
3
 cells MDA-MB-453-hGH cells generated tumors in 4/8 mice, whereas, 
MDA-MB-453-Vec cells generated tumors in1/8 mice. Our collaborator Dr. 
Wu Zhengsheng (USTC) has done these animal works. 
 













3.2.9 Forced expression of hGH increases migration and invasion of 
ER-BC cells in vitro 
We have previously reported that forced expression of hGH enhanced the 
migration and invasion of ER+MC and endometrial carcinoma cell lines [315, 
339]. To determine the migratory and invasive capacity of ER-BC cells with 
forced expression of hGH, I utilized a transwell migration assay. Forced 
expression of hGH in MDA-MB-453 and SKBR3 cells enhanced cell 
migration, as compared to the respective control cell lines (Figure 3-9A). 
Similarly, MDA-MB-453-hGH and SKBR3-hGH cells demonstrated a 
significantly increased capacity to invade through Matrigel
TM
 as compared to 
MDA-MB-453-Vec and SKBR-Vec cells, respectively (Figure 3-9B).   
 
Figure 3-9 Forced expression of hGH in ER-BC cells enhances cell migration 
and invasion 
The migration (A) and invasion (B) of MDA-MB-453 and SKBR3 cells with forced 
expression of hGH was determined by transwell assay. *, p<0.05; **, p<0.01.  
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3.2.10 Forced expression of hGH enhances metastasis of MDA-MB-453 
cells in vivo 
To determine whether hGH contributes to the in vivo metastatic ability of 
ER-MC cells, we injected 5×10
6
 MDA-MB-453-hGH or MDA-MB-453-vec 
cells into the fourth mammary fat pad of immunodeficient nude mice and 
examined their ability to form liver and lung metastases (have been done in 
collaboration with Prof. Zhu Tao’s group). Metastatic nodules were readily 
detectable by histology in the lungs of 5/6 mice, in the livers of 3/6 mice, one 
month after injection with MDA-MB-453-hGH cells, however, 
MDA-MB-453-vec cells did not induce lung or liver metastases in nude mice 
(Table 3-2;Figure 3-10). The lesion from the MDA-MB-453-hGH primary 
tumors had an ill-defined margin that blended with surrounding tissues and 
appeared highly invasive, infiltrating the underlying adipose tissue (Figure 













MDA-MB-453-Vec and MDA-MB-453-hGH cells were injected into the fourth 
mammary fad pad of immunodeficient nude mice with Matrigel as vehicle. After one 
month of inoculation, the mice were sacrificed. Primary tumor, lung and liver 
sections were stained with H&E. Arrows indicate location of metastatic nodules.   
 
Table 3-2 Lung and liver metastasis of MDA-MB-453 cells with forced 
expression of hGH 
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3.2.11 hGH and ALDH1 are co-expressed in ER-BC 
ALDH1 expression correlates with a poor clinical outcome in breast cancer 
[138, 310]. To determine a potential association between hGH and ALDH1 
expression in ER-BC, we performed qPCR on a cohort of 24 ER-BC to 
compare the relative expression of hGH mRNA and ALDH1 mRNA (have 
been done in collaboration with Prof. Zhu Tao’s group). We observed that 
hGH mRNA expression was positively and highly correlated with ALDH1 
mRNA expression (Pearson coefficient: 0.728; P<0.0001) (Figure 3-11).  
 
Figure 3-11 Association of hGH expression with ALDH1 in ER-BC. 
Pearson’s correlation coefficient was determined between the mRNA expression of 
hGH and ALDH1 by qPCR in a cohort of twenty four ER-BC patients. hGH 









Herein I reported the tumor initiating potential of hGH in two ER-BC cell 
lines. I demonstrated that hGH significantly enhanced the migrational and 
invasive capacity of MDA-MB-453 and SKBR3 cells in vitro. Furthermore, 
the tumor initiating and metastatic effects of hGH in MDA-MB-453 cells were 
investigated in vivo. These results provide evidence of a role for hGH in the 
promotion of tumor initiation and metastasis of ER-BC cells.  
Previous studies have implicated the involvement of GH in fetal development 
[462]. Functional GH and GH receptors (GHRs) are expressed in mouse and 
bovine preimplantation embryos [219, 340]. In skeleton development GH and 
IGF-I have been demonstrated to maintain the stem cell population in the 
germinal zone of growth plate by stimulating proliferation of prechondrocytes 
[251, 332]. GH has also been observed to promote proliferation of embryonic 
and adult rat neural stem cells (NSCs) [2, 8, 71, 288], as well as human fetal 
NSCs [343]. In addition, GH protects embryonic striatal neural precursor cells 
from apoptosis in mouse [372]. These studies indicate functional roles of GH 
in normal stem cells.  
Analysis of transcriptional profiles has demonstrated enriched GHR 
expression in mouse embryonic (ESC), neural (NSC), and hematopoietic 
(HSC) stem cells, compared with respective differentiated counterparts [365]. 
Hereafter, Dontu et al. has demonstrated that mammary stem/progenitor cells 
grown in mammospheres express significantly higher level of GHR compared 
to the same cells induced to differentiate by attachment to a collagen 
substratum [104], which indicates that GH may regulate the behavior of 
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normal mammary stem/progenitor cells. In favor of this hypothesis is the fact 
that GH markedly enhances the effect of oestrogen on expansion of Sca-1+ 
mammary stem cell population in vitro[108]. Growing body of evidence has 
supported the CSC hypothesis that cancer originates in stem/progenitor cells 
[139]. The mammary stem/progenitor cells have been found to be highly 
susceptible to immortalization and transformation [157], suggesting that they 
are the primary targets of mammary carcinogenesis. Circumstantial evidence 
indicates that GH/IGF-I axis regulates the number of mammary stem cells, 
which is a risk factor of breast cancer [139, 390].  The prenatal level of IGF-I 
in umbilical cord blood plasma is strongly correlated with the concentration of 
hematopoietic stem/progenitor cells, which serves as surrogates of overall 
stem cell potential, including the mammary stem cells [390]. 
Pregnancy-triggered protection from breast cancer is partially attributed to the 
reduced number of proliferative mammary stem cells [30, 384]. It has been 
postulated that pregnancy stimulates differentiation of highly proliferative 
mammary stem cells, and therefore reduces the risk of malignant 
transformation of these mammary stem cells [384]. The gene profiling 
analysis of mammary gland has demonstrated the reduced expression of GHR 
and IGF-I in parous rats compared with their nulliparous counterparts [30]. 
Concomitantly, pregnancy reduces the concentration of circulating hGH, 
resulting in a changed hormone milieu [30]. Together with evidence of the 
increased expression of GHR gene in normal mammary stem cell [104], it is 
highly plausible that GH may promote the malignant transformation of 
mammary stem/progenitor cells. Interestingly, consecutive expression of 
autocrine mGH, which is supposed to be repressed during pregnancy and 
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lactation, induces hyperproliferation of mammary epithelial cells and prevents 
lactogenic differentiation in mouse model [314].  
Previous studies have intensively investigated the oncogenic effects of 
autocrine hGH in breast cancer cells (reviewed in [349]). The CSC-like 
properties promoted by autocrine hGH in breast cancer has yet been elucidated. 
ALDH1 has been identified as a marker of normal and malignant human 
mammary stem cells [59, 138, 224], and ALDH1 protein expression is 
associated with poor clinical outcome in breast cancer [138, 310]. The current 
study demonstrated that hGH mRNA expression was associated with ALDH1 
mRNA in a cohort of 24 ER-BC samples. However, this result is inconclusive 
due to small sample number used. A systematic study with a larger cohort of 
ER-BC patient samples is necessary to determine the potential association of 
tumor expression of hGH with ALDH1. In current study, forced expression of 
hGH augmented the population of ALDH1+ cells in ER-BC cell lines. In 
addition, the tumor initiating potential of MDA-MB-453 cells in 
immunodeficient mice was enhanced by forced expression of hGH. Thus 
autocrine hGH may regulate the CSC-like properties of ER-MC cells. 
Mammosphere formation has been identified to be enriched with mammary 
stem/progenitor cells [104]. These stem/progenitor cells are able to 
differentiate along the three mammary epithelial lineages and reconstitute the 
normal human mammary gland in mice [104]. Mammosphere formation can 
be used to investigate CSC-like properties of breast cancer cells [224, 403, 
499]. This assay can be utilized to identify factors important for self-renewal, 
tumorigenesis and drug resistance in CSCs, and characterize the signaling 
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pathways and genes involved [106, 256, 499, 512]. In the current study, forced 
expression of hGH significantly enhanced the mammosphere formation 
capacity of MDA-MB-453 and SKBR3 cells. I also investigated the effect of 
functional antagonism of hGH using the hGHR-specific antagonist B2036. 
B2036 has been demonstrated to be effective in inhibiting growth of a human 
colorectal carcinoma cell line in a xenograft mouse model [84]. Moreover, our 
group has previously demonstrated that B2036 abrogated autocrine 
hGH-mediated transcriptional activation and protection from apoptosis in 
MCF-7 cells [209]. However, the potential effects of B2036 on CSC-like 
properties have not previously been investigated. I demonstrated that B2036 
inhibited mammosphere formation of MDA-MB-453 parental cells in a dosage 
dependent manner. However, B2036 treatment did not affect mammosphere 
formation of the SKBR3 parental cell line.  The differential effects of B2036 
on mammosphere formation may be due to the presence of alternative 
signaling pathway triggered by hGH. hGH can bind an hGHR homodimer or a 
heterodimer consisting of the hGHR and human prolactin receptor (hPRLR) 
[38, 50, 82, 128, 188, 409], and  trigger signal transduction through hGHR or 
hPRLR [476]. The hGHR-specific antagonist B2036 is only able to inhibit 
signal transduction through hGHR, rather than through hPRLR [142]. hGHR 
and hPRLR expression were both identified in MDA-MB-453 and SKBR3 
cells by RT-PCR (data not shown). It is quite possible that hGH triggered 
signal transduction is mediated through hGHRs in MDA-MB-453 cells, but 
through hPRLRs in SKBR3 cells. Previous studies have demonstrated that 
B2036 is able to antagonize the proliferative, antiapoptotic, transcriptional, 
and morphological effects of autocrine hGH in breast cancer cells [209]. The 
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current study indicates that B2036 has the potential to reduce the population of 
CSCs in ER-BC cells. However, the hGHR antagonist G120R, which is able 
to impede both hGHR and hPRLR-mediated signal transduction [491], may 
perform much better than B2036 in this regard. 
IGF-I is known to be the major mediator of endocrine hGH on regulating 
puberty mammary gland development [348]. Increased expression of IGF-I 
and IGF-I receptor (IGF-IR) has been detected in majority of human breast 
cancer, indicating the tumorigenic potential of IGF-I in human breast cancer 
[81, 493]. Previous studies have shown that IGF-I treatment increases invasion, 
and triggers EMT progress in breast cancer cells [455]. The effects of IGF-I on 
invasion and EMT appear to be mediated through activated PI3K/AKT and 
MAPK signaling pathways [455]. Furthermore, IGF-I regulates CSC-like 
properties by cross-talk with a diversity of signaling pathways [268]. In 
ER+BC cells, the putative CSC population expresses higher level of IGF-IR 
compared with non-tumorigenic population, and activated IGF-IR maintains 
the CSC population through activated PI3K/AKT/mTOR signaling pathway 
[56]. Similarly, IGF-I treatment enriches the CSC population of colon cancer 
in a PI3K/AKT dependent mechanism [168]. However, in current study the 
tumor initiating and metastatic potential mediated by forced expression of 
hGH is IGF-I-independent, as IGF-I expression was not detected in 
MDA-MB-453-hGH and SKBR3-hGH cells by qPCR arrays (data not shown). 
Despite of the pivotal role of IGF-I played in the effects of GH on mammary 
development [213, 416], GH acting independently of IGF-I is not 
unprecedented. Previous studies have demonstrated that GH synergized with 
E2 to stimulate the proliferation of ER+BC cells T47D independent of IGF-I 
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[126], as GH treatment did not induce IGF-I expression, nor activate IGF-IR. 
In addition, our previous studies have shown that autocrine hGH does not 
induce expression of detectable level of IGF-I in MCF-7 cells [208], together 
with subsequent studies demonstrating that autocrine hGH induced 
proliferation, oncogenic transformation, EMT, and angiogenesis in MCF-7 
cells are IGF-I independent [39, 208, 315, 515].  
Increased expression of hGH gene has been observed to be associated with 
metastatic breast cancer, suggesting a functional effect of autocrine hGH on 
metastatic progression [362]. Histopathological study has demonstrated that 
hGH mRNA expression in breast cancer is positively associated with lymph 
node metastasis [472]. We have previously demonstrated that autocrine hGH 
promotes local invasion of MCF-7 cells in vivo [315]. Increased invasive 
capacity of MCF-7 cells is partially attributed to EMT induced by autocrine 
hGH. Furthermore, autocrine hGH activated MMP2 and MMP9, degrading 
extracellular matrix proteins to allow subsequent invasion to surrounding 
tissues, also facilitate the local invasion of MCF-7 cells. However, the 
autocrine hGH promotion of metastasis in breast cancer cells has yet been 
determined. Besides increased local invasion, my current study also 
demonstrated that autocrine hGH induced liver and lung metastasis of 
MDA-MB-453 cells in vivo. Although EMT has been demonstrated to play an 
important role in the metastasis of breast cancer [140] and several other types 
of cancer [197, 490, 511], hGH promotion of invasion and metastasis in 
ER-BC cells was most likely independent of EMT as qPCR arrays found that 
hGH did not regulate the expression of EMT-related markers and transcription 
factors.  The autocrine hGH enriched CSCs in ER-BC cells may represent a 
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potential mechanism of promoting tumor metastasis. My current study has 
determined that autocrine hGH increased the population of ALDH1+ CSCs in 
ER-BC cell lines. Besides increased tumor initiating potential, ALDH1+ CSCs 
also recapitulate the metastatic capacity of breast cancer cells in xenograft 
assay [58, 59]. Furthermore, ALDH1 expression represents a prognostic 
marker to predict early metastasis and poor clinical outcome in patients 
suffering from inflammatory breast cancer [58].  
 MDA-MB-453-hGH/Vec SKBR3-hGH/Vec 
Gene Ratio p-value Ratio p-value 
E-Cadherin 1.23 1.61E-02 No expession # 
N-Cadherin 1.22 1.23E-01 2.07 6.32E-01 
Occludin 1.24 8.66E-03 1.27 2.21E-01 
Vimentin 2.34 4.02E-02 1.53 3.68E-01 
Fibronectin 1.77 2.23E-02 1.55 3.50E-01 
α-catenin 1.23 1.70E-04 1.29 2.06E-01 
β-catenin 1.16 5.07E-03 1.21 1.57E-01 
SNAIL1 1.32 1.98E-02 1.26 1.86E-01 
SNAIL2 1.01 4.68E-02 0.97 4.64E-01 
BMI1 1.14 2.07E-02 1.06 5.17E-02 
SALL4 1.09 1.46E-01 1.17 2.07E-02 
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KLF4 1.35 3.21E-02 1.69 4.18E-01 
POU5F1 1.13 1.25E-01 0.71 3.22E-01 
LIN28A 0.91 6.88E-02 1.61 5.15E-01 
Table 3-3 Expression of EMT markers and transcriptional factors in 
MDA-MB-453 and SKBR3 stable cells. 
In summary, hGH expression in ER-BC cells enhance tumor cell CSC-like 
properties, and cell migration and invasion, leading to increased tumor 
initiating potential and metastasis in vivo. Thus, hGH expression may serve as 
a useful biomarker in ER-BC to predict the likelihood of tumor recurrence and 
metastasis. Functional inhibition of hGH may be useful to eradicate CSCs and 









CHAPTER 4 Autocrine Human Growth Hormone Promotes Invasive 
and Cancer Stem Cell-Like Behaviours of Hepatocellular Carcinoma 
Cells by STAT3 Dependent Inhibition of Claudin-1 Expression 
4.1 Introduction 
Hepatocellular carcinoma (HCC) is one of the most lethal cancers, accounting 
for 85%- 90% of primary liver cancer [127]. Despite advances in the diagnosis 
and treatment of HCC, the long-term survival is still unsatisfactory due to the 
high incidence of recurrence and metastasis[447]. The identified existence of 
cancer stem cells (CSCs) in HCC further dampens the prospective of current 
routine treatments [212, 477], and underscores the necessary for novel 
therapeutic strategies.  
The liver is an essential target tissue of pituitary human growth hormone (hGH) 
to exert pleiotropic effects on postnatal somatic growth and metabolism 
processes through stimulation of hepatic insulin-like growth factor-1 
(IGF-1)[348]. The relationship between endocrine growth hormone (GH) and 
cancers has been widely reported in human and animal models [158, 322, 463].  
In addition to the classical endocrine actions, hGH also has important effects 
at an autocrine or paracrine level [169].  The oncogenic potential of autocrine 
hGH has been intensively investigated in human mammary and endometrial 
cancer cells [339, 461]. In addition to promoting oncogenic transformation of 
the immortalized human mammary epithelial cell line MCF-10A [515], 
autocrine hGH has been demonstrated to promote cell proliferation [208], cell 
survival [293], neovascularization [39], radio- and doxorubicin- resistance [33, 
502], and induce epithelial-mesenchymal transition (EMT) [315] of breast 
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cancer cells. Recently, we have demonstrated that autocrine hGH is capable of 
promoting cancer stem cell (CSC) like behaviours in estrogen receptor 
negative (ER-) breast cancer cells. GH- activated Janus kinase 2 and signal 
transducers and activators of transcription (JAK/STATs) pathways, 
extracellular signal-regulated kinase (ERK), and phosphatidylinositol 3-kinase 
(PI-3 kinase) pathway have been thought to be involved in tumorigenic 
progress of mammary carcinoma [461]. In a genome-wide association study, 
the GH signaling pathway has been identified as one of three pathways highly 
associated with breast cancer susceptibility [290]. However, the oncogenic 
potential of autocrine hGH in HCC is still unclear. A previous study has 
demonstrated the increased expression of hGHR in HCC samples, compared 
to normal liver tissues [134]. Furthermore, we have recently observed that 
tumour expression of hGH associates with poor relapse-free survival (RFS) 
and overall survival (OS) outcomes in a cohort of 148 HCC patients (have 
been done in collaboration with Dr. Wu Zheng-Sheng), which implicates that 
autocrine hGH may play a pivotal role in the tumor progression of HCC.  
Claudins (CLDNs) are a family of trans-membrane proteins with 27 identified 
members expressed in a tissue-specific pattern, that are important constituents 
of tight junctions (TJs), where they establish the paracellular barrier and 
maintain the cellular polarity[402].  More recently, studies have 
demonstrated that the TJ proteins are involved in cellular signal transduction 
affecting cell proliferation, motility, and invasion [448].  Aberrant expression 
of CLDNs was demonstrated in diverse types of human cancers, including 
HCC [402]. Immunohistochemical investigation has indentified attenuated 
expression of claudin-1 as a potential marker for poor prognosis in poorly 
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differentiated HCC [177]. In addition, recent studies have shown that 
overexpression of claudin-1 promotes the invasive capacity of human liver 
cells by inducing EMT [423, 497].  
In the current study, I observed that autocrine hGH promoted HCC cell 
invasion and CSC-like properties. I further described that autocrine hGH 
promotion of oncogenicity in HCC cells was mediated by STAT3 dependent 













4.2.1 hGH, hGHR, and hPRLR expression in hepatic cell lines 
The histopathological studies demonstrated the expression of hGH in HCC 
patient samples (have been done in collaboration with Dr. Wu Zheng-Sheng).  
Before determining the functional effects of autocrine hGH on HCC cells, I 
firstly determined the expression of hGH by RT-PCR  in several HCC cell 
lines, including a normal hepatic cell line LO2 and a hepatoma cell line 
HepG2. I observed that in these cell lines, Huh7 was the only cell line with 
expression of endogenous hGH mRNA, albeit slight (Figure 4-1).  I also 
determined the presence of human growth hormone receptor (hGHR) and 
human prolactin receptor (hPRLR) mRNA in all of these cell lines by RT-PCR, 
and observed that all of these cell lines expressed detectable level of hGHR 
mRNA and hPRLR mRNA with the exception of LO2 cells, which did not 
express detectable hPRLR mRNA(Figure 4-1). The CSC-like properties of 
Huh7, Hep3B and HepG2 cells were intensively investigated [68, 264].  
Previous studies have determined the response of HepG2 cells to rhGH 
stimulation [342, 458].  
 
Figure 4-1 Expression of hGH, hGHR, and hPRLR in hepatic cell lines 
The level of hGH, hGHR and hPRLR mRNA in parental hepatic cell lines was 
determined by semi-quantitative RT-PCR. β-ACTIN was used as input control. 
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4.2.2 Establishment of HCC cell lines expressing hGH 
In order to determine the effect of autocrine hGH on HCC cells, stable cell 
lines were generated in two HCC cell lines (Huh7 and Hep3B) and one 
hepatoma cell line (HepG2). These cell lines were either transfected with an 
empty pcDNA3.1 vector or a vector containing the full length hGH gene.  
The established stable cell lines were designated Huh7-Vec, Hep3B-Vec, 
HepG2-Vec, or Huh7-hGH, Hep3B-hGH, HepG2-hGH respectively. To 
confirm hGH mRNA expression in Huh7-hGH, Hep3B-hGH and HepG2-hGH 
cell lines, a semi-quantitative RT-PCR was performed. Huh7-Vec, 
Hep3B-Vec and HepG2-Vec cells did not express detectable levels of hGH 
mRNA, whereas Huh7-hGH, Hep3B-hGH and HepG2-hGH cell lines 
exhibited high levels of hGH mRNA (Figure 4-2A). Subsequently, hGH 
protein levels were determined by western blot analysis, identifying the 
expression of 22kDa hGH protein in Huh7-hGH, Hep3B-hGH and 






Figure 4-2 Forced expression of hGH in HCC cell lines 
(A) The levels of hGH mRNA in stably transfected Huh7, Hep3B and HepG2 cells 
were determined by semi-quantitative RT-PCR. β-ACTIN was used as the input 
control. (B) The hGH protein levels in stably transfected cell lines were determined 














4.2.3 Forced expression of hGH increases HCC cell number in vitro 
Previous studies have demonstrated that forced expression of hGH enhances 
proliferation of mammary and endometrial carcinoma cells [208, 209, 339]. 
To examine the effect of forced expression of hGH on Huh7 and HepG2 HCC 
cell number, a total cell number assay was performed over 8 days. In the 
growth media (supplemented with 10% FBS), Huh7-hGH and HepG2-hGH 
cells exhibited a significantly higher cell number than the respective control 
cell lines, Huh7-Vec and HepG2-Vec, over 8 days (Figure 4-3).  
 
Figure 4-3 Total cell number assays 
Total cell number assays of stably transfected Huh7 (A) and HepG2 (B) cells were 
performed in DMEM growth media supplemented with 10% FBS for 8 days. *, 








4.2.4 Forced expression of hGH increases HCC cells in the S-phase 
Previous studies have demonstrated that forced expression of hGH in breast 
cancer cells increases cell number partially due to the increased proportion of 
cells in the proliferative S-phase of the cell cycle [209]. In order to determine 
whether forced expression of hGH also increases the number of S-phase HCC 
cells, BrdU incorporation assays were conducted in Huh7 and HepG2 stable 
cell lines. Huh7-hGH and HepG2-hGH cells cultured in growth media 
(supplemented with 10% FBS) incorporated significantly more BrdU than 
their respective control cell lines, Huh7-Vec and HepG2-Vec (Figure 4-4). 
These results indicate that the increased cell number of Huh7 and HepG2 cells 
with forced expression of hGH is at least partially due to an increased 
proportion of cells in the S-phase.  
 
Figure 4-4 Forced expression of hGH increases the proportion of HCC cells in 
S-phase of cell cycle 
BrdU incorporation assays were performed after 24 hours of incubation in growth 
media to determine the fraction of cells in S-phase of cell cycles (Huh7-Vec/hGH and 




4.2.5 Forced expression of hGH protects HCC cells from apoptosis 
In addition to increasing cell proliferation, forced expression of hGH also 
protects breast cancer cells from serum deprivation-induced apoptosis [209]. 
In order to determine whether forced expression of hGH also protects HCC 
cells from serum deprivation-induced cell apoptosis, Huh7 and HepG2 stable 
cells were starved in serum free DMEM for 24 hours, and then the activities of 
Caspase3/7 were assessed. The Huh7-hGH and HepG2-hGH cells exhibited 
significantly lower activities of Caspase 3/7 than their respective control cell 
lines, Huh-Vec and HepG2-Vec (Figure 4-5). These results indicate that 
forced expression of hGH protects HCC cells from serum deprivation-induced 
cell apoptosis.  
 
Figure 4-5 Forced expression of hGH protects HCC cells from apoptosis 
After 24 hours of serum starvation, the activities of Caspase 3/7 in Huh7 (A) and 
HepG2 (B) stable cells were measured. The activities of Caspase 3/7 in Vec cells 





4.2.6 Forced exression of hGH enhances anchorage-independent growth 
and three-dimensional growth of HCC cells 
One characteristic of oncogenically transformed cells is the capability for 
anchorage-independent growth [339]. Forced expression of hGH in 
Huh7-hGH cells enhanced anchorage-independent growth as indicated by 
colony formation in soft agar. In the soft agar assay, Huh7 and HepG2 stable 
cells were embedded in agarose and cultured for 14 days before counting the 
number of cell colonies. Huh7-hGH cells formed more colonies in soft agar 
than Huh7-Vec cells (Figure 4-6A). The same effect was also observed in 
HepG2-hGH cells (Figure 4-6A).  We also determined the three-dimensional 
Matrigel
TM
 growth of Huh7 and HepG2 cells in growth factor reduced 
Matrigel
TM
. After 7 days culture in 4% Matrigel
TM
, Huh7-hGH and 
HepG2-hGH cells exhibited higher absorbance than Huh7-Vec and 
HepG2-Vec cells as measured by MTT assay (Figure 4-6B). In addition, the 
colonies formed by Huh7-hGH and HepG2-hGH cells were much larger than 




Figure 4-6 Forced expression of hGH increases colony formation in soft agar 
and three-dimensional growth of HCC cells 
(A) Colony formation of Huh7-Vec/hGH and Hep3B-Vec/hGH cells in soft agar after 
14 days. Colonies were stained with MTT and counted. (B) Colony formation of 
Huh7-Vec/hGH and Hep3B-Vec/hGH cells in 4% growth factor reduced Matrigel
TM
 









4.2.7 Forced expression of hGH promotes migration and invasion of HCC 
cells 
Previous studies have demonstrated that forced expression of hGH promotes 
migration and invasion of human mammary and endometrial carcinoma cells 
[315, 339]. In order to determine the migratory potential of hGH in HCC cells, 
the wound-healing assay was used. In the wound-healing assay, I observed 
that forced expression of hGH did indeed stimulate Huh7 and HepG2 cell 
migration with more rapid closing of the wound than observed in Huh7-Vec 
and HepG2-Vec cells, respectively (Figure 4-7A). Additionally, increased 
migration of Huh7-hGH and HepG2-hGH cells in comparison with Huh7-Vec 
and HepG2-Vec cell lines was also confirmed by the Transwell assay (Figure 
3-7B). Furthermore, Huh7-hGH and HepG2-hGH cells also exhibited a 
significantly increased ability to pass through Matrigel in a standard invasion 




Figure 4-7 Forced expression of hGH promotes migration and invasion of HCC 
cells 
(A) Wound-healing assay. Wounded areas of Huh7 and HepG2 stable cells were 
examined under ×100 magnification. Huh7 and HepG2 stable cells were seeded into 
transwell chambers for migration (B) or 10% Matrigel
TM
 precoated transwell 
chambers for invasion (C) with serum free media. After 48 hours, migrated or 
invaded cells were stained by Hoechst 33342, and counted under fluorescent 








4.2.8 Forced expression of hGH modulates the expression of adherens 
junction and tight junction constituents 
During progression of carcinoma towards a less differentiated and more 
invasive state, cells convert from an epithelial to mesenchymal phenotype, 
concomitant with changes in gene expression, in a process referred to as EMT 
[435]. Previous studies have shown that autocrine hGH induces EMT in 
mammary and endometrial carcinoma cells [315, 339]. Deregulation of TJ 
structures, affecting apical barrier of epithelial sheet and cell invasion, is 
another feature of malignant transformation [448]. To identify whether forced 
expression of hGH promoted migration and invasion in HCC cells was 
mediated via EMT or altered expression of TJ constituents, we investigated 
the expression of several EMT markers and TJ components by western blot 
analysis (Figure 4-8). Forced expression of hGH decreased the expression of 
TJ component claudin-1 at the protein level in Huh7, HepG2 and Hep3B cells. 
However, the expression of TJ proteins zonula occludens protein 1 (ZO-1) and 
occludin was not affected by autocrine hGH. Concordantly, epithelial marker 
gene E-Cadherin was down regulated by autocrine hGH, although the 
endogeneous expression level of E-Cadherin in all of these three cell lines was 
low. In addition, forced expression of hGH increased the protein level of the 
extracellular matrix protein fibronectin-1 in all of these three cell lines. In 
HepG2-hGH cells the expression of mesenchymal marker N-Cadherin was 




Figure 4-8 Forced expression of hGH modulates protein levels of AJ and TJ 
components in HCC cells 
Huh7, HepG2 and Hep3B stable cells were subjected to western blot analysis. Protein 
input control is indicated by β-ACTIN. The epithelial markers include E-Cadherin, 
claudin-1, ZO-1, β-catenin and occudin; the mesenchymal markers include 
N-cadherin, fibronectin-1, and vimentin.  The numbers represent relative density of 






4.2.9 Forced expression of hGH promotes STAT3 phosphorylation in 
HCC cells 
Previous studies have demonstrated that hGH activates JAK/STATs, 
mitogen-activated protein kinase (MAPK)/ERK and PI-3 kinase/Akt pathways 
in mammary carcinoma [461]. I first examined the phosphorylation status of 
STAT3, ERK1/2 and Akt1 in HCC cells with forced expression of hGH. I 
observed significant increase of STAT3 phosphorylation in HCC cells with 
forced expression of hGH without a corresponding change in total STAT3, 
compared with respective Vec control cells (Figure 4-9). In addition, forced 
expression of hGH increased phosphorylation of ERK1/2 in Hep3B cells. 
However, forced expression of hGH did not result in increased 






Figure 4-9 Forced expression of hGH activates STAT3 in HCC cells 
Western blot analysis to investigate the potential signaling pathways activated by 
forced expression of hGH in Huh7, HepG2 and Hep3B cells. β–ACTIN was indicated 











4.2.10 Forced expression of hGH promotes spheroid formation in HCC 
cells 
The existence of CSCs in HCC patient samples and well-established cell lines 
has been intensively investigated. It has been demonstrated that 
stem/progenitor cells and CSCs can form spheroids in non-attached condition 
[104, 486]. Spheroid formation has also been identified as a CSC-like 
characteristic of HCC cells [166, 486]. 
To determine the effect of forced expression of hGH on CSC-like behaviours 
of HCC cells, Huh7, HepG2 and Hep3B cells with forced expression of hGH 
were cultured under ultra-low attachment condition. Huh7 and Hep3B cells 
with forced expression of hGH exhibited significantly increased growth 
(number) of spheroids compared with the respective control cells (Figure 4-10). 
However, HepG2 cells did not form spheroids under ultra-low attachment condition 
(data not shown).  To confirm that the increase in spheroid formation represented 
the progeny of individual CSCs rather than the aggregation of quiescent cells, I 
determined the ability of primary spheroids to form secondary and tertiary 
spheroids.  The secondary and tertiary spheroids generated from Huh7 and 
Hep3B cells with forced expression of hGH was significantly increased as 
compared with those generated from respective control Vec cells (Figure 








Figure 4-10 Forced expression of hGH increases spheroid formation in HCC 
cells 
Huh7-Vec/hGH and Hep3B-Vec/hGH cells were seeded in ultra low attachment 
plates in CSC growth media the number of spheroids formed was counted after 9 
days in culture. The first generation (G1) of spheroidic cells were sequentially 
cultured for the second generation (G2), and third generation (G3) of spheroid 
formation.  Images represent the first generation of spheroids formed by 







4.2.11 Expression of claudin-1 and STAT3 activity have been modulated 
in CSC-rich population from HCC cells 
Previous studies have demonstrated that mammospheres grown from 
mammary epithelial cells are enriched in mammary stem/progenitor cells with 
capabilities of self-renewal and multi-lineage differentiation [104]. In order to 
verify the CSC-like phenotype of spheroid cells in HCC cell lines, we 
examined the mRNA expression of several stem cell markers in spheroids 
compared with cells grown on monolayer. Huh7 and Hep3B cells were first 
grown in spheroid culture in ultra low attachment plates. Then spheroids were 
isolated, and the expression of stem cell markers was examined using qPCR 
assays. The mRNA level of stem cell markers, ABCG2, CSF1, DVL1, KLF4, 
NANOG and SALL4, was significantly increased in spheroid compared with 
the monolayer grown Huh7 and Hep3B cells (Figure 4-11A). Meanwhile, the 
mRNA expression of transcription factors SNAIL1, SNAIL2, ZEB1, and ZEB2 
was also increased in spheroid HCC cells (Figure 4-11A). Conversely, 
claudin-1(CLDN1) mRNA level was reduced in spheroid Huh7 and Hep3B 
cells, compared with respective monolayer grown cells (Figure 4-11A). In 
addition, I also examined STAT3 activity and clandin-1 protein in spheroid 
Huh7 and Hep3B cells. Western blot analysis demonstrated that Huh7 and 
Hep3B spheroid cells exhibited significantly higher levels of STAT3 
phosphorylation than their respective monolayer grown cells (Figure 4-11B). 
Consistent with the qPCR results, claudin-1 protein level in spheroid Huh7 
and Hep3B cells was significantly lower than respective monolayer grown cell 




Figure 4-11 Claudin-1 and STAT3 possess a functional role in promoting the 
CSC-like population in HCC cells 
(A) qPCR assay to determine the expression of CLDN1 and several stem cell markers 
in Huh7 and Hep3B cells grown under monolayer or spheroidic conditions. CSC 
growth media was used in both conditions.  (B) Western blot analysis to determine 
claudin-1 protein level and STAT3 phosphorylation in Huh7 and Hep3B cells grown 
under monolyar and spheroidic conditions. β-ACTIN was used as input control. **, 
P<0.01. The numbers represent relative density of every protein band. 
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4.2.12 Forced expression of hGH increases the side-population in HCC 
cells 
Previous studies have demonstrated that side-population (SP) isolated from 
HCC cell lines exhibit CSC-like properties, related to tumorigenesis, 
metastasis and therapeutic resistance [68, 410]. In the current study I 
determined increased mRNA expression of ABCG2 in the CSC-enriched 
population from Huh7 and Hep3B cell lines (Figure 4-11A), which indicates 
that the SP also represents a CSC-enriched population from Huh7 and Hep3B 
cell lines. I therefore utilized a Hoechst 3342 efflux assay to determine the 
effect of autocrine hGH on Huh7 and Hep3B SPs. Flow cytometry analysis 
demonstrated that forced expression of hGH significantly increased the 
number of cells in SP of both Huh7 and Hep3B cells compared with respective 






Figure 4-12 Forced expression of hGH enhances SP in Huh7 and Hep3B cell 
lines 
Cells were stained with Hoechst 3342 in the absence or presence of verapamil, an 
ABC transporter inhibitor. Verapamil was used to establish the baseline fluorescence 
of these cells. Incubation of cells with Hoechst3342 in the absence of verapamil 
stained a small but distinct side population of cells in the respective stably transfected 












4.2.13 Forced expression of hGH inhibits claudin-1 expression via 
activated STAT3 in HCC cells 
I demonstrated that forced expression of hGH in HCC cells inhibited claudin-1 
protein level (Figure 4-8) and activated STAT3 (Figure 4-9). To determine 
whether expression of claudin-1 was inhibited by forced expression of hGH 
through enhanced JAK2 to phosphorylate STAT3 in HCC cells, we treated 
Huh7 and Hep3B stable cells with JAK2 inhibitor AG490 to determine the 
phosphorylation status of STAT3 and protein level of claudin-1. I observed 
that AG490 treatment inhibited STAT3 posphorylation in Huh7-hGH and 
Hep3B-hGH cells, and meanwhile claudin-1 protein expression was restored 
(Figure 4-13A). Consistently, AG490 treatment increased the basal protein 
level of claudin-1in Huh7-Vec and Hep3B-Vec cells as compared with DMSO 
treated counterparts, respectively (Figure 4-13A). Depletion of STAT3 
expression by siRNA (siSTAT3) also restored claudin-1 protein expression in 
Huh7 and Hep3B cells with forced expression of hGH, as well as led to an 
increased basal expression level of claudin-1 protein in Huh7-Vec and 
Hep3B-Vec cells (Figure 4-13B). In contrast, forced expression of claudin-1 







Figure 4-13 hGH inhibits claudin-1 expression through activated STAT3 in 
HCC cells 
(A) AG490 treatment. Huh7 and Hep3B stable cells were treated with 10µM AG490 
or DMSO. After 12 hours of treatment, cells were harvested for western blot analysis 
to determine the phosphorylation status of STAT3 and claudin-1 protein level. 
β–actin was used as loading control.  Huh7 and Hep3B stable cells were transiently 
transfected with siSTAT3 (B) or claudin-1expresing plasmids (C). After 48 hours of 
transfection, cells were harvested for western blot analysis. The numbers represent 
the relative density of every protein band.  
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4.2.14 Forced expression of hGH inhibits claudin-1 gene transcription in 
HCC cells 
Given that forced expression of hGH decreased the protein level of claudin-1 
in HCC cells (Figure 4-8), I next determined whether hGH represses claudin-1 
expression at the transcriptional level. I first utilized RT-PCR to determine the 
mRNA level of claudin-1 regulated by forced expression of hGH in HCC cells. 
I observed that the expression of claudin-1 mRNA was decreased in HCC 
cells with forced expression of hGH as compared with respective control cells 
(Figure 4-14A). Furthermore, I examined the promoter activity of the 
claudin-1 gene by luciferase reporter assay. The human claudin-1 promoter 
driven luciferase constructs contained 1.7kb of the cluadin-1 gene promoter 
region. I noticed that forced expression of hGH significantly reduced 
claudin-1 promoter activity in Huh7-hGH, HepG2-hGH, and Hep3B-hGH 





Figure 4-14 Forced expression of hGH inhibits claudin-1 gene transcription in 
HCC cells 
(A) RT-PCR. hGH stably transfected Huh7, HepG2 and Hep3B cells were harvested 
for RT-PCR to determine the mRNA expression level of claudin-1 gene. β–ACTIN 
was used as loading control. (B) Luciferase reporter assay to determine claudin-1 
promoter activity in Huh7, HepG2 and Hep3B cells with forced expression of hGH. 
The human claudin-1 promoter-driven luciferase constructs were cotransfected with 
Renilla plasmids into Huh7, HepG2 and Hep3B stable cells. After 48 hours, relative 
luciferase activity of claudin-1 promoter was determined by normalizing against the 










4.2.15 Recombinant hGH inhibits claudin-1 promoter activity in HCC 
cells 
I also examined the effect of exogenous hGH on claudin-1 promoter activity in 
HCC cells through treatment with recombinant hGH (rhGH). Huh7 and 
HepG2 parental cells transfected with claudin-1 promoter-driven plasmids 
were treated with rhGH at a concentration of 100ng/ml at different time points 
(6 hours, 12 hours and 24 hours).  I observed that rhGH inhibited claudin-1 
promoter activity, with the highest inhibitory effect after 12-hour of treatment 
with rhGH (Figure 4-15).  
 
Figure 4-15 rhGH inhibits claudin-1 promoter activity 
Huh7 and HepG2 cells were transfected with claudin-1 promoter-driven constructs. 
After 24 hours, transfected cells were starved in serum free media for another 24 
hours, and then treated with 100 ng/ml rhGH for 6, 12, and 24 hours respectively. The 
control groups were treated with BSA. The relative luciferase activity was normalized 







4.2.16 STAT3 modulates claudin-1 promoter activity in HCC cells 
STAT3 is a DNA-binding transcription factor, which plays an instructive role 
in transcriptionally regulating gene expression after activation by cytokines 
and growth factors [91, 131]. STAT3 is commonly known as a transcriptional 
inducer [90, 259]. However, several studies have described a suppressor role 
of STAT3 in transcriptional regulation [93, 501]. Given that forced expression 
of hGH decreased the protein level of claudin-1 through STAT3 activity in 
HCC cells (Figure 4-13), I decided to investigate whether STAT3 inhibits the 
transcriptional activity of claudin-1 gene. Using Huh7, HepG2 and Hep3B 
cells, I observed that expression of constitutive STAT3 (STAT3CA) reduced 
claudin-1 promoter activity, whereas forced expression of dominant-negative 
(STAT3DN) significantly increased claudin-1 promoter activity (Figure 
4-16A). Consistently, STAT3 depletion by siSTAT3 also increased claudin-1 
promoter activity (Figure 4-16B). In concordance with the luciferase reporter 
assay, western blot analysis demonstrated that forced expression of STAT3DN 
or STAT3 depletion by siSTAT3 in Huh7 and HepG2 cells increased 
claudin-1 protein expression, and conversely forced expression of STAT3CA 







Figure 4-16 STAT3 inhibits claudin-1 promoter activity in HCC cells 
(A) Huh7, HepG2 and Hep3B cells were cotransfected transfected with claudin-1 
promoter-driven constructs and expression plasmids, STAT3DN, STAT3CA, or 
control plasmids (CT). After 48 hours, claudin-1 promoter activity was determined by 
luciferase reporter assay. (B) Huh7, HepG2 and Hep3B cells were cotransfected with 
claudin-1 promoter-driven constructs and siRNAs, non-sense siRNA or siSTAT3. 
After 48 hours, claudin-1 promoter activity was determined. The significance levels 
were based on the respective control cells stransfected with control plasmids or 
non-sense siRNA. **, p<0.01 (C) Western blot. Huh7 and HepG2 cells were 
transfected with STAT3DN or siSTAT3. The control groups were transfected with 
empty plasmids or non-sense siRNA, respectively. After 48 hours, transfected cells 
were harvested for western blot analysis to determine claudin-1 protein level. 
β–ACTIN was used as input control. The numbers represent the relative density of 





4.2.17 hGH regulates claudin-1 promoter activity through activated 
STAT3 in HCC cells 
Given that forced expression of hGH reduced claudin-1 protein level through 
STAT3 activation in HCC cells (Figure 4-13), I decided to investigate whether 
hGH regulates claudin-1 promoter activity through STAT3. Using Huh7 and 
HepG2 cells, I observed that treatment with exogenous rhGH and STAT3CA 
transfection reduced claudin-1 promoter activity. Furthermore, treatment with 
rhGH, together with STAT3CA transfection, achieved the highest level of 
inhibition compared with single treatment. Conversely, AG490 treatment or 
STAT3DN transfection abrogated the inhibitory effect of rhGH on claudin-1 













Figure 4-17 hGH inhibits claudin-1 promoter activity through STAT3 in HCC 
cells 
Huh7 and HepG2 cells were co-tranafected with claudin-1 promoter-driven constructs 
and indicated plasmids (STAT3CA and STAT3DN). After 48 hours, serum–starved 
cells were stimulated with rhGH (100ng/ml) or BSA for 12 hours as indicated. 
Additionally, tranafected cells were pretreated with AG490 (10µM) one hour before 
12-hour stimulation of rhGH.  Significance levels were based on the respective wild 




4.2.18 Identification of STAT3-targeted region within the human 
claudin-1 promoter 
I observed, thus far, that STAT3 is involved in hGH-mediated inhibition of 
claudin-1 gene expression and the 1.7kb promoter region may be important in 
this involvement. Next, I asked whether the claudin-1 gene promoter contains 
STAT3-binding sites. As illustrated in Figure 4-18A, three putative 
STAT3-binding sites have been identified in the proximal region (1.7kb) of 
the human claudin-1 promoter. A CAAT box and two GC boxes have also 
been identified in the claudin-1 promoter region. I then examined the ability of 
nuclear STAT3 to bind to the three putative STAT3-binding sites within the 
human claudin-1 promoter using the in vivo protein-DNA Chromatin 
immunoprecipitation (ChIP) assay. As indicated in Figure 4-18B, p-STAT3 
and STAT3 indeed bound to the three putative STAT3-binding sites in 
claudin-1 promoter.  The normal rabbit IgG was used as negative control in 
immunoprecipitation and did not yield any detectable bands, indicating the 






Figure 4-18 Identification of STAT3-targeted region within the human claudin-1 
promoter 
(A) Schematic illustration of the proximal region of the human claudin-1 promoter 
region. The human claudin-1 promoter contains three putative STAT3-binding sites 
(designated as #1, #2 and #3). A CAAT box is located at nt -768 to -765. In addition, 
two GC boxes are identified at the upstream (nt-982 to -977) and downstream (nt 
-280 to 278) of CAAT box, respectively. (B) Nuclear STAT3 binds to the human 
claudin-1 gene promoter.  HepG2 cells were subjected to in vivo binding assay ChIP, 
as we described in methodology. Briefly, p-STAT3 and total STAT3 (tSTAT3) 
antibody were used in immunoprecipitation. Normal rabbit IgG was used as negative 
control for immunoprecipitation, whereas, input chromatins were used as positive 







4.2.19 hGH regulates STAT3-binding to the claudin-1 promoter region 
As I already determined that hGH regulated claudin-1 protein expression and 
promoter activity via STAT3 activation, I next investigated whether hGH 
modulates the ability of p-STAT3 to bind to the three putative STAT3-binding 
sites within the human claudin-1 promoter region using HepG2-Vec/hGH cells. 
As indicated in Figure 4-19A, forced expression of hGH increased the binding 
of p-STAT3 to the three putative STAT3-binding sites in the claudin-1 
promoter, compared with the HepG2-Vec cells. In addition, I also investigated 
the effect of exogenous rhGH on p-STAT3 binding to the putative 
STAT3-binding sites in the claudin-1 promoter. Serum-deprived HepG2 cells 
were treated with 100ng/ml rhGH for 12 hours before conducting the ChIP 
assay. Consistent with the effect of forced expression of hGH in HepG2 cells, 
rhGH stimulation also enhanced the binding of p-STAT3 to the putative 
STAT3-binding sites in the claudin-1 promoter, compared with the BSA 




Figure 4-19 hGH enhances the binding of p-STAT3 to putative STAT3-binding 
sites in the claudin-1 promoter 
 (A) Forced expression of hGH in HepG2 increases the binding of p-STAT3 to the 
three putative STAT3-binding sites in the human claudin-1 promoter region. (B) 
Exogenous hGH stimulation enhances the binding of p-STAT3 to the three putative 
STAT3-binding sites in the human claudin-1 promoter region. The HepG2 cells had 
been stimulated with 100ng/ml rhGH for 12 hours before ChIP assay analysis. The 









4.2.20 STAT3 regulates claudin-1 promoter activity via the three putative 
STAT3-binding sites 
 To analyze the functionality of the STAT3 consensus sites, I did site-directed 
mutagenesis to generate the STAT3-binding site-mutated claudin-1 
promoter-driven plasmids from the wild-type (WT) claudin-1 promoter-driven 
constructs. The single-site, double-site and triple-site mutated constructs were 
designated as M1, M2, M3, M1+2, M1+3, M2+3, M1+2+3, respectively 
(Figure 4-20A). We transfected these mutated and WT claudin-1 
promoter-driven plasmds into HepG2 cells, and observed that the 
STAT3-binding site mutated claudin-1 promoter exhibited significantly higher 
transcriptional activities than the WT claudin-1 promoter by luciferase 
reporter assay (Figure 4-20B). In Huh7 stable cells, the promoter activity of 
WT claudin-1 promoter was inhibited by forced expression of hGH. However, 
in STAT3-binding site mutated claudin-1 promoter-driven plasmids, the basic 
transcriptional activity was increased, compared with the WT claudin-1 
promoter-driven plasmid. Meanwhile, the hGH mediated transcriptional 
inhibitory effect on claudin-1 promoter was abrogated by STAT3-binding site 
mutation (Figure 4-20C). A similar phenomenon was also observed in HepG2 




Figure 4-20 STAT3 regulates claudin-1 promoter activity via the three putative 
STAT3-binding sites 
(A) Schematic illustration of the mutations (M1-M3) introduced in the 
STAT3-binding sites of claudin-1 promoter-driven construct. (B) Transcriptional 
activities of mutated claudin-1 promoter-driven constructs were increased, compared 
with the WT claudin-1 promoter-driven construct in HepG2 cells. Significance levels 
were based on the control cells transfected with wild type claudin-1 promoter 
constructions. **, p<0.01. (C and D) hGH mediated transcriptional inhibition of 
caudin-1 promoter was abrogated by mutating the STAT3-binding sites within 
claudin-1 promoter. (D) Serum-starved HepG2 cells, transfeced with WT or 
STAT3-binding site mutated claudin-1 promoter-driven plasmids, had been treated 
with 100ng/ml rhGH for 12 hours before luciferase reporter assay. *, P<0.05; **, 
P<0.01; #, no statistical significance. 
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4.2.21 Claudin-1 abrogates the invasive behaviour promoted by forced 
expression of hGH in HCC cells 
Previous studies have demonstrated that claudin-1 inhibits metastasis of lung 
adenocarcinoma [57]. Loss of claudin-1 expression also correlates with worse 
clinical outcome and intrahepatic recurrence in poorly differentiated HCCs, 
which implies that attenuation of claudin-1 expression may correlate with the 
metastatic and invasive potential of HCCs [66, 177]. Given that forced 
expression of hGH decreases the expression of the claudin-1 gene in HCC 
cells at both protein and mRNA levels, and inhibits the claudin-1 promoter 
activity (Figure 4-8, Figure 4-14A and B), I decided to determine whether 
forced expression of hGH promoted invasion was mediated by decreased 
claudin-1 expression. I transiently transfected pIRES-CLDN1 plasmids into 
Huh7 and Hep3B stable cells, and the expression of claudin-1 protein was 
confirmed by western blot assay (Figure 4-13C). In standard Transwell 
invasion assays the hGH promoted invasive capability of Huh7-hGH and 
Hep3B-hGH cells was abrogated by claudin-1 overexpression, and 
concordantly overexpression of claudin-1 further attenuated the basal invasive 





Figure 4-21 Claudin-1 abrogates hGH promoted invasion in HCC cells 
Huh7 and Hep3B cells with forced expression of hGH were transiently transfected 
with claudin-1. After 48 hours, transfected cells were used to conduct a standard 














4.2.22 Claudin-1 abrogates the CSC-like behaviours promoted by forced 
expression of hGH in HCC cells 
There is currently no study to investigate the potential effect of claudin-1 in 
the CSC-like population. I have already observed the reduced expression of 
claudin-1 in CSC-enriched population of HCC cells (Figure 4-11), which 
indicates that claudin-1 may be involved in regulating CSC-like behaviour of 
HCC cells. To determine whether claudin-1 mediates the CSC-like behaviours 
promoted by forced expression of hGH in HCC cells, pIRES-CLDN1plasmids 
were transiently transfected into Huh7 and Hep3B cells with forced expression 
of hGH and their respective control Vec cells (Figure 4-13C). Overexpression 
of claudin-1 abrogated the stimulatory effect of forced expression of hGH on 
spheroid formation in both Huh7 and Hep3B cell lines (Figure 4-22). To 
determine whether hGH utilized repression of claudin-1 to modulate the SP in 
HCC cells, we compared the percentage of SP cells in Huh7 and Hep3B stable 
cells with or without transfection of pIRES-CLDN1plasmids. Overexpression 
of claudin-1 reduced the basal percentage of the SP in Huh7-Vec and 
Hep3B-Vec cells. Claudin-1 overexpression also largely abrogated the 





Figure 4-22 Claudin-1 abrogates spheroid formation induced by hGH in HCC 
cells 
Huh7 and Hep3B cells with forced expression of hGH were transiently transfected 
with claudin-1. After 48 hours, transfected cells were seeded into ultra low 
attachment plates at a concentration of 1000cells/ml with CSC growth media. After 9 




Figure 4-23 Claudin-1 abrogates Side-Population promoted by hGH in HCC 
cells 
Huh7 (A) and Hep3B (B) cells with forced expression of hGH were transiently 




4.2.23 Depletion of claudin-1 attenuates cell viability of HCC cells 
To further indentify the tumor suppressor potential of claudin-1, I depleted the 
expression of claudin-1 by two small interfering RNAs (siRNA) specifically 
targeting claudin-1 (designated as siCLDN1-1 and siCLDN1-2) in Huh7 and 
Hep3B parental cells. Huh7 and Hep3B cells were transfected with siCLDN1s 
or scrambled siRNA (siSC), the depletion of claudin-1expression in Huh7 and 
Hep3B cells were confirmed by western blot assay (Figure 4-24A). The 
western blot assay also demonstrated that depletion of claudin-1 did not affect 
STAT3 phosphorylation. We selected the siCLDN1-1 for further functional 
study. 
To examine the effect of claudin-1 on HCC cell viability, MTT assay was 
performed. Huh7 and Hep3B cells were transfected with claudin-1 specific 
siRNAs or scrambled siRNA. The viability of transfected cells was 
determined by MTT assay. As described in Figure 4-24, depletion of claudin-1 
significantly reduced the viability of Huh7 and Hep3B cells, compared with 




Figure 4-24 Depletion of claudin-1 reduces HCC cell viability 
(A) Western blot. Huh7 and Hep3B cells were transfected with scrambled siRNA 
(siSC) or claudin-1 specific siRNA (siCLDN1). After 48 hours, claudin-1 protein 
level and STAT3 phosphorylation were determined by western blot. β–actin was used 
as input control. The numbers represent the relative density of every protein band. (B) 
Cell viability. Huh7 and Hep3B cells were transfected with claudin-1 specific 
siRNAs or scrambled siRNA. After 48 hours, transfected cells were seeded into 
96-well plates with the same cell density, and cultured with DMEM medium 








4.2.24 Depletion of claudin-1 reduces HCC cell proliferation 
In order to determine whether reduced cell viability by claudin-1 knock-down 
is mediated through cell proliferation. I first examined the protein level of cell 
proliferation marker, ki67, in Huh7 and Hep3B cells. As described in Figure 
4-25A, the protein level of ki67 was significantly reduced in Huh7 and Hep3B 
cells transfected with claudin-1 specific siRNAs, compared with respective 
control cells transfected with scrambled siRNA. I next examined whether 
claudin-1 knock-down reduces the S-phase HCC cells by BrdU incorporation 
assay. I observed that BrdU incorporation was decreased in Huh7 and Hep3B 
cells transfected with claudin-1 specific siRNA, as compared to cells 
transfected with scrambled siRNA (Figure 4-25B). These results indicate that 
the reduced cell viability of Huh7 and Hep3B cells with claudin-1 depletion is 







Figure 4-25 Depletion of claudin-1 reduces HCC cell proliferation 
(A) Western blot. Huh7 and Hep3B cells were transfected with scrambled or 
claudin-1 specific siRNAs. After 48 hours, ki67 and claudin-1 protein levels were 
determined by western blot. β–actin was used as input control. (B) BrdU 
incorporation assay. Huh7 and Hep3B cells, transfected with scrambled siRNA or 
claudin-1 specific siRNAs, were seeded into 96-well plates at the same cell density. 
BrdU incorporation assays were performed after 24 hours of incubation with BrdU in 









4.2.25 Depletion of claudin-1 does not modulate HCC cell apoptosis 
In order to determine whether reduced cell viability induced by claudin-1 
knock-down partially due to cell apoptosis, Huh7 and Hep3B cells transfected 
with scrambled or claudin-1 specific siRNAs were serum-deprived for 24 
hours before assessing the activities of Caspase 3/7. As described in Figure 
4-26, Depletion of claudin-1 in Huh7 and Hep3B cells did not significantly 
increase activities of Caspase 3/7, compared with the respective control cell 
lines transfected with scrambled siRNA. These results indicate that depletion 
of claudin-1 does not enhance serum deprivation-induced HCC cell apoptosis.  
 
Figure 4-26 Knock-down of claudin-1 does not modulate HCC cell apoptosis 
Huh7 and Hep3B cells transfected with scramble of claudin-1 specific siRNAs had 
been starved in serum-free DMEM media for 24 hours, and then the activities of 






4.2.26 Depletion of claudin-1 enhances invasive and CSC-like behaviours 
of HCC cells 
  To determine whether claudin-1 modulates the invasive potential of HCC 
cells, the standard Transwell invasion assay was performed, which 
demonstrated that Huh7-siCLDN1 with abrogated expression of claudin-1 
exhibited dramatically increased invasive capacity as compared with the 
Huh7-siSC control cells (Figure 4-27). A similar effect of invasion was also 
observed in Hep3B-siCLDN1 cells (Figure 4-27).  Concordantly, I also 
examined the effects of claudin-1 depletion on CSC-like behaviours of HCCs 
(Figure 4-28). Depletion of claudin-1 expression resulted in increased spheroid 
cell growth (Figure 4-28A) and increased SP (Figure 4-28B) in both 
Huh7-siCLDN1 and Hep3B-siCLDN1 cells, compared with respective siSC 
transfected cells.  
 
Figure 4-27 Depletion of claudin-1 enhances invasion of HCC cells 
Huh7 and Hep3B cells were transfected with claudin-1 specific siRNA. After 48 




Figure 4-28 Depletion of claudin-1 stimulates CSC-like behaviours in HCC cells 
(A) Spheroid formation. Huh7 and HepG2 cells were tranfected with claudin-1 
specific siRNA. After 48 hours, tranfected cells were seeded into ultra low 
attachment plates at a density of 1000 cells per ml with CSC growth media. After 9 
days in culture the cell colonies formed were counted. Bar, 100µm; **, p<0.01. (B) 
Side population. Huh7 and HepG2 cells transfected with scrambled siRNA or 
claudin-1 specifc siRNA were analyzed by Hoechst 33342 efflux assay to determine 






HCC, accounting for more than 85% of primary liver cancers, is one of the 
most prevalent and lethal malignancies worldwide [127]. Partially due to the 
lack of biomarkers that facilitate detection of incipient disease, HCC is usually 
diagnosed at advanced stage with large primary tumor and intrahepatic 
metastasis level, hence limiting therapeutic options. Currently, systemic 
chemotherapy remains the only option for the treatment of HCC patients at an 
advanced stage or relapse of surgical resection. However, the efficacy of 
systemic chemotherapy is dismal, due to the chemoresistance, toxicity, and 
cirrhotic liver condition under which most of the HCCs are developed [439, 
447]. Due to the lack of survival benefit of treatment with conventional drugs, 
development of novel therapeutic strategy is urgently needed. The recent 
progression in identification of critical signal pathways in HCC development, 
like IL6-JAK/STAT3 singal pathway, has led to the emergence of 
molecular-targeted therapy in advanced HCC [12]. 
The liver is a major target tissue of pituitary GH. Together with GH promotion 
of hepatic IGF-I, GH modulates postnatal growth and development [387]. In 
animal models, GH transgenic mice have exhibited increased rates of 
spontaneous development of HCC [408] and carcinogen diethylnitrosomine 
(DEN)-induced HCC [407] with persistently high levels of hepatocellular 
proliferation and apoptosis [408]. In humans, aberrant increase of circulating 
hGH has been detected in patients with chronic liver disease [22]. In addition, 
increased circulating hGH has also been identified in HCC patients [391]. In 
situ hybridization (ISH) and immunohistochemical techniques have detected 
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higher levels of hGHR in HCC tissues than in normal liver tissues [134]. In 
hGHR positive HCC cell line Bel-7402, rhGH treatment has been reported to 
promote cell proliferation [242].  
In addition to the anterior pituitary gland, expression of GH has also been 
observed in a number of extrapituitary sites [28, 147, 305, 338, 471], exerting 
tissue specific effects in an autocrine/paracrine pattern [253]. The oncogenic 
effects of autocrine hGH in mammary and endometrial carcinoma have been 
intensively investigated in well-established cell models with hGH 
overexpression [348]. In a large scale clinical study, our group has 
demonstrated that in situ hGH expression in mammary carcinoma samples is 
positively associated with higher clinical stage and poorer clinical outcome 
than patients without in situ hGH expression [472]. In our recent study, we 
analyzed the expression of hGH in normal liver and HCC patient samples by 
in situ hybridization and immunohistochemical staining; and we observed 
increased mRNA and protein expression of hGH in HCC tumor tissues 
compared with normal liver tissues. hGH expression was significantly 
associated with tumor size and tumor histological grade. In addition, The 
Kaplan-Meier analyses demonstrated that HCC patients with high levels of 
tumor expressing hGH mRNA exhibited worse RFS and OS outcomes than 
patients with low tumor expressing levels of hGH mRNA (have been done in 
collaboration with Dr. Wu Zheng-Sheng). The clinicopathological analysis has 
implicated the oncogenic effects of autrocrine hGH in HCC development. The 
purpose of my current study is to investigate the oncogenic role of hGH in 
HCC cells, and elucidate the potential molecular mechanisms using 
established HCC cell models with hGH overexpression.  
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4.3.1 The oncogenic potential of autocrine hGH in HCC cells 
To examine the role of autocrine/paracrine hGH in hepatocellular carcinoma, I 
constructed a cell based model system in which the HCC and hepatoblastoma 
cell lines, Huh7, Hep3B and HepG2 were transfected with an expression 
vector pcDNA3.1 containing the hGH gene while the control cell lines were 
transfected with empty pcDNA3.1 plasmids. Expression of hGH was 
determined by RT-PCR and western blot in hGH stably transfected cells while 
the control cell lines did not expression detectable levels of hGH.  
The acquired capacities to sustain cell proliferation and resist apoptosis are 
key hallmarks of oncogenic process [165]. Previous studies have demonstrated 
that GH administration accelerates hepatic regeneration in hypophysectomised 
rats with partial hepatoctomy (PH) through induced expression of hepatic 
growth factor (HGF) [111]. Recent studies in GHR-deficient mice have 
demonstrated the importance of GHR mediated expression of hepatic EGFR 
and ERK1/2 activation in hepatic regeneration [504]. In addition, hGH 
administration promotes proliferation of human hepatocytes grafted into 
immunodeficient mice [279] and restores liver regeneration in steatotic 
patients through activation of EGFR and STAT3 [77]. In GH transgenic mice, 
persistent hepatocellular proliferation and apoptosis has also been observed 
during the process of hepatocellular carcinoma formation [408]. Exogeneous 
rhGH treatment stimulates the proliferation of GHR positive HCC cells 
Bel-7402 [242]. In this study, I observed that autocrine hGH increased the cell 
number of Huh7 and HepG2 cell lines. In addition, autocrine hGH promoted 
BrdU incorporation and reduced cell apoptosis in serum-free condition by 
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decreasing caspase3/7 activity, indicating that autocrine hGH increased HCC 
cell number attributed to enhanced cell survival and proliferation. Similar 
effects of autocrine hGH on cell proliferation and apoptosis have also been 
observed in mammary carcinoma cells MCF-7 [208, 293] and immortalized 
human mammary epithelial cell line MCF-10A[515]. In MCF-10A cells 
autocrine hGH induces the expression of cell proliferation and survival genes 
c-Myc, Cyclin D1 and Bcl-2 [515]. In MCF-7 cells autocrine hGH induced 
cell proliferation is abrogated by specific inhibition of p38 and p44/42 MAPK 
signal pathways [208], both of which have been determined to be activated by 
exogenous hGH [180, 306]. Further studies have demonstrated the increased 
expression of transcription factor CHOP/GADD153 mediated by p38 MAPK 
exerts anti-apoptotic effect of autocrine hGH in MCF-7 cells [293]. In this 
study, I have examined the potential signal pathways activated by autocrine 
hGH in HCC cells. Western blot analysis demonstrated that autocrine hGH in 
HCC cells did not activate ERK1/2 or AKT1, which indicated that autocrine 
hGH-activated cell proliferation and protection from apoptosis in HCC cells 
were not mediated by p44/42 MAPK or PI3K/Akt signal pathways. Instead, I 
observed that autocrine hGH activated STAT3 in HCC cells by stimulating 
Y705 phosphorylation. Previous studies have demonstrated tha hGH activates 
STAT3 in hepatoma cell line HepG2 [458]. In addition, hGH also activates 
STAT3 in endometrial carcinoma [429] and fibrosarcoma cell lines [163]. The 
STAT3 mediated signaling pathways control cell proliferation and survival by 
regulating the expression of various target genes, including CYCLIN D1, 
c-MYC, SURVIVIN, and BLCXL [36, 154]. In endometrial carcinoma, 
activated STAT3 mediated oncogenic effects of autocrine hGH [429]. 
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Autocrine hGH induced proliferative and anti-apoptotic effects in endometrial 
carcinoma cells were significantly impaired by inhibition of STAT3 activity or 
depletion of STAT3 expression [429]. In this study autocrine hGH may also 
enhance HCC cell proliferation and survival through activated STAT3. The 
essential role of STAT3 in liver regeneration has been determined by 
stimulating hepatic cell proliferation and survival [432]. Up-regulation and 
constitutive activation of STAT3 has been detected in the vast majority of 
human HCC patient samples [172, 506]. STAT3 regulates cell proliferation, 
survival, tumor differentiation and metastasis of HCC cells [243]. Furthermore, 
inhibition of STAT3 activity suppresses growth and metastasis of human HCC 
[155, 243, 248, 363]. In this study, I observed that autocrine hGH promoted 
STAT3 phosphorylation through JAK2 activity. treatment with AG490, a 
JAK2 specific inhibitor, attenuated the basal Y705 phosphorylation level of 
STAT3, and abrogated autocrine hGH induced phosphorylation of STAT3 in 
HCC cells.  
Anchorage-independent growth, which represents resistance to anoikis, is 
another hallmark characteristic of oncogenically transformed cells [165]. I 
conducted the soft agar assay and determined that autocrine hGH significantly 
increased the anchorage-independent growth of Huh7 and HepG2 cells. 
Concordantly, the growth of Huh7 and HepG2 cells in 3D Matrigel culture 
was also greatly enhanced by autocrine hGH. The enhanced colony formation 
in soft agar and growth in 3D Matrigel by autocrine hGH has also been 
observed in human mammary carcinoma [509] and endometrial carcinoma 
[339, 429]. In addition, autocrine hGH promotes oncogenic transformation of 
the immortalized, but otherwise normal mammary epithelial cell line 
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MCF-10A, conferring to the capabilities of anchorage-independent colony 
formation in vitro and tumor formation in a xenograft mouse model [515]. 
Autocrine hGH-enhanced anchorage-independent growth of endometrial 
carcinoma cells was dramatically impaired by inhibition of STAT3 activity 
[429], indicating STAT3 as the major mediator of autocrine hGH induced 
anchorage-independent growth.  
4.3.2. Autocrine hGH promotes migration and invasion of HCC cells 
Metastasis is the major cause of cancer-related death, accounting for 90% of 
mortality from cancer [414]. Despite of progress in diagnosis and treatment of 
HCC in recent decades, the prognosis of HCC patients is still unsatisfactory 
due to high rate of recurrence,local spread and metastasis [155].  
In this study, I determined that autocrine hGH promoted the migratory and 
invasive potential of HCC cells in vitro using wound healing assay and 
standard migration and invasion assays. The metastatic potential of hGH has 
been implicated in a number of clinicopathological stuties. In situ RT-PCR 
and ISH have demonstrated increased expression of hGH gene in metastatic 
mammary carcinoma [362]. Histopathological study has identified that hGH 
mRNA expression in mammary carcinoma is positively associated with lymph 
node metastasis [472]. A further study in a panel of 60 human cancer cell lines 
has shown that the expression of hGHR gene in metastatic melanoma cell lines 
is 50-fold higher than in other cell lines, indicating the potential effect of hGH 
signal pathways on tumor metastasis [424]. Conversely, suppression of hGHR 
expression inhibits migration and invasion of human pancreatic ductual 
adenocarcinoma in vitro[421]. Autocrine hGH stimulation of migration and 
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invasion has been observed in mammary and endometrial carcinoma cell lines 
[315, 339]. Autocrine hGH stimulates local invasion of MCF-7 xenograft in 
immmunodeficient mice [315]. Moreover, autocrine hGH stimulation of lung 
and liver metastasis was observed in ER-BC cell xenograft mouse model 
(CHAPTER 3).  
EMT is a prostulated key step for tumor invasion process whereby the 
integrity of epithelial cell layer is disrupted with loss of cell polarity and 
cell-cell contacts and increased cell motility [489].  The process of EMT has 
been involved in the formation of multiple tissue types during early embryonic 
morphogenesis [328], as well as tissue regeneration during wound healing 
[205]. EMT facilitates the infiltration of cancer cells into surrounding tissues 
through remodelling ECM [199].  The hallmark of EMT is down-regulation 
of epithelial specific proteins, including E-cadherin, occludin, claudins and 
catenin proteins; and upregulation of mesenchymal proteins, such as 
N-cadherin, vimentin, and fibronectin [70, 199, 433, 478]. Autocrine hGH 
promotion of migration and invasion of mammary carcinoma cells has been 
accompanied with the phenotypic conversion resulted in the acquisition of 
morphological and molecular charactheristics of a mesenchymal phenotype 
[315]. Production of autocrine hGH in mammary carcinoma cells results in 
suppression of plakoglobin and occludin expression and relocalization of 
E-cadherin from cellular membrane to cytoplasm; meanwhile, the expression 
of the extracellular matrix protein fibronectin was increased by autocrine hGH 
[315]. In current study, I examined the expression patterns of several EMT 
marker genes in HCC cells with forced expression of hGH. I identified that 
autocrine hGH promoted the expression of fibronectin in HCC cells. 
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Meanwhile the expression of epithelial markers E-cadherin and claudin-1 was 
repressed by autocrine hGH in HCC cells. These results indicate that autocrine 
hGH may promote metastasis of HCC cells through the EMT process. 
Therefore, autocrine hGH can be suggested as a potential therapeutic target to 
retard the invasion and progression of metastatic hepatocellular carcinoma.  
The current study identified that decreased expression of claudin-1 as a 
consequence of autocrine hGH was required for the invasive potential of HCC 
cells. Claudin-1 is a member of CLDN family, consisting of 27 tetraspan 
transmembrane proteins ranging from 20 to 27 kDa [402]. The CLDNs 
participate in formation of TJs through direct interaction with occludin, ZO-1, 
ZO-2, ZO-3 and indirect interaction with AF-6 (afadin), maintaining cell 
polarity and regulating permeability [434]. The expression of CLDNs changes 
in a tissue specific pattern; and aberrant CLDNs expression has been 
demonstrated in tumorigenesis [402]. Earlier studies have mainly identified 
CLDNs as tumor suppressor genes, as loss of TJs and acquirement of cell 
motility during malignant progression. However, this consensus is now 
challenged and it has been apparent that the expression of CLDNs is highly 
contextual and tissue specific. Claudin-4 has been demonstrated to inhibit liver 
metastasis of pancreatic cancer [295]. The frequent overexpression of 
claudin-3 and claudin-4 has been identified in ovarian epithelial cancers, but 
not in ovarian cystadenomas, indicating that the expression of these proteins is 
associated with malignant progression of ovarian cancer [367].  Loss of 
claudin-7 expression has been observed in invasive ductal carcinoma [220], 
non-small cell lung cancer[482], metastatic breast cancer [388], and 
esophageal squamous carcinoma [450]. By contrast, increased expression of 
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claudin-7 has been accordant with the progress of cervical neoplasia [232]. 
The analogous dual, oncogenic and tumor suppressor role of claudin-1 have 
also been observed in various cancers. Overexpression of claudin-1 has been 
associated with malignant phenotype in colon [101], papillary thyroid [320], 
melanoma [234], and ovarian cancer [216]. In contrast, the down-regulation of 
claudin-1 has been observed in invasive breast cancers and some human 
cancer cell lines [225, 426, 442], and correlated with disease recurrence [312].  
Expression of claudin-1 has been observed in normal liver tissues. In HCC 
tissues, attenuated claudin-1 expression is associated with several pathological 
features. Claudin-1 expression is significantly reduced in poorly differentiated 
HCCs and associated with portal invasion. Moreover, attenuated expression of 
claudin-1 is significantly associated with a poor overall survival rate, 
suggesting claudin-1 as an independent prognostic factor in HCC [177].  
Consistent with the clinicopathalogical study, my current works demonstrate 
that claudin-1 is a tumor suppressor gene in HCC cells. Overexpression of 
claudin-1abrogated autocrine hGH induced invasion in HCC cells. Moreover, 
depletion of claudin-1 expression significantly increased invasion of HCC 
cells in vitro. In conjunction with increased invasion, the proliferation of HCC 
cells was inhibited by depletion of claudin-1. Based on these observations, 
autocrine hGH promoted proliferation and protection from apoptosis of HCC 
cells is claudin-1 independent. Instead, other signal pathways involving 
STAT3 activated by autocrine hGH in HCC cells may control cell 
proliferation and survival by upregulation of   CYCLIN D1, c-MYC, 
SURVIVIN, and BLCXL [36, 154].  My study demonstrated that claudin-1 did 
not modulate HCC cell survival in monolayer culture as previous study 
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described in breast cancer [181]. However, in suspension culture claudin-1 
induces breast cancer cell apoptosis [181], suggesting that loss of claudin-1 
may protect detached cancer cells from anoikis and facilitate tumor metastatic 
progression.  
The expression of claudin-1 is regulated by diverse mechanisms, reflecting the 
tissue specific dual functions of claudin-1 in various cancers. In rat 
hepatocytes, TGF-β induces EMT with inhibition of claudin-1 expression 
through activated p38 MAPK, PI3K/ATK and protein kinase c (PKC) signal 
pathways [218]. However, PKC has been determined to promote claudin-1 
expression in melanoma; and claudin-1 promotes metastatic progression of 
melanoma [234]. Transcription factors (TFs) snail and slug inhibits claudin-1 
expression on transcriptional level through binding to the two E-box elements 
in the 5’ proximal region of claudin-1 promoter [276]. Moreover, Snail and 
slug have been demonstrated to trigger EMT through inhibiting transcription 
of E-cadherin and occludin [194, 261].  The tumor suppressor transcription 
factor RUNX3 has been demonstrated to promote claudin-1 expression 
through binding to the RUNX3 consensus sites in the promoter region of 
claudin-1 gene. Down-regulation of RUNX3 expression has been observed in 
hepatocellular carcinoma tissues and livers with cirrhosis, suggesting the 
involvement of RUNX3 in the initiation of hepatocarcinogenesis [300].  
Inhibition of claudin-1 expression by autocrine hGH was demonstrated to be 
mediated through activated STAT3, as evidenced by functional deprivation of 
STAT3 activity. Constitutive STAT3 activation has pivotal functions in 
various types of cancers [65, 201, 248]. STAT3 plays a vital role in inducing 
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EMT during tumorigenesis [65, 201, 259, 400]. STAT3 is the major mediator 
potentiating IL6 and IL22 mediated liver regeneration, as well as 
hepatocarcinogenesis [425].  Constitutive STAT3 activation has been 
observed in HCC tissues, and significantly associates with HCC invasion and 
metastasis [506]. Claudin-1 has not previously been shown to be a direct 
transcriptional target of STAT3. STAT3 has been demonstrated to regulate the 
expression and activation of snail1, snail2 and twist1 [259, 479], suggesting 
that STAT3 may indirectly regulate claudin-1 expression through these TFs 
[229, 485].  However, I did an intensive search to investigate the putative 
STAT3 binding elements in CLAUDIN-1 promoter region, and identified three 
putative STAT3 binding elements in the 1.7kb CLAUDIN-1 promoter region. 
STAT3 activated by hGH inhibited CLAUDIN-1 transcription through directly 
interacting with the consensus STAT3 binding elements in the promoter 
region of CLAUDIN-1 gene.  Although STAT3 is widely accepted to 
promote gene transcription [90], my study suggests that STAT3 may also act 
as a transcriptional repressor in HCC cells. Previous studies has demonstrated 
the importance of DNA-binding domain of STAT3 in inhibiting the 
transcription of inducible nitric oxide synthase (iNOS) and IL-8 through direct 
interaction with NF-κB [93, 500, 501]. Whether STAT3 cooperates with NF- 
κB or other factors to regulate the transcription of CLAUDIN-1 gene is still not 
yet defined. I also identified putative NF-κB elements in the 5’ proximal 
region of CLAUDIN-1 promoter. However, there is no evidence that NF-κB 
regulates claudin-1 expression. Further study is required to determine the 
mechanism of STAT3 inhibition of claudin-1 expression.     
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4.3.3 Autocrine hGH promotes CSC-like behaviours of HCC cells 
Since the pioneering work from Bonnet and Dick that identified CSCs in acute 
myeloid leukaemia [31], the existence of CSCs has been determined in a 
variety of solid tumors, and considered as an emerging hallmark of cancer 
[165].  Numerous further studies have correlated CSCs with drug resistance, 
tumor metastasis and relapse [96, 241]. The existence of CSCs in HCC has 
been defined by diverse cell surface markers and characteristics as in other 
solid tumors [68, 166, 264, 265, 422, 486].  
My current study demonstrated that autocrine hGH enhanced the CSC-like 
properties of HCC cells as evidenced by the spheroid formation potential and 
side-population.  Elevated expression of the GHR gene in embryonic and 
tissue specific stem cells has been determined through analysis of gene 
expression profiles, indicating the functional effects of GH/GHR signal 
pathways in stem cells [104, 365]. Supporting evidence is from observations 
of elevated self-renewal capability of neural and mammary stem/progenitor 
cells in response to GH treatment [108, 288, 343]. Moreover, constitutive 
expression of autocrine GH in mammary gland maintains hyperproliferation of 
mammary epithelial cells and prevents lactogenic differentiation [314]. 
Concordantly, we also observed the autocrine hGH promotion of CSC-like 
properties in ER-BC cells (CHAPTER 3). 
Spheroid growth from mammary epithelial cells (designated as mammosphere) 
represents enriched mammary stem/progenitor cells with upregulation of 
several signal pathways that modulate proliferation and self-renewal of 
mammary stem/progenitor cells [104]. My study determined the enrichment of 
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CSCs in spheroid colonies growing under low-attachment conditions by 
comparing their gene expression with monolayer HCC cells. The elevated 
expression levels of stem cell markers (SCF1, DVL1, KLF4, NANOG, and 
SALL4) indicated that the spheroid colonies were enriched with CSCs of HCC 
cells. SALL4 has been demonstrated as a vital transcription factor maintaining 
pluripotency and self-renewal of embryonic stem cells [113, 368, 488]. 
Expression of SALL4 is detected in fetal liver specimens in contrast to adult 
liver, indicating the stem-like property of SALL4 in liver [333]. Expression of 
SALL4 in HCC patient samples is associated with dismal prognosis, 
characterized by poor differentiation and aggressiveness [496]. Moreover, the 
gene expression pattern of SALL4 positive HCC patients is in concordance 
with the pattern in hepatic progenitor cells [496].  Elevated expression of 
ATP-binding cassette (ABC) transporters has been determined as a stem cell 
marker and identified in a variety of stem cells, representing the 
side-population phenotype with enrichment of stem cells [513]. Increased 
ABC transporters endow the drug resistant properties to stem cells through 
preventing intracellular accumulation of toxins. Elevated expression of ABC 
transporters has been defined as a characteristics of CSCs in various cancers, 
and protects CSCs from cytotoxicity of chemotherapy [105]. ABCG2 has been 
determined as a CSC marker in HCC, and associates with the capacity of 
tumorigenecity, drug resistance, and tumor metastasis [507]. My current study 
demonstrated elevated expression of ABCG2 in CSC-enriched population of 
HCC cells, implicating a potential mechanism of prevalent drug resistance of 
HCC patients to conventional therapy [96]. Increases of side-population by 
autocrine hGH in HCC cells may also produce drug resistance, as previous 
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studies have demonstrated the drug resistant properties promoted by autocrine 
hGH in mammary and endometrial carcinoma cells [34, 299, 303].  
Intriguingly, in this study I identified reduction of claudin-1 expression in the 
CSC-enriched population in both mRNA and protein levels, indicating that 
claudin-1may be functionally involved in regulation of CSC-like behaviours in 
HCC cells. Further in vitro experiments demonstrated that depletion of 
claudin-1 in HCC cells significantly increased the spheroid formation potential 
and side-population. In contrast, overexpression of claudin-1 abrogated 
autocrine hGH promoted CSC-like behaviours in HCC cells, indicating that 
autocrine hGH stimulation of CSC-like behaviours was mediated through 
down-regulation of claudin-1in HCC cells. Previous studies in ovarian cancer 
have determined that claudin-1functions as an oncogene, increasing 
proliferation and self-renewal of ovarian CSCs [257, 361]. These contradicting 
works reflect the tissue-specific effects of claudin-1 in tumorigenesis.  
Increased activity of STAT3 in CSC-enriched population of HCC cells 
indicates that STAT3 activation participates in regulation of CSC-like 
properties in HCC. Activation of STAT3 has been demonstrated to maintain 
the pluripotency of embryonic stem cells [369]. Activation of STAT3 and 
expression of stem cell markers NANOG and OCT4 have been determined in 
liver stem/progenitor cells [431]. Aberrant activation of IL-6/STAT3 signal 
pathway has been supposed to regulate the CSC population of liver cancer in 
collaboration with TGF-β signal pathway [431].  Moreover, STAT3 activity 
participates in maintaining CSC population of HCC through increases of 
NANOG expression [233]. Whereas, inhibition of STAT3 activity reduces the 
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CSC population of mammary carcinoma and attenuates the tumor initiating 
capacity in a xenograft model [92]. Previous study has determined that 
autocrine hGH activation of JAK2/STAT3 signal pathway mediates oncogenic 
transformation of endometrial carcinoma [339]. My current study 
demonstrated autocrine hGH promoted CSC-like properties through STAT3 
mediated repression of claudin-1 expression, and determined claudin-1 as a 
novel STAT3 targeting gene that gets involved in regulation of CSC-like 
properties.  
The reasons for poor prognosis in late stage HCC include invasive 
dissemination and tumor relapse, which can be ascribed to EMT and CSC 
characteristics.  The link between EMT and CSC has been well-established in 
various cancers, including HCC [87, 271, 309, 411]. The transcription factors 
twist1 and snail1, that promote EMT progress, concordantly induce CSC 
phenotype [87, 271]. In our study, the CSC-enriched population in spheroid 
colonies exhibited increased expression of stem cell markers, as well as 
transcription factors that regulates EMT transformation. This result indicates 
that the CSCs in HCC may play a vital role in tumor metastatic dissemination 
and relapse. A previous study has determined that in addition of promoting 
EMT, TGF-β induced snail1 stimulates CSC phenotype through NANOG 
transcription in liver cancer [87]. In my study, claudin-1 is not only an 
epithelial marker, expression of which was repressed in CSC-enriched 
population, but also identified as the mediator of autocrine hGH stimulation of 
EMT and CSC phenotypes in HCC cells. Previous studies have identified a 
subtype of claudin
low
 mammary carcinoma with increased expression of stem 
cell and EMT markers [80, 174], indicating a high association between low 
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claudin expression and mammary EMT/CSC phenotypes. As previous studies 
in mammary carcinoma ([315] and CHAPTER 3), autocrine hGH was 
identified as a dual effector regulating EMT and CSC-like properties in HCC 
cells, indicating the hGH/hGHR singal pathways is an ideal target to prevent 
HCC metastasis and relapse.     
In summary, overexpression of hGH in HCC cells induced oncogenic effects. 
In addition, autocrine hGH promoted invasive and CSC-like properties in 











CHAPTER 5 Conclusion and future directions 
The main purpose of this thesis was to investigate the oncogenic effects of 
autocrine hGH by analyzing the CSC-like and invasive properties in two 
different types of cancer: the estrogen receptor negative breast cancer (ER-BC) 
and hepatocellular carcinoma (HCC). The existence of CSCs has been 
intensively studied in leukemia and solid tumors [31, 96], and considered as 
the culprit for tumor metastasis [241, 271], drug resistance and tumor 
recurrence [96]. Tumor metastasis is the major cause of cancer-related death, 
and thus the most significant limiting factor for curable cancer treatment [414]. 
The first aim of this thesis was to determine the effects of autocrine hGH on 
tumor initiation and metastasis in ER-BC cells. The role of autocrine hGH in 
breast cancer has been intensively examined by our group in previous studies 
but its specific role in tumor initiation and metastasis has yet been delineated. 
The second aim of this thesis was to investigate the oncogenic effects of 
autocrine hGH in HCC cells. Liver is the major target organ of endocrine hGH 
in regulating metabolism and somatic growth [348]. Our histopathalogical 
analysis has demonstrated increased in situ expression of hGH in HCC patient 
samples, and the inverse correlationship between hGH expression and clinical 
outcome, indicating that autocrine hGH may play a vital role in progression of 
HCC.  
I first examined the role of autocrine hGH in regulation of tumor initiation and 
metastasis of ER-BC cells in vitro and in vivo. I have demonstrated that 
autocrine hGH promotes CSC-like, migratory and invasive properties of 
ER-BC cells in vitro. In addition, the xenograft assays have demonstrated that 
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autocrine hGH enhances the tumor initiating and metastatic potentials of 
ER-BC cells. Further studies would examine the specific signal pathways 
involved in the autocrine hGH-mediated stimulation of tumor initiation and 
metastasis. CSC-like properties modulated by autocrine hGH has been 
demonstrated as increased mammosphere formation, ALDH1+ population and 
SP. The increased CSC-like properties have been linked with tumor initiating 
potential by limiting dilution analysis of xenograft assay. Functional 
antagonism of hGH has demonstrated that B2036 has an inhibitory effect on 
CSC-enrichment in vitro, indicating the therapeutic potential of hGH 
antagonism in ER-BC. Whereas, the inefficiency of B2036 on SKBR3 cells 
maybe explained by the low endogenous expression of hGH in SKBR3 cells. 
Another explanation may be that B2036 is a hGHR specific antagonist, 
whereas hGH may trigger signal transduction through hPRL in SKBR3 cells, 
rather than through hGHR. Previous studies have demonstrated that specific 
antagonism of hGH promotes chemo- and radio-sensitivities of breast and 
endometrial cancer cells [33, 34]. As autocrine hGH modulates the CSC 
population of ER-BC cells and promotes tumor initiation, further studies 
would determine whether functional antagonism of hGH inhibits tumor 
initiation and promotes therapeutic sensitivity of human breast cancer 
xenografts in a panel of animals. The metastatic potential of autocrine hGH in 
ER-BC cells has been determined by standard migration and invasion assays 
in vitro, and increased lung and liver metastatic nodules in xenograft assay. 
Distinct from previous studies which have determined that autocrine hGH 
induces EMT and local invasion of breast cancer [315], our current study has 
demonstrated that autocrine hGH stimulation of metastasis is independent of 
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EMT progress in ER-BC cells, as the qPCR and western blot assays have not 
determined the expression change of EMT-related markers. Further studies 
would determine whether autocrine hGH-enriched CSCs are responsible for 
the increased metastatic property of ER-BC cells. Previous studies have 
determined distinct signal transductions between CSC and non-CSC 
populations [59, 274, 430], and have demonstrated that CSCs are involved into 
tumor metastasis [58, 59, 255]. Increased expression of hGHR in enriched 
mammary stem/progenitor cells, compared with differentiated mammary 
epithelial cells [104], indicates that autocrine hGH may induce different 
behaviours in CSC and non-CSC populations. It is reasonable to postulate that 
autocrine hGH induced increase of CSCs may get involved in lung and liver 
metastasis of ER-BC cells.  
The second focus of this thesis was the potential role of autocrine hGH in 
HCC cells, and elucidated a potential signal pathway that mediated autocrine 
hGH stimulation of oncogenic behaviours in HCC cells. In vitro assays have 
confirmed the increased anchorage-independent growth, cell proliferation and 
anti-apoptosis promoted by autocrine hGH in HCC cells. The activation of 
JAK2/STAT3 signal pathway may represent a mechanism to mediate 
autocrine hGH-promoted oncogenic effects in HCC cell, which needs further 
investigation. Depletion of claudin-1 did not modulate cell apoptosis, but 
reduced cell proliferation, indicating that activated STAT3 by autocrine hGH 
may regulate cell proliferation and survival through other factors, rather than 
claudin-1. Further studies would identify the factors potentially involved in 
this process. I then identified that autocrine hGH promoted migratory, invasive 
and CSC-like properties of HCC cells in vitro.  Further studies would 
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examine the autocrine hGH stimulation of tumor metastasis and initiation in 
xenograft assays.  Our previous studies have demonstrated autocrine hGH 
stimulation of EMT in breast cancer cells [315]. In this study, I have 
identifided that autocrine hGH induces EMT in HCC cells as determined by 
reduced expression of E-cadherin and claudin-1, and increased expression of 
fibronectin. Immunohistochemical investigation has determined that 
attenuated expression of claudin-1 associates with poor prognosis in poorly 
differentiated HCC [177]. The qPCR and western blot assays in our study 
have indentified reduced expression of claudin-1 in CSC-enriched population 
of HCC cells. I could then speculate that claudin-1 played a role in autocrine 
hGH-mediated invasive and CSC-like behaviours in HCC cells. I then 
confirmed that over-expression of claudin-1 abrogated autocrine hGH 
stimulation of invasive and CSC-like behaviours in HCC cells; Conversely, 
depletion of cluadin-1 significantly promoted invasion and CSC-like 
properties in HCC cells. Further studies would identify potential signaling 
pathways regulating repression of claudin-1 mediated invasion and CSC-like 
behaviours. Claudin-1 is not only an integral constituent of TJs, but also gets 
involved in signal transduction through different mechanisms. ZO-1 is a 
potential target of claudin-1 mediated signal transduction. ZO-1 interacts with 
the intracellular domain of claudin-1 through its PDZ domain. Claudin-1 
overexpression has been determined to increase the expression of ZO-1 in 
lung adenocarcinoma [57]. Loss of ZO-1 expression associated with tumor 
progression [182].  In my current study, the expression of ZO-1 was not 
reduced with down-regulation of claudin-1 expression by autocrine hGH. 
Cytoplasmic/nuclear translocation of ZO-1 has been associated with 
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oncogenic transformation and EMT [148, 195, 373]. ZO-1 binds with the 
Y-box transcription factor ZONAB and co-translocated into nucleus from TJs, 
regulating cell proliferation and dedifferentiation [16, 247]. Further studies 
would determine the cellular localization of ZO-1 in HCC cells with hGH 
overexpression. In this study, I determined STAT3 as a transcription repressor; 
STAT3 inhibited claudin-1 expression through direct binding to the putative 
STAT3 consensus binding sites in the promoter region of claudin-1 gene. 
However, our current study could not exclude the possibility of an indirect 
regulation of claudin-1 expression mediated by STAT3, which needs further 
investigation. The transcription factors snail1 and snail2, which have been 
demonstrated to inhibit the transcription of claudin-1, can be induced by 
STAT3 activation [276, 479].  
Studies from our group have demonstrated the critical role of autocrine hGH 
in neoplastic progression of breast cancer. In this thesis I identified the tumor 
initiating and metastatic effects of autocrine hGH in breast cancer. In addition, 
I also determined the oncogenic effects of autocrine hGH in HCC cells. These 
works imply that targeting GH may represent a promising therapeutic option 
to improve cancer treatment. Our previous studies have demonstrated an 
increase of cell proliferation, survival, chemo- and radio-resistance, migration, 
invasion, EMT, and angiogenesis by hGH in breast cancer cells[33, 34, 39, 
115, 207, 208, 293, 315, 509, 515]. Moreover, autocrine hGH induces 
oncogenic transformation of immortalized mammary epithelial cells [515]. 
Functional antagonism of hGHR may be considered as a practical therapeutic 
approach. B2036 is the protein constituent of Pegvisomant
®
 (Pfizer), that has 
been approved by FDA for treatment of acromegaly [221, 444]. In this thesis, I 
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determined that specific inhibition of hGHR by B2026 prevented 
CSC-enrichment in ER-BC cells. The involvement of CSCs in drug resistance, 
tumor metastasis, and recurrence has been intensively investigated.  
Antagonism of hGHR may represent an avenue to prevent tumor relapse. 
Further studies would determine the cancer inhibitory effects of B2036 in 
HCC cells. Preclinical studies have determined that Pegvisomant
®
 impedes the 
growth of human meningioma, colon cancer and breast cancer xenografts in 
animal models [83, 102, 286]. Currently, Pegvisomant
®
 is under phase1 
clinical trials to treat several advanced solid tumors in combination with 
Figitumumab (Pfizer), a monoclonal antibody targeting the IGF-IR.  
In conclusion, this study brings new perspectives to potential improvement of 
breast cancer and HCC treatment. In addition, I unraveled a potential signal 
pathway that regulates autocrine hGH mediated oncogenic effects in HCC 
cells, and indicated GH signal pathway as a potential therapeutic target in 
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